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The morphological changes required for the ensheathment of peripheral nerve
axons by Schwann cells are believed to be regulated by the cell cytoskeleton and its
associated proteins. Control of the levels of these proteins is likely to be necessary for
the assembly of compact myelin and the stability of the sheath.
L-periaxin was initially identified as a putative cytoskeleton-associated protein
expressed by myelin-forming Schwann cells based upon its insolubility in non-ionic
detergent. The pattern of developmental expression of L-periaxin and its shift in
localisation from the adaxonal to abaxonal membranes of myelinating Schwann cells
following their association with axons, implied a role in the stabilisation of the myelin
sheath. In this work, an F-box containing protein termed Fbxl6, was found to associate
with the C-terminal acidic region of L-periaxin, in a search for binding partners of L-
periaxin using the yeast two-hybrid method. The observed interaction was verified by
in vitro pull down assays using mouse sciatic nerve homogenate and L-periaxin
generated by in vitro transcription/ translation.
F-box proteins have been identified as components of a multi-enzyme complex
termed SCF (Skp 1 / Cullin 1/F-box), which is responsible for the recruitment of
substrates for ubiquitination and subsequent destruction. Fbxl6 belongs to the leucine-
rich repeat (LRR)-containing subfamily of F-box proteins. The C-terminal LRR region
of the protein serves as the binding site for L-periaxin. whereas the F-box motif permits
association with the core SCF complex. L-periaxin was detected as a ubiquitin
conjugate in sciatic nerve explant cultures. Ubiquitination of the protein acts as a signal
for degradation by the 26S proteasome, as revealed by stabilisation of L-periaxin upon
inhibition of the proteasome by epoxomicin.
xv
The participation of L-periaxin in a recently identified dystroglycan- dystrophin-
related protein 2 (DRP2) complex, suggests an indirect role for Fbxl6 in the structural
and signalling functions of the cortical cytoskeleton. Regulation of the levels of L-
periaxin by the ubiquitin/ proteasome pathway, mediated by Fbxl6, is likely to be
important for the stabilisation of the Schwann cell-axon unit.
XVI
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Protein-protein interactions are commonly the way in which the dynamic
functions of proteins are manifested. An efficient way of ensuring that the correct
interactions between proteins are formed is by controlling the levels of expression
of these polypeptides in the appropriate location at the right time, so they can be
readily available to their binding partners. Cells employ a highly selective
mechanism to regulate their protein content, which involves the covalent
modification of proteins to be eliminated by a small protein, termed ubiquitin. The
process of attachment to ubiquitin, referred to as ubiquitination, is energy
dependent and targets proteins for destruction by a self-compartmentalised protease
system, the 26S proteasome.
Protein interactions are strongly implicated in the process of myelination
resulting in the compaction of the myelin sheath. The adhesion of adjacent layers
of the multi-lamellar sheath has been described to be largely accomplished by
processes that involve the formation of protein complexes (Peters et al., 1970).
Stabilisation of the myelin sheath in the peripheral nervous system is influenced
by the presence of L-periaxin protein expressed by myelin-forming Schwann cells
(Gillespie et al., 1994). Its localisation to the periaxonal Schwann cell membranes,
at the early stages of myelination, suggested a role in axon-glial communication
and its possible binding partners have been sought among proteins associated with
the axolemma or the Schwann cell cytoskeleton. Recently L-periaxin has been
shown to interact with dystrophin-related protein 2 (DRP2) in the context of a
dystroglycan-glycoprotein complex. It has been known for some time that the
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expression of genes important for myelin assembly is regulated by Schwann cell
contact with the basal lamina (Bunge et ah, 1986). L-periaxin as part of the DRP2
complex, is required to support stabilisation of the myelin sheath in the later stages
of the myelination process, as suggested by evidence from periaxin-deficient mice
(Gillespie et al., 2000). L-periaxin associates with DRP2 through a highly basic
domain localised near the N-terminus of the protein, downstream of a PDZ domain
which is responsible for homodimerisation of the protein. This self-association of
the protein is probably responsible for the clustering of the DRP2 complex in the
plasma membrane of the Schwann cell (Sherman et al., 2001).
The object of this study was to identify other possible binding partners of L-
periaxin by employing the yeast two-hybrid method (Fields and Song, 1989) using
the C-terminal part of the protein, which comprises an acidic domain, as "bait".
Detection and subsequent characterisation of periaxin's interacting partners would
provide clues to characterising its specific role in the Schwann cell and its
involvement in peripheral nerve myelination.
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1.2 MYELINATION IN THE PERIPHERAL NERVOUS SYSTEM
1.2.1 Myelinated fibres
1.2.1.1 Myelin and its formation
Myelin is a multilamellar structure with a high lipid to protein ratio (80:20 by
weight), which serves as an insulator of nerve fibres and permits saltatory
conduction of nerve impulses. Myelin is present in both the CNS and PNS and is
elaborated by two different types of glial cells.
Oligodendrocytes are responsible for myelination in the CNS, whereas in the
PNS myelin formation is accomplished by Schwann cells. In both cases, myelin is
deposited by the repeated spiral wrapping of an extension of the plasma membrane
of these cells around the axon (Kandel and Schwartz, 1985). The cytoplasm is
extruded thus bringing adjacent cytoplasmic and adjacent extracellular membrane
surfaces into apposition resulting in the formation of mature compact myelin
sheath (Figures 1 and 2). However, Schwann cell -cytoplasm filled regions do
persist in the periaxonal and adaxonal rim of the mature sheath, within the
paranodal loops and in channels called Schmidt-Lanterman incisures (Figure 3)
(Bunge et al., 1989(a)). The effect is imperfect myelin compaction due to the
prevention of adjacent cytoplasmic membranes from fusing. The functional
significance of the Schmidt-Lanterman incisures is not clear. It is known that they
provide a pathway for protoplasmic connections between the inner and outer
compartments of the Schwann cell and so they may serve as a route by which
delivery of metabolic material to the distal regions of the sheath is accomplished
(Thomas et al., 1984).
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FIGURE 1. Adult rat sciatic nerve myelinated axon. The transversely sectioned
axon (Ax), is surrounded by a myelin sheath formed from the spiraled Schwann
cell (SC) membrane. The intraperiod (IL) and major dense lines (DL) of the
sheath can be distinguished. The spiral of the lamellae starts at the internal
mesaxon (mesi) on the inside of the sheath and ends at the outer mesaxon (meso) on
the outside of the sheath. Outside the Schwann cell is a basal lamina (B) which is
in contact with collagen fibres (Col). X100,000 (After Peters et al.,1970).
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FIGURE 2. Peripheral myelin sheath formation. (A) Early in development a
Schwann cell contains both bundles of small and individual larger axons. (B)
Following an increase in Schwann cell numbers due to mitosis, each Schwann cell
associates with a single axon. (C) The internal mesaxon is formed by the apposition of
the enveloping processes. (D) The lips of the enveloping process extend to elongate
the mesaxon and the intraperiod lines begin to form. (E) The major dense line results
from the loss of the cytoplasm from the spiraling process. (F) Compaction of the




FIGURE 3. Schematic diagram of an "unrolled" Schwann cell. The myelin sheath
of a myelinated nerve fibre has been "unrolled" to reveal the presence of cytoplasmic
channels, referred to as Schmidt-Lanterman incisures, which traverse the compact
myelin (N: Schwann cell nucleus) (Adapted from Zigmond et al., 1999).
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Myelin sheaths are interrupted at regular intervals giving rise to a segmental
appearance. These interruptions are the nodes of Ranvier (Ranvier, 1878), regions
of bare axonal membrane exposed to the extracellular fluid, that exhibit electrical
activity (Figure 4). The concentration of axonal sodium channels in these sites,
and the accumulation of potassium channels in the juxtaparanodal and internodal
regions, constitutes the basis of saltatory conduction of nerve impulses leading to a
substantial increase in the velocity of conduction (Figure 4, lower panel)(Bunge
and Fernandez-Valle, 1995). Segments of myelin between adjacent nodes are
termed internodes. They appear as a result of a single myelin-forming Schwann
cell establishing a 1:1 relationship with an individual axon. In mammalian fibres
the internodal segments range in length from 200-250 //m to 1500 /<m exhibiting a
direct relationship between their length and the diameter of the axon. The larger
the fibres, the longer the internodes they display (Young, 1942) (Thomas, 1955).
The origin of the relationship between internodal length and axon diameter has
been attributed to the stage of development at which myelin sheaths are acquired.
Axons destined to have larger final diameters in the adult are myelinated first so
they have longer internodes than smaller axons. The earlier onset of myelination in
larger fibres is believed to fix the total number of Schwann cells along the length of
the axon by inhibiting further cell division. Any subsequent increase in the length
of the axon following the initial deposition of myelin segments involves only an
increase in the length of existing internodes and not the addition of new ones














FIGURE 4. The Node of Ranvier in the peripheral nervous system.
Longitudinal section of the nodal region of a myelinated axon of an adult rat sciatic
nerve.(upper panel) The nodal region (Nd) of the axon (Ax) is flanked by pockets
of paranodal cytoplasm (P) and it is covered by processes (arrows) from the
Schwann cell (SC). The microtubles (m) and neurofilaments (nf) of the axon can be
seen as well as the arrangement of the endoneurial collagen fibres (Col) X 110,000
(After Peters et ah, 1970). (lower panel) Schematic diagram of the same node. Na
channels are clustered in the nodal area, whereas K channels accumulate at the
juxtaparanodal region. This distribution allows saltatory conduction of action
potentials to occur (Adapted from Sneil, 1997).
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The thickness of the myelin sheath has also been observed to be related to the
thickness of the axon. Larger diameter axons possess thicker sheaths of myelin
(Friede and Miyagishi, 1972). Although early in peripheral nerve myelination there
is little correlation between these two parameters, a ratio is established later, during
myelin sheath growth, that becomes relatively constant over a wide range of fibre
diameters (Fraher, 1976) (Webster et al., 1987).
The myelin spiral terminates on the outside of the sheath at the external
mesaxon and on the inside of the sheath at the internal mesaxon. In mature
compact myelin, intraperiod lines are observed under the electron microscope
where two areas of Schwann cell plasma membrane appose each other at the
extracellular surfaces of the mesaxons, thus closing the 12-14 nm gap to 2.0-2.5
nm. These lines alternate with major dense lines which are produced by the fusion
of the cytoplasmic or inner faces of the same pair of plasma membranes (Peters et
al., 1970). The number of the major dense lines (and intraperiod lines) present in a
myelin sheath corresponds to the number of times that a Schwann cell has
encircled the axon. The fact that large diameter axons possess thicker myelin
segments and thus a greater number of membrane turns has been performed,
implies that axons may regulate the action of Schwann cells and influence the
process ofmyelination (Bunge et al., 1986).
1.2.1.2 The structure and chemical composition of PNS myelin
The majority of the original observations concerning the composition of myelin
were carried out on material obtained from white matter of the central nervous
system due to the ease of its extraction without the presence of contaminating
fractions. It was found that CNS myelin possessed a number of features that
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distinguished it from other cellular membranes, such as a higher lipid to protein
ratio, a large proportion of cholesterol and galactosphingolipid, the presence of
relatively saturated long chain fatty acids and an apparently relatively simple
protein composition (Thomas et al., 1984).
Subsequent studies of PNS myelin revealed differences in its constitution
compared to the CNS myelin despite their apparent similarity in structure and
function. It was discovered that the two types of myelin differ both in protein and
lipid composition. PNS myelin contains a much larger proportion of sphingomyelin
and is much richer in glycoprotein.
The major proteins of myelin were initially thought to be structural in nature but
subsequent studies revealed additional roles for these proteins. The fact that they
tend to be strongly conserved among the higher vertebrates implies their potential
involvement in the formation and maintenance of the myelin sheath. Most of these
proteins are known to exist as isoforms derived from alternative splicing (Braun,
1977) (Figure 5).
The major integral membrane protein of peripheral nerve myelin is the PO
protein, a member of the immunoglobulin superfamily, characterised as such due
to the presence of an Ig-like domain. PO accounts for over 50% of the total protein
in compact myelin. It is a glycoprotein with a molecular mass of 28 kDa. It is
thought to interact homotypically on apposed Schwann cell extracellular membrane
surfaces at the intraperiod line, thus playing an important role in myelin
compaction (D'Urso et al., 1990) (Filbin et al., 1990). It may also support the
stabilisation of the major dense line via interactions of its highly charged
intracellular portions with the phospholipid head-group of apposed membranes.
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A group of small (12-22 kDa) peripheral membrane proteins localised in the
major dense line, are the myelin basic proteins (MBPs). They are involved in the
process of the apposition of the cytoplasmic membrane regions that gives rise to
the major dense line and they constitute 5-15% of the protein content (Lees and
Brostoff, 1984). Their absence from shiverer mice indicates their importance in the
formation of compact myelin. Shiverer mice are homozygous for a recessive
mutation which results from deletion of five of the six exons of the MBP gene
(Molineaux et al,, 1986) (Montague et al., 1999). The animals display deficient and
abnormal myelination. They experience tremors and convulsions and tend to have a
short life span. The number of Schmidt-Lanterman incisures in shiverer mutants
has been found to be more than double compared to that of normal PNS myelin
sheaths, which suggests that MBPs may play a critical role in the process of
compaction of the sheath (Gould et al., 1995).
Peripheral myelin protein 22 (PMP22) is a 22 kDa protein that contributes a
further 2-5% of PNS myelin protein. Although its deduced amino acid sequence
predicts a protein of 17 kDa, the presence of a single N-linked glycosylation site
results in the increased Mr value of 22 kDa by SDS-PAGE. PMP22 is membrane-
associated, with a rather complex structure comprising four transmembrane
domains, two extracellular loops, one intracellular loop and two short intracellular
tails which represent the N- and C- termini respectively. It is a very hydrophobic
protein localised to compact myelin (Thomas et al., 1984). Its expression is
dependent upon axonal contact and is affected by intracellular levels of cAMP.
Elevation in intracellular cAMP levels leads to upregulation of Pmp gene
expression in cultured Schwann cells (Spreyer et al., 1991) (Pareek et al., 1993).
Point mutations in the Pmp gene and gene dosage, as supported by transgenic
mouse models result in peripheral neuropathies such as Charcot-Marie-Tooth type
1A (CMT1A), Dejerine-Sottas syndrome (DSS) and hereditary neuropathy with
liability to pressure palsy (HNPP) (Lupski et al., 1991) (Roa et al., 1993) (Chance
et al., 1993). The effects of these mutations have suggested that PMP22 plays a
vital role in myelin formation and may also be involved in the regulation of the
thickness and the maintenance of the myelin sheath (Lupski, 1999; Maef and Suter,
1999).
One of the minor but potentially important myelin proteins involved in the
early events of myelination is myelin-associated glycoprotein (MAG) which
exists in two isoforms of 67 and 72 kDa termed, respectively, S-MAG and L-
MAG. MAG is present in both the CNS and PNS constituting about 0.1% of the
total protein. In the PNS it is specifically localised to the periaxonal membranes,
Schmidt-Lanterman incisures, paranodal loops and the outer mesaxon, but it is not
present in compact myelin (Sternberger et al., 1979) (Trapp and Quarles, 1982).
Immunocytochemical and biochemical approaches in Schwann cell-neuron co-
cultures have revealed that MAG expression precedes the development of the
myelin sheath and its removal from the Schwann cell membrane is necessary to
allow myelin compaction, mediated by P0, to occur (Owens and Bunge, 1989).
However, mice that lacked a functional MAG gene (Mag null) generated by
homologous recombination, were able to form myelin in both the CNS and PNS
displaying phenotypes with no significant abnormalities in young animals (Li et al.,
1994) (Montag et al., 1994). At later stages of development, however, (8 months of
age) animals appeared to exhibit a phenotype w ith axon and myelin degeneration in
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30% of peripheral nerve fibres (Fruttiger et al., 1995). These observations lead to
the assumption that MAG expression is not necessary in the initial stages of axonal
ensheathment and spiralisation but is involved in the maintenance of the myelin
sheath. The two major functions ascribed to MAG include maintenance of the
structural integrity of periaxonal regions of the myelin sheath and mediation of
intercellular interactions (Martini and Schachner, 1986) (Trapp et al., 1984b).
MAG is also thought to be responsible for the formation and stabilisation of the 12-
14 nm Schwann cell-cytoplasmic periaxonal collar (Trapp et al., 1984a).
Proteolipid protein (PLP) is the principal integral membrane protein of CNS
myelin (50% of total protein) but contributes less than 1% to the PNS myelin
protein content. Alternative splicing of the Pip gene gives rise to two isoforms; a
30 kDa isoform commonly referred to as PLP and a smaller isoform, DM-20, with
a molecular mass of 26 kDa. DM-20 predominates in the PNS and is found in the
cytoplasmic regions of the internode, the satellite cells of cranial, spinal and
autonomic ganglia as well as ensheathing cells of the olfactory bulb (Campagnoni
et al., 1992). Unlike DM-20, the larger PLP isoform is localised to the perinuclear
regions of myelin- forming Schwann cells. Neither isoform has been observed to
be present in compact myelin.
Protein P2, whose concentration appears to be highly variable among species
(1% total myelin protein in rodents, 14% in humans), is a 15 kDa protein located in
the major dense line. It is believed to play a significant role in fatty acid elongation
or transport during myelination, as it is closely related to Iipid-binding proteins
(Narayanan et al., 1988).
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More than 40 enzymes have been identified in CNS myelin including a 2', 3'-
cyclic-nucleotide phosphodiesterase (CNPase). It has been reported that the lipid
and protein components of myelin have measurable turnover rates even during the
period that follows active myelination (Benjamins and Smith, 1977). More recent
studies have revealed that myelin membranes possess receptor and signal
transduction activities in addition to related enzyme activities. The former category
includes high-affinity muscarinic cholinergic receptors and G-proteins while the
latter involves adenylate cyclase, phospholipases as well as enzymes that
participate in phosphoinositide metabolism (Bernier et al., 1989) (Boulias and
Moscarello, 1989) (Braun et al., 1990) (Golly et al., 1990). A further protein
associated with uncompacted myelin is eonnexin-32 (Cx32). This is a gap junction
protein whose structure resembles that of PMP22 featuring four transmembrane
domains and intracellular carboxy and amino-termini (Peters et al., 1970).
Although it appears to play an important part within myelinating Schwann cells, as
its absence results in peripheral demyelinating neuropathy (CMT1X), further
studies are required to establish its exact function in myelinating glia.
The adhesive glycoprotein E-cadherin has also been detected at the paranodal
loops, inner and outer mesaxons and in Schmidt-Lanterman incisures (Bunge et al.,
1989(b)) (Fannon et al., 1995) (Hall and Williams, 1970). It is a member of a
superfamily of calcium-dependent proteins, present in adherens-type junctions, that
are involved in tissue differentiation and structure. Their roles include cell
recognition and segregation, morphogenic regulation and tumour suppression
(Magee and Buxton, 1991) (Grunwald, 1993). E-cadherin has been reported to be
absent in the Schwann cell-axon interface or between two Schwann cells. Instead,
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it has been observed to mediate homophilic (autotypic) interactions between
plasma membranes synthesised by a single Schwann cell (Fannon et al., 1995).
Although it is not directly involved in the process of myelination, it has been
shown to be necessary for the stabilisation of the structure of individual Schwann
cells (Fannon et al., 1995).
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FIGURE 5. Ultrastructural and molecular properties of myelin. A cutaway view
of the nodal region of a myelinated sheath shows the higher density of the axoplasmic
neurofilaments at the node of Ranvier and displays the alternating layers of intraperiod
(IPL) and major dense lines (MDL). The major dense line contains specific myelin
proteins: MAG, myelin-associated glycoprotein; MBP, myelin basic protein; PO,
protein zero, PMP-22, peripheral myelin protein 22 (After Shepherd, 1994).
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1.3 ROLE OF THE SCHWANN CELL IN PERIPHERAL MYELINATION
Schwann cells associate with axons in the peripheral nervous system. They
ensheathe all peripheral nerve fibres, thus forming an interface between the neural
tissue and the surrounding connective tissues. This arrangement provides a partial
intervening basal lamina and ensures that the peripheral nerve contains
considerable amounts of connective tissue that confer considerable mechanical
strength. They exist in two types: myelin-forming Schwann cells that elaborate a
myelin sheath around axons, and non-myelin-forming cells, which associate with
smaller axons.
1.3.1 Embryological development of the Schwann cell
Both myelinating and ensheathing Schwann cell types arise from a common
precursor. They are derived from the neural crest, a longitudinal cluster of
ectodermal cells located near the dorsal edge of the embryonic neural tube (lessen
and Mirsky, 1992) and they appear at a very early stage during the development of
peripheral nerve accompanying outgrowing bundles of axons.
The Schwann cell lineage involves the formation of two intermediates: the
Schwann cell precursor, detected in rat at embryonic day 14 and 15 (E14 and
El5) and in mouse at E12 and El3, and the immature Schwann cell found from
E17 in rat (mouse El5). Differentiation of the immature cell type starts just after
birth, with mature myelin-forming cells appearing before the non-myelinating type




FIGURE 6. The Schwann cell lineage. Early migrating neural crest cells give rise to
Schwann cell precursors, which subsequently form immature Schwann cells. These
are able to differentiate into either myelin-forming or non-myelinating mature
Schwann cells (After Jessen, 1999).
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1.3.2 Determination of the Schwann cell phenotype
Signalling from axons is thought to be responsible for the differentiation of
the neural crest cells to Schwann cell precursors, and those precursor cells to the
myelin-forming and non-myelin forming phenotypes. One view supports the
"lineage neutrality" of neural crest cells, according to which axorial contact is
required to trigger their ability to support glial or neuronal differentiation (Mirsky
and Jessen, 1996). Neuregulins represent alternatively spliced products of the same
gene that are important candidates as Schwann cell lineage regulators. P-neureguiin
has been considered as an axonal signal required for precursor survival. It is also
believed to function as mitogen and survival factor for perinatal Schwann cells.
An alternative hypothesis supports the idea that crest cells have entered the
glial lineage prior to their association with axons. This is based on the observation
that migrating crest cells express PO, which is considered as a Schwann cell-
specific protein, indicating that crest cells may be able to select the glial pathway
very early in development (Mirsky and Jessen, 1996).
Myelin-forming Schwann cells express MAG, PO, MBP and PMP22 whereas
ensheathing cells synthesise, instead, glial fibrillary acidic protein (GFAP), neural
cell adhesion molecule (N-CAM), nerve growth factor receptor (NGFR), growth
associated protein 43 (GAP-43) and LI, an immunoglobulin-related adhesion
protein. Both subtypes express lipids including galactocerebroside (Martini and
Schachner, 1986) (Mirsky et al., 1986) (Jessen and Mirsky, 1991).
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1.3.3 Factors involved in Schwann cell proliferation and differentiation
Schwann cells potentially proliferate at least twice during their life-time: early
in development in order to increase in number and ensheathe the rapidly growing
nerve fibre and subsequently after nerve injury. Schwann cell proliferation is
influenced by a number of factors. These include axonal mitogens, components of
the extracellular matrix (eg. fibronectin), soluble factors such as cAMP and agents
that increase intracellular cAMP levels, glial growth factor as well as myelin itself.
It has been suggested that a mitogen is released from myelin via lysosomal
processing which follows the ingestion of myelin released during wallerian
degeneration. Myelin that lacked MBPs was observed to be devoid of mitogenic
activity (Baichwal and De Vries, 1991).
A number of transcription factors are believed to be involved in the
differentiation of Schwann cells. The POU-domain factors Oct-6 (also known as
Tst-1 and SC1P) and Egr-2 (Krox-20) are expressed in Schwann cells and play
important roles in the development of the myelin-fonning lineage. Inactivation of
either Oct-6 or Egr-2 in mice, has been found to block the development of the
Schwann cell at a pro-myelinating stage. Schwann cells that associate with large
diameter axons, are able to envelop but not perform the spiralisation process, thus
failing to generate myelin. This block in myelination observed in Oct-6 knock out
mice is temporary, which implies a role of additional POU-containing transcription
factors in Schwann cells that are able to replace the function of Oct-6 (Jessen and
Mirsky, 1999).
The zinc-finger protein Egr-1 (Krox-24) and SOX-10, a member of the SRY-
like HMG (high mobility group) domain class, are also considered as transcription
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factors with a role in Schwann cell development. Egr-1 is expressed only by
immature and non-myelin forming Schwann cells. Another transcription factor,
Pax-3, may have a role in controlling gene expression in non-myelin forming
Schwann cells, since it is able to activate GFAP, N-CAM, LI and NGFR
promoters. The leucine zipper transcription factor c-Jun is expressed by Schwann
cells and its levels appear to rise, following disruption of axonal contact. In
combination with SV40 T antigen, it represses PO expression (Bharucha et al.,
1994).
1.3.4 Axon-Schwann cell interactions determine the length of the myelin
segment and induce the formation of a basal lamina
Interaction of axons with Schwann cells influences axonal diameter and also
determines the length of the myelin internode. Experiments performed in tissue
culture have demonstrated an increase in axon diameters in areas of the culture that
contain Schwann cell ensheathment as opposed to adjacent areas in the same
culture where axons are not ensheathed (Windebank et al., 1985).
The function of Schwann cells is largely dependent upon the formation of a
basal lamina which is induced by axonal contact. When Schwann cell basal lamina
assembly is prevented, the Schwann cells are unable to ensheathe or myelinate
axons (Bunge et al., 1982). Although the precise reason for this observation is
unknown, it is believed that the presence of a basal lamina permits polarisation of
the Schwann cell plasmalemma in a way that the abaxonal and adaxonal surfaces
are restricted to contact with components of the extracellular matrix and the axon
respectively. This polarisation, in conjunction with potential signaling to the
cytoskeleton, is associated with cell shape changes that accompany ensheathment
(Bunge et al., 1982). Neurons affect the production of a basal lamina through a
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number of signals that regulate different stages in the synthesis, secretion and
assembly of basal lamina constituents (laminin, type IV collagen and heparan
sulfate proteoglycan) (Bunge et al., 1986) (Clark and Bunge, 1989).
1.3.5 Schwann cells and their precursors control neuronal survival and
development
Trophic support from Schwann cells and their precursors is believed to be
necessary for the survival of neurons. Loss of dorsal root ganglia (DRG) as well as
sensory and motor neurons in Erbb knockout mice, that lack Schwann cell
precursors and mature Schwann cells, was observed during the second half of
embryonic development (Riethmacher et al., 1997). The number of DRG and
motor neurons in these animals displayed an 80% reduction by E14 and E18,
respectively. The absence of ERBB3 protein in neurons themselves was not
responsible for their depletion, as suggested by data obtained from chimeric mice.
It has been proposed that DRG survival depends, initially, on glial-derived signals
from Schwann cell precursors, and subsequently, once the axons have established
contact with their targets, on signals originating from those targets. In the case of
motor neurons, where cell death was observed after the neurons had reached their
targets, it is possible that glial-derived and target-derived signals act
simultaneously and not sequentially, as in DRG. It is also believed that the glial
signal responsible for motor neuron survival is derived from immature Schwann
cells (Jessen and Mirsky, 1999).
A single or a number of neuronal survival factors acting synergistically, may
be required. Glial cell-line derived neurotrophic factor (GDNF), found in Schwann
cell precursors and immature Schwann cells in embryonic nerves, is considered a
good candidate for neuronal survival factor. Mice that lack GDNF lose
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approximately 20% of their motor neurons by birth (Moore et al., 1996).
Neurotrophin 3 (NT3) is thought to act as a trophic signal derived from Schwann
cell precursors. It is expressed by Schwann cells at birth and by tissues associated
with ganglia in the embryo. Experimental evidence suggests that NT3 acts to
support DRG neurons before target innervation but there is no proof that the
survival of early DRG neurons depends upon an NT3-containing signal from
Schwann cell precursors (Jessen and Mirsky, 1999).
Myelinating Schwann cell-derived signals have been implicated in the
regulation of axonal structure and function. The formation of the three types of
nerve sheath that serve as protection barriers for axons, namely the epineurium,
perineurium and endoneurium, is induced by Desert Hedgehog, a signalling
molecule secreted by Schwann cells (Parmantier et al., 1999).
1.3.6 Schwann cells regulate their own survival via an autocrine
mechanism
Following injury, Schwann cells distal to the site of assault are deprived of
axonal contact but must survive in order to guide axonal re-growth and ensure
nerve regeneration by providing the necessary trophic factors. Schwann cell
survival in the absence of axons is accomplished by an autocrine loop which
operates in mature Schwann cells but not their precursors. This autocrine system is
likely to include a number of growth factors such as insulin-like growth factor 2
(1GF2), platelet-derived growth factor BB (PDGF-BB) and NT3 (Meier et al.,
1999). It is not mitogenic for Schwann cells and unable to sustain precursor
survival. Further experiments for the characterisation of this autocrine survival
signal would be required.
1.4 PERIAXIN: A PROTEIN EXPRESSED BY MYELIN- FORMING
SCHWANN CELLS
Axonal contact triggers Schwann cell differentiation but the morphological
changes that take place to allow ensheathment and myelination to occur are
probably regulated by the cell cytoskeleton and the proteins associated with it. In
an attempt to identify Schwann cell cytoskeletal and cytoskeleton-associated
proteins with expression and localisation patterns regulated developmentally during
differentiation and myelination, periaxin was isolated and was subsequently
detected in early post-natal nerve at the periaxonal membranes of myelin-forming
Schwann cells (Gillespie et al., 1994).
After completion of the spiralisation process as the myelin sheath begins to
mature the localisation of periaxin shifted to the abaxonal membranes (Figure 7).
This implied involvement of the protein in the stabilisation of the mature sheath
possibly by participating in membrane-protein interactions. Within the Schwann
cell it was found in the periaxonal membranes, paranodal loops and the Schmidt-
Lanterman incisures but it was absent from compact myelin (Gillespie et al., 1994).
Expression of periaxin appeared to be under the control of axon-Schwann cell
interactions, preceding that of the major myelin proteins PO, MBP and possibly
even MAG (Salzer et ah, 1980(b)) (Scherer et ah, 1995).
FIGURE 7. Periaxin localisation shifts to the abaxonal membranes as
the myelin sheath begins to mature. (A) Longitudinal section of P3
sciatic nerve (initial stages of myelination). Immunoelectron microscopy
reveals that the protein (gold particles) is abundantly detected in both the
adaxonal and abaxonal membranes of the myelin sheath. (B) However, by
P28 in a rat trigeminal nerve section, the protein appears to have shifted to
the abaxonal membranes. Arrows indicate the axolemma at the interface
of the axon (a) and the compact myelin sheath (m) which is surrounded by
a basal lamina (between arrowheads) (After Scherer et al.,1995).
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1.4.1 Pcriaxin isoforms and the structure of the periaxin gene
The structure of the murine periaxin gene is shown in Figure 8. It is composed
of 7 exons interrupted by 6 introns and spans 20.6 kb. Two isoforms of periaxin (L-
periaxin 147 kDa and S-periaxin 16 kDa) have been identified, encoded by 4.6 and
5.2 kb mRNAs respectively. The smaller isoform arises by a relatively rare
alternative splicing event which involves the retention of intron 6. A large fusion
exon is generated, which comprises exon 6, intron 6 and exon 7. This introduces
an in-frame stop codon that encodes a 21 amino acid C-terminus unique to S-
periaxin. Intron retention is dependent upon the presence of suboptimal splice sites
at the 5' and 3' ends of the intron. These sequences differ from the consensus
sequences that promote splicing and require enhancer elements in the downstream
exon, termed exonic splice enhancers (ESEs), for splicing to occur (Dytrych,
1997).
1.4.2 Primary structure and developmental regulation of periaxin
L- and S- periaxin contain a single PDZ (PSD95/discs large/zona occludens)
domain which is typically present in proteins that interact with the cytoplasmic tail
of plasma membrane proteins and with the cortical cytoskeleton. This suggests that
the L-isoform which is localised to the periaxonal membranes might be implicated
in signal transduction pathways whereas the cytoplasmic distribution of the S-
isoform implies the existence of other factors that affect PDZ-protein binding. L~
periaxin, furthermore, contains a basic region near its N-terminus (amino acids
118-196), a region of a series of repeats (432-725 aa) and a highly acidic domain
towards its C-terminus (1036-1163 aa). The domain structure of L- and S-periaxin
is shown in Figure 9.
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FIGURE 8. The structure of the murine periaxin gene. The murine periaxin
gene comprises 7 exons (shown as solid vertical lines). Coding exons (4,5, 6 and 7)
are indicated by light blue. Intron 6, retained in S-periaxin is indicated by yellow.
Arrows point to the position of Stop codons for each isoform. Exon sizes (in kb)












Unique 21 aa C-terminus
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FIGURE 9. Domain structure of L- and S-periaxin. (Amino acid residues
shown).
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The basic domain is responsible for nuclear targeting of the protein which has
been observed both in vivo and in vitro in embryonic Schwann cells. The nuclear
localisation signal (NLS) of L-periaxin is tripartite (Sherman and Brophy, 2000).
Nuclear expression is developmental!)' regulated and ceases after El7.5. The repeat
region consists of a pentameric core (aliphatic non-polar: proline: glutamic acid or
aspartic acid: aliphatic non-polar: variable; either alanine or glutamine), which is
interrupted by a tripeptide spacer (leucine: proline: lysine). The function of this
region is unclear (Sherman. 1998). It appears to be less flexible than the rest of the
polypeptide and it has been suggested to act as a spacer that keeps the potentially
functional basic and acidic domains separated (Gillespie et al., 1994). Acidic
domains have been widely implicated in protein-protein interactions (Kobe and
Deisenhofer, 1995a). Analysis of the primary structure by hydrophobicity plots has
indicated the absence of any transmembrane domains which suggests that periaxin
is not an integral membrane protein. Despite the presence of a single potential N-
glycosylation site, the protein was not found to be glycosylated (Gillespie et al.,
1994).
Multiple potential phosphorylation sites are also present whose role is currently
being investigated. It appears to display a rather linear conformation, with very-
little secondary structure, which might point to a role in coupling cortical proteins
to the cytoskeleton.
1.4.3 L-periaxin participates in a dystroglycan transmembrane complex
Dvstroglycan associates with dystrophin (or its homologue utrophin),
sarcoglycans, sarcospan, syntrophins and dystrobrevin to form the dystrophin
glvcoprotein complex (DGC) (Winder. 2001). In both skeletal muscle and the PNS,
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the DGC links extracellular matrix molecules to the cytoskeleton. Dystrophin-
related protein 2 (DRP2) is a member of the dystrophin family. It comprises two
spectrin-like repeats, closer to the N-terminus, followed by a WW domain, two EF
hands, a ZZ domain and two coiled- coil regions proximal to the C-terminus. The
two spectrin-like repeats of DRP2 interact with the three basic subdomains of L-
periaxin, BD1 (aa 116-145), BD2 (aa 146-176) and BD3 (aa 176-196) which have
been characterised as components of the tripartite NFS of the protein (Sherman et
al., 2001). DRP2 was also found to associate with (3-Dystroglycan and hence
localise to the Schwann cell plasma membrane. A complex that contains L-
periaxin, DRP-2, «- and (3- dystroglycan, utrophin and the truncated form of
dystrophin. Dpi 16, was isolated from peripheral nerve lysates by immunoaffinity
chromatography (Sherman et al.. 2001). L-periaxin does not bind directly to Dpi 16
and utrophin, which is indicative of their participation in a distinct DGC.
Association of L-periaxin with DRP2 is essential for the stability of the DRP2
complex (Figure 10). Homodimerisation of L-periaxin via its PDZ domain and
interaction with DRP2 through the basic region, clusters the complex to the cortical
cytoskeleton and stabilises the DRP2 complex. In the absence of L-periaxin, in Prx
null mice, the majority of the DRP2 is lost and the remaining is not detectable in
clusters but diffuse in the cytoplasm. The dependency of the correct localisation of
DRP2 on L-periaxin suggests a role of the latter as a scaffold for the assembly of
the complex. (3-Dystroglycan, utrophin and Dpi 16 expression and localisation are
independent of L-periaxin. Prx knockout mice seem to be able to form a myelin
sheath, which is however unstable, leading to the development of a late-onset
demyelinating neuropathy (Gillespie et al., 2000). Because myelin instability in Prx
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null mice is observed following initial formation of the sheath, it is suggested that
the L-periaxin-DRP2 complex is implicated in the regulation of terminal stages of
the myelination process. L-periaxin translocates from the adaxonal to the abaxonal
membrane of the Schwannn cell at a later stage of myelination when the sheath
begins to mature, at a position where it could associate with the cortical DRP2
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FIGURE 10. The I)RP2-L-periaxin- dystroglycan complex at the Schwann cell
plasma membrane. Periaxin associates via its basic domain (BD) with the spectrin-
like repeats of DRP2 which also associates with (Fdystroglycan. Clustering of DRP2
to the membrane could be a consequence of L-periaxin homodimerisation through its
PDZ domain. SG, sarcoglycans, a and (3 dystroglycan (After Sherman, 2001).
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1.4.4 Periaxin null mice display peripheral deniyelination and neuropathic
pain
The Prx gene was inactivated by homologous recombination in mice, in an
effort to assess the effects of lack of periaxin on the formation and stabilisation of
the PNS myelin. The Schwann cells of these mice were able to generate a myelin
sheath in an apparently normal fashion. Light microscopy on peripheral nerves of
6-week old homozygous Prx mice, revealed focal thickenings referred to as
tomacula and infoldings of internodal myelin. However, the levels of major myelin
proteins such as PO. MAG and MBP were found normal when assessed by Western
Blot on sciatic nerves from mutant mice, supporting the view that demyelination at
this age was not extensive. The phenotype of the animals until up to 6 weeks of age
also appeared normal, although they displayed a distinctive clasping of their
hindlimbs when lifted by the tail, from about 4 to 6 weeks and some animals
showed a slight tremor. Older mutant mice (6-9 months of age), however,
displayed an unsteady gait and a difficulty to support themselves on their
hindlimbs. Electron microscopy revealed extensive demyelination in sensory,
motor and autonomic nerves. Disruption of the normal function of sensory nerves
leads to the perception of neuropathic pain (Devor, 1989). Periaxin knockout mice
display symptoms of mechanical allodynia and thermal hyperalgesia which could
be reversed upon intrathecal administration of the selective N-methyl D-aspartate
(NMDA) receptor antagonist, 3-([R] 2-carboxy-piperazin-4-yl (-propyl-1 -
phosphonic acid ((R)-CCP), indicating that some form of central change may be
implicated in the Prx null phenotype that could be responsible for the manifestation
of neuropathic pain (Gillespie et al., 2000).
1.4.5 Mutations in human periaxin arc responsible for Dejerine- Sottas
neuropathy (DSN) and Charcot-Marie-Tooth Disease 4F (CMT4F)
DSN and CMT are heterogeneous inherited peripheral myelinopaties. DSN
results from dominant mutations in PMP22, PO, and EGR2, with recessive
mutations in PMP22 also documented as cause for the disease (Hayasaka et al.,
1993) (Roa et al., 1993). Loss- of- function mutations in human Prx result in
sporadic and autosomal recessive DSN with phenotypes of reduced conduction
velocities and onion bulb formations (Boerkoel et al., 2001).
CMT constitutes a group of inherited peripheral motor and sensory
neuropathies. The clinical symptoms of the disease are manifested as chronic distal
weakness with progressive muscular atrophy and sensory loss in distal extremities
(Guilbot et al., 2001). Inheritance of CMT may be autosomal dominant, autosomal
recessive (ARCMT), or X-linked, A non-sense mutation in human L-periaxin,
which converts Arginine at position 196 into a STOP codon (R 196X), gives rise to
a truncated molecule that comprises only the PDZ and basic domains. This
mutation is believed to be responsible for the onset of CMT 4F, a form of ARCMT,
which maps to human chromosome 19q 13 at the same locus where the human Prx
gene is mapped (Guilbot et al., 2001). Non-sense frameshift mutations have been
described, which delete the acidic domain of human L-periaxin (Boerkoel et al.,
2001). A mutation in Cysteine 715, which converts it to a STOP codon (C715X)
gives rise to L-periaxin that lacks the acidic domain and the rest of the C-terminus.
Patients who are homozygous for this mutation, display an autosomal recessive
demyelinating neuropathy similar to CMT 4F. The neuropathy has a very early
onset and is strikingly sensory with a relatively mild motor weakness (A. Williams,
personal communication). The phenotype of human demyelinating neuropathies
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caused by Prx mutations is similar to the phenotype observed in the Prx null mice.
Histopathology from the sural nerve obtained from a CMT4F patient revealed
demyelination, onion bulb formation and the presence of supernumerary Schwann
cells, which are features seen in the Prx null mice (Guilbot et al., 2001). This
implies that these animals could prove valuable in the study of the molecular
pathophysiology of disease. New candidate genes for other autosomal recessive
forms of CMT may be identified by deduction of the rest of the components of the
periaxin complex.
1.5 DETECTION OK SPECIFIC INTERACTIONS BETWEEN
PROTEINS: THE YEAST-TWO HYBRID APPROACH
The yeast-two hybrid is a molecular genetic test for protein interactions used to
identify proteins that interact with a protein of interest (Gietz et al.. 1997). This
assay relies on the modular domain structure of eukaryotic transcription factors,
many of which comprise two physically distinct and separable domains: the DNA-
binding domain and the transcriptional activation domain. The former localises the
transcription factor to specific DNA sequences upstream of the genes to be
regulated and the latter interacts with the RNA polymerase complex resulting in
transcriptional initiation. The interaction between two candidate proteins is tested
by producing a fusion protein that consists of the DNA binding domain coupled to
the DNA sequence of a target protein ("bait") and a construct that comprises the
activation domain fused to another protein ("prey" fusion protein). Interaction of
the two fusion proteins will result in reconstitution of a functional transcription
factor that will initiate the transcription of a reporter gene.
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The yeast two-hybrid genetic system was devised to study interactions between
proteins by taking advantage of the properties of the GAL4 protein of the yeast
Saccharomyces cerevisiae (Fields and Song. 1989). This protein controls
transcription of genes whose products are involved in the metabolism of galactose.
GAL4 binds to an upstream activating sequence (UASg) and activates transcription
of genes under the control of the GAL1 promoter in the presence of galactose. To
generate hybrid proteins containing parts of the GAL4 protein, the GAL4 DNA
binding domain is fused to a protein X and the GAL4 activation domain is fused to
a protein Y. This permits the assessment of interaction between those two proteins.
The activation of the reporter gene lacZ is an indicator of the formation of a
protein-protein complex that brings the GAL4 domains in close proximity to allow
transcription (Figure 11).
Another reporter gene present in yeast is H1S3 whose expression permits growth
on media that lack the amino acid histidine. This gene is normally under the control
of the native yeast H1S3 promoter. However, in yeast strain CG1945 the entire
HIS3 promoter has been replaced by the entire GAL1 promoter which links the
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FIGURE 11. The yeast two-hybrid assay for detection of protein-protein
interactions, (a) The native yeast transcription factor GAL4 binds to an upstream
activation sequence in the nucleus and induces transcription of a reporter gene (BD:
DNA dindind domain, AD: transcription activation domain). Hybrid proteins
containing either the DNA binding domain (b), or the transcriptional activation domain
(c), are unable to induce transcription independently, (d) Interaction between hybrid
proteins reconstitutes the activity of the native transcription factor and results in
activation of the reporter gene.
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1.6 INTRACELLULAR CONTROL OF PROTEIN ABUNDANCE
1.6.1 The uhiquitin pathway of protein degradation
Regulation of the abundance of cellular proteins is essential for cell survival
and normal function. To overcome the dangerous effects of protein accumulation
the cell employs various mechanisms that act to prevent aggregation, attempt
refolding or promote degradation of abnormal proteins. A highly discriminative,
energy dependent pathway operates in the cytoplasm to ensure removal of
damaged proteins. This pathway, mediated by the protein ubiquitin, is a complex
cascade of reactions that involve multi-enzyme complexes whose action is
temporally and tightly controlled and plays an important part in a broad range of
cellular processes. In addition to destroying damaged proteins, the pathway targets
many naturally short-lived polypeptides and proteins that are involved in regulatory
processes. Conjugation to ubiquitin, in the majority of cases, targets substrates for
degradation by the 26S proteasome, an energy dependent self-compartmentalised
protease (Hochstrasser, 1996). Ubiquitination of certain plasma membrane proteins
has been found to be responsible for their internalisation and subsequent
degradation by the lysosome (Hicke and Riezman, 1996). It is not yet known how
the proteasomal and endocytic signals conferred by ubiquitin are distinguished
(Thrower et ah, 2000). It has been proposed that the length of the Ub-chain may be
the determinant of such distinction. A minimum of four Ub residues in a chain is
thought to be required for proteasomal recognition, whereas mono-ubiquitination is
considered responsible for endocytosis (Hicke, 1999). However, the major
ubiquitinated form of neuronal nitric oxide synthase (nNOS) was found to be a
conjugate of one or only a few Ub molecules, and is still degraded by the
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proteasome (Bender et al., 2000). Control of cellular protein levels also occurs via
an unregulated vacuolar pathway that is mediated by lysosomes, endosomes and
the endoplasmic reticulum.
The ubiquitin pathway of protein degradation is responsible for the turnover of
key short-lived regulatory proteins that participate in processes as diverse as the
cell cycle, cellular signalling in response to stress and extracellular signals,
morphogenesis, the secretory pathway, DNA repair and organelle biosynthesis
(Carrano and Pagano, 2001; Maniatis, 1999; Ulrich and Jentsch, 2000; Wiederkehr
et al., 2000).
1.6.2 Discovery of an energy dependent proteolytic process mediated by
ubiquitin
Ubiquitin (Ub) is a 76- amino acid protein that is highly conserved in
organisms as diverse as yeast and humans. Its globular structure may serve to
prevent it from proteolysis during the hydrolysis of its bound proteins (Bebington
et al., 2001). The involvement of ubiquitin in protein degradation and the
mechanism through which the process is accomplished, were discovered by
Hershko and Ciechanover in a series of biochemical experiments in a cell free
system from rabbit reticulocytes (Hershko et al., 1980). The energy requirement of
intracellular protein degradation, in particular that of the enzyme tyrosine amino¬
transferase (TAT) in hepatoma cells, lead Hershko to the assumption that there was
an unknown proteolytic system that utilised energy to ensure high selectivity in the
mechanism of protein degradation, considering that proteolysis per se is an
exergonic process (Hershko, 1996). Their approach was to reproduce ATP-
dependent proteolytic degradation in a cell- free system that had already been
described by Et linger and Goldberg (Htlmger and Goldberg. 1977) and
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subsequently fractionate such a system to deduce the function of its components.
Using lysozyme as an artificial substrate for in-vitro proteolysis, Hershko and co¬
workers deduced that several molecules of ubiquitin form conjugates with the
substrate polypeptide. In their original model, proposed in 1980, conjugation of
ubiquitin was accomplished via the action of a protein amide synthetase. The
protein-Ub conjugate was screened by a "correction" amidase prior to degradation
by a cytoplasmic endopeptidase. An isopeptidase was responsible for recycling Ub
molecules removed from the substrate.
This model has since been modified but the basic principles remain the same.
According to the current information available, the pathway comprises two distinct
steps and requires the co-ordinated action of three classes of enzymes. First, the
target protein is modified by the covalent attachment of ubiquitin molecules and
subsequently degraded by the 26S proteasome complex (Coux et al., 1996).
Ubiquitin is activated through the formation of a thiolester bond between its C-
terminus and the active site cysteine residue of a ubiquitin activating enzyme (El).
It is subsequently transferred to a ubiquitin-conjugating enzyme (E2) which is
either capable of relaying ubiquitin to the substrate by itself, or requires the
participation of a ubiquitin ligase enzyme (E3) (Flershko and Ciechanover, 1998;
Hershko et al., 2000). Association with the substrate is accomplished by the
formation of an isopeptide bond between the C-terminus of ubiquitin (Gly 76) and
lysine residues either on the target protein or on the last Ub residue of a protein-
bound multi-ubiquitin chain. The presence of ubiquitin residues on the substrate
serves as a cue for its recognition by the 26S proteasome whose role is to remove
the ubiquitin tag and degrade the target protein. Prior to its association with the
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proteasome, the protein-Ub conjugate is monitored by a class of thiol proteases that
recognise the C-terminus of ubiquitin. These enzymes form two groups: ubiquitin-
carboxy-terminal hydrolases (Uch) and Ub-specific proteases (UBPs). Their role is
to remove Ub moieties from incorrectly targeted polypeptides (Figure 12).
It is clear that El. E2 and E3 perform the function originally ascribed to protein
amide synthetase, the endopeptidase required for degradation is in fact the
proteasome. A "correction" amidase and the isopeptidase needed for Ub recycling
are members of the Uch/UBP family. The specific role of each of the distinct
components of the ubiquitin/ proteasome pathway will be discussed next.
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FIGURE 12. The ubiquitin/proteasome pathway of protein degradation. (1)
Ubiquitin is activated by the formation of a thiolester bond with an El enzyme,
that requires AIT. (2) Ubiquitin is subsequently ligated to an E2 conjugating
enzyme, in an energy independent manner, releasing El. (3) A class of enzymes
termed E3 ubiquitin ligases, mediates the transfer of ubiquitin residues from E2
to the substrate protein. (4) Ubiquitin C-terminal hydrolases (Uch) and ubiquitin
specific proteases (UBP) remove ubiquitin moieties from erroneously tagged
proteins, in a "proof-reading" mechanism that ensures degradation of
appropriate substrates. (5) Degradation substrates are targeted to the proteasome
to be destroyed in an energy-dependent mechanism. The Ub tag is removed by
proteases of the 19S subunit, and recycled. (6) The 20S core of the 26S
proteasome cleaves the substrate which is released in small peptide fragments or








1.6.3 Components of the ubiquitination machinery
1.6.3.1 El ubiquitin activating enzyme
Initiation of the ubiquitination cascade depends on ubiquitin activation. This
is accomplished via its interaction with an activating enzyme (El) in a reaction that
requires energy in the form of ATP. Reactive lib is then passed on to a carrier
protein (E2). Eukaryotic genomes encode one or at least only a few ubiquitin
activating enzymes (Joazeiro and Weissman. 2000). El enzymes from different
species appear to be highly conserved. The majority possesses a Gly-X-Gly-XX-
Gly motif (where X indicates any amino acid) (McGrath et al., 1991).
1.6.3.2 E2 ubiquitin conjugating enzymes
Activated Ub is bound to a ubiquitin-conjugating enzyme (Ubc) in an energy
independent manner, to be subsequently transferred on to the target protein.
Association with the substrate occurs, most commonly, through the mediation of an
E3 enzyme complex. However, the direct interaction of E2 with the target protein
has also been reported. Such associations have been detected using protein-protein
interaction screening methods and their physiological role remains unclear. An
example of a protein tagged by ubiquitn in the absence of a ligase is Huntingtin
which is ubiquitinated by E2-25 kDa (Kalchman et ah, 1996). A large number of
ubiquitin conjugating enzymes have been identified (13 genes encode E2-1 ike
enzymes in yeast S. cerevisiae) (Hershko and Ciechanover. 1998).
E2 enzymes have been isolated that perform overlapping functions, such as
Ubc2/Rad6 in S. cerevisiae that is required for both DNA repair and the proteolysis
of N-end rule substrates (see section 1.6.3.3). Diverse functions are also performed
by Ubc4 and Ubc5 whose action is needed for the elimination of a number of
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abnormal and normal short-lived proteins (Hochstrasser, 1996). Specific roles of
E2 enzymes have also been described. A mutation in the Drosophila bendless gene
which encodes an H2 enzyme, results in impairment of synaptic connectivity
during development, whereas disruption of the murine UbcM4 gene (homologous
to yeast Ubc4/Ubc5) is responsible for impairment of the placenta's formation
(Harbers et al., 1996; Muralidhar and Thomas, 1993). All E2 enzymes can be
inactivated by mutating the active Cys residue that is used for conjugation to Ub
(Ciechanover, 1998). The identity of E2s and their cognate E3s determines the
stringency of their interactions. Several E2s, such as Ubc4, are able to associate
with more than one E3 enzyme. Conversely, some E3s may interact with several
E2s. The identification of membrane-associated E2s implied their possible
involvement in degradation of abnormal or virus-targeted ER proteins.
1.6.3.3 E3 ubiquitin ligases
E3 ubiquitin ligases mediate the critical step of substrate recruitment to the
pathway. They may either bind the substrate directly or via the intervention of an
adapter molecule. The mechanism of Ub transfer to the substrate also differs
among various E3 enzymes. They either bind Ub by forming a thiolester bond prior
to its transfer to the substrate or facilitate direct transfer of Ub from E2 to the target
by tightly binding E2 and the substrate protein.
To describe the different modes of action of the E3 family of Ub ligases, the
following definition has been proposed bv Hershko and Ciechanover. They define
E3 as an enzy me that binds specific protein substrates, either directly or indirectly
and promotes the transfer of ubiquitin, directly or indirectly, from a thiolester
intermediate to amide linkages with proteins or poly-ubiquitin chains (Hershko and
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Ciechanover, 1998). According to this definition, the known E3s may be classified
in four families: 1. Ligases that recognise substrates following the N-end rule
according to which the metabolic stability of a protein depends on the identity of its
N-terminal residue. The N-end rule pathway operates in organisms as diverse as
yeast and mammals and is also functional in bacteria despite the absence of the
ubiquitination machinery (Varshavsky, 1997). It relies on the existence of N-
degrons, which are a set of degradation signals. They comprise a destabilising N-
terminal residue and an internal lysine which serves as the site of formation of the
Ub chain (Varshavsky, 1996). N-terminal destabilising residues form three groups:
primary, secondary and tertiary (Table 1).
Primary destabilising residues (N-dp) are active upon direct binding to a
ubiquitin ligase enzyme (E3). They are subdivibed into Typel (N-dpl) and Type 2
(N-dp2) according to the type of E3 binding site they recognise. Type 1 residues are
basic (arginine, lysine, histidine) whereas Type 2 includes bulky hydrophobic
amino acids (phenylalanine, leucine, tryptophan, tyrosine, isoleucine).
Secondary destabilising residues (N-ds), require association with Arg-tRNA-
protein transferase to confer their activity. These residues are arginine and lysine in
E. coli, aspartic acid and glutamic acid in S. cerevisiae, aspartic acid, glutamic
acid and cysteine in mammalian cells.
Tertiary destabilising residues (N-d') are asparagine and glutamine, whose
activity depends on accessibility to N-terminal amidohydrolase.
The pathway operates in both the cytosol and the nucleus and results in protein











D, E, R, K. H
D, E N.Q
TYPE 2
L, F, Y, 1, W
Table 1. The N-end rule. Primary, secondary and tertiary destabilising
residues according to the N-end rtde pathway (single-letter abbreviations of
amino acids shown).
The first E3 discovered, (E3a) is a 200 kDa protein that binds N-end rule
protein substrates bearing a Type I (basic) or Type II (bulky hydrophobic) N-
terminal amino acid residue, via its two distinct binding sites. 2. A second type of
E3 ligases contains what is described as a HECT (Homology to E6-AP Carboxy
Terminus) domain. This is a region of approximately 350 amino acids homologous
to E6-associated protein (E6-AP), an E3 type enzyme recruited by the human
papilloma virus E6 oncoprotein to induce degradation of the tumour suppressor
p53 (Cummings et al., 1999). A large family of HECT domain-containing proteins
has been identified in many eukaryotic organisms (Huibregtse et al.. 1995). All
HECT domain proteins contain a conserved active site Cys residue for conjugation
to Ub, near the carboxy-terminus and display highly variable amino-terminal
regions which are the sites involved in the recognition of specific substrates. Ub is
transferred from E2 to the HECT motif of the ligase and subsequently to the target
protein. HECT- domain proteins are usually large polypeptides (90-200 kDa)
whose N-terminal domains appear to display substrate binding sites. The majority
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of HECT-containing proteins possess a C2 domain at the N-terminus which is
implicated in Ca+: -dependent phospholipid binding (Hoppe et al., 2000). The
HECT region is located at the C-terminus of the protein. The presence of WW
domains allows binding to proteins containing proline-rich (PPXY) motifs. 3. A
ubiquitin ligase activity specifically associated with cell-cycle regulatory proteins
has been ascribed to a large (~ 1500 kDa) multi-subunit complex termed the
cyclosome or anaphase-promoting complex (APC) (see section 1.6.6). 4. The
fourth class of E3s comprises multi-subunit complexes, the majority of which
appear to depend on phosphorylation of the substrate.
1.6.4 RING-finger proteins mediate ubiquitin ligasc activity
The discovery of a novel motif termed the RING finger has changed the
original classification of E3 enzymes. RING (Really Interesting New Gene)
fingers are defined by the occurrence of a total of eight cysteine and histidine
residues that encase two structurally essential zinc ions. The consensus sequence of
a RING finger motif is the following: Cys-X(2)-Cys-X(9-39)-Cys-X( l-3)-His-X(2-
3)-Cys/His-X(2)-Cys-X(4-48)-Cvs-X(2)-Cvs. where X represents any amino acid.
Ring fingers are subdivided into two categories; RING-HC and RING-H2
depending on the presence of a Cys or a His at the fifth co-ordination site
(underlined), respectively (Joazeiro and Weissman, 2000). They were originally
thought to play a role in mediating dimerisation of several proteins. It was later
deduced that they were also involved in mediation of protein degradation according
to the N-end rule and the process of transferring lib both to heterologous substrates
and themselves (Freemont, 2000; Joazeiro and Weissman. 2000) (Jackson et al.,
2000).
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The identification of a RING finger domain in Ape 11. an essential anaphase
promoting complex (APC) component that controls the anaphase-to-metaphase
transition and destruction of cyclin B to allow exit from mitosis, suggested its
association with control of cellular protein levels by ubiquitination. This view
was further supported by studies that identified a small noncanonical RING
finger protein, Rbx 1 (also referred to as Rod and Hrtl) as an integral
component of both VHL-containing and SCF complexes that were shown to
possesss E3 activity (Chen et al., 2000), The current view supports the division
of E3 ligases in two groups based on the presence of either the HECT domain or
a complex that includes cullin and a RING-H2 subunit.'The latter group defines
a superfamily of four types of complexes, namely the SCF (Cul 1-based), the
CBC (Cul2-based) also referred to as VHL-like. the APC/cyclosome and a
putative Cul3-5 based ligase (Tyers and Jorgensen, 2000) (Figure 13). A new-
class of ubiquitin ligases has been identified recently, which comprises a U-box
motif. The prototype U-box protein, Ufd2, was identified in yeast as a factor
believed to be required for the assembly of poly-ubiquitin chains, acting in
concert with El, E2 and E3. The U-box is a ~ 70 aa domain which displays 3D
structural similarities to the RING finger motif. U-box containing proteins have
been observed to function as E3s in E2-dependent ubiquitination (Hatakeyama
et ah, 2001). The U-box protein CHIP associates with the chaperones HspOO and
Hsp70 to induce ubiquitination of the glucocordicoid receptor and immature
cystic fibrosis transmembrane regulator (C.FTR), respectively.
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FIGURE 13. RING-finger containing E3 ubiquitin ligases: the SCF, CBC
and APC complexes. The RING-finger type of E3 ubiquitin ligases are
multicomponent enzymes that mediate the transfer of Ub molecules to
substrates. The SCF, VBC and APC subtypes consist of a core that comprises
cullin/Apc2, a RING-finger protein (Rbx/Apcl 1) and a protein that facilitates
the association of the core with the adaptor-substrate complex, namely
Skpl/ElonginBC/Apcl. The substrate is recruited by an adaptor protein (F-
box/VHL-like/Ccd20) that displays binding sites for both the target protein and
the Skpl/ElonginBC/Apcl component of the complex.
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SCF complex CBC complex
APC/C complex
1.6.5 The SCF ubiquitin ligase complex
The first SCF- mediated pathway was identified in yeast S. cerevisiae through
analysis of the G1 to S-phase transition. Initiation of DNA synthesis (S-phase) in
yeast requires the action of cyclin-dependent kinase (Cdk) w hich is inhibited by
Sicl. Destruction of Sic 1 is essential to allow DNA replication to proceed. This is
dependent on phosphory lation of the inhibitor by G1 cyclin-Cdk kinases in late G1
phase and requires the action of the E2 enzyme, Cdc4 (Craig and Tyers, 1999).
Schwob and coworkers demonstrated that budding yeast cdc4 cdc34" and cdc53
,s
mutants failed to enter S-phase due to inability to destroy Sicl (Schwob et al.,
1994). The components of the SCF pathway were discovered and characterised in
a number of studies performed in several laboratories.
1.6.5.1 Subunits of the SCF complex
Assembly of four distinct subunits gives rise to the heterotetrameric structure
of the SCF ubiquitin ligase. The " core" component consists of Cullinl(or its yeast
homologue Cdc53), Skpl and the RING-finger protein Rbxl/ROCl (Hrtl in yeast).
The substrate is targeted by an F-box-containing protein (eg. Cdc4) w hich is linked
to the rest of the complex via association with Skpl. The role of Cul 1 and Rbx 1 is
to recruit the ubiquitin conjugating enzyme (E2).
All known SCE subunits are highly conserved throughout eukaryotes (Deshaies.
1999). Substitution of Cdc53, ySKPl and HRT1 with their respective human
homologues CULl. hSKPl and RBX1/ROC1 in yeast results in assembly of an
active SCF ligase which supports the view of functional conservation of these
proteins (Bai et al.. 1996) (Skowyra et al.. 1999).
1.6.5.2 Structure and function of the SCF components
1.6.5.2(a) Skp 1
Skp 1 has been found to associate directly to both Cull/Cdc53 and a number of
F-box proteins (Skowyra et al., 1997) (Yam et al., 1999). The human homologue
comprises two domains, based on sequence comparisons and deletion analyses: an
N-terminal domain of approximately 110 amino acids that is related to Elongin C
and a ~53 aa unique C-terminal region. A 30 aa insertion within the N-terminal
domain of the yeast Skpl (ySkpl) does not seem to play a significant functional
role, as skp temperature sensitive mutants are complemented by hSKFl.
Yeast two-hybrid assays have revealed that amino acids 1-91 in hSkpl bind to
hCull, whereas association with the F-box protein Skp2 was accomplished via
residues 37-163 and 1-65 with an efficiency of 15 and 20% respectively, compared
to the full length hSkpl (Ng et al., 1998). It is apparent that the first 91 amino acid
residues of hSkpl contain binding determinants for both Cullin and the F-box
motif. The ability of ySkpl to bind to both Cdc4 and Cdc53, lead to the assumption
that its main function is to link the cullin and F-box components of the SCF.
However, the assembly of a functional SCF that comprises the F-box protein Grrl
in insect cells in the absence of hSkpl (Skowyra et al.. 1997) and the association of
a mutant Skp2, that has lost its ability to bind hSkpl. with hCull (Lisztwan et al.,
1998) suggest an alternative role for hSkpl. It is possible that it acts to mediate the
optimal position of the cullin and F box components in order to facilitate the
transfer of Ub from E2 to the substrate (Deshaies, 1999).
1.6.5.2 (b) Cullinl/Cdc53
Cullinl/Cdc53 associates with Skpl through the first 219 amino acids of its N-
terminus, as revealed by yeast two-hybrid and GST pull- down assays (Michel and
Xiong, 1998). It also contains an internal domain responsible for the interaction
with yCdc34 (E2) and Hrtl. At least five different cullins (Cull. Cul2, Cul3,
Cul4(A&B) and Cul5 have been identified in mammalian cells to interact with
Rbxl (Kamura et al.. 1999), although Cul5 preferentially interacts with the
Rbxl/ROCl homologue. ROC2 (Chen et al., 2000). Cul2-Cul5 do not bind to Skpl
in the yeast two-hybrid screen (Michel and Xiong, 1998). N-terminal deletion
mutants of Cull abolish interaction with Skpl but binding to Cdc34 and Hrtl
remains unaffected. The region involved in recruiting the E2-RING-domain
subunit is referred to as the cullin homology (CH) domain and displays similarities
to the APC/C component Apc2 (Zachariae et al., 1998). The C-tenninus of Cull is
the most conserved region among cullins but its function remains largely unknown
(Deshaies, 1999). It has been found to serve as the attachment site for Rubl, a
ubiquitin-related protein (Patton et al.. 1998).
1.6.5.2(c) Hrtl/Rbxl/Rocl
Hrt 1/Rbxl/Rocl is a small protein (-121 amino acids) that consists of a 53 aa
N-terminal domain and the RING-finger- containing carboxy terminus which spans
approximately 67 amino acids (Deshaies, 1999). Its ability to bind Cdc53/hCull
directly (Ohta et al.. 1999) (Seol et al , 1999), stabilises the yCdc34-Cdc53
interaction (Skowyra et al., 1999) and bind Cdc53/Cull at regions that overlap
yCdc34 binding, suggests a role of Hrtl in linking \Cdc34 to the CH domain of
cullin by directly binding to both proteins. Mutation of the conserved Cys and His
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residues of the RING finger motif results in abrogation of ubiquitin ligase activity
in vitro (Kamura et al., 1999),but binding to cullin still occurs, which implies the
involvement of the RING motif in recruitment of E2 to the complex.
1.6.5.2 (d) F-box -containing proteins
F-box proteins are the specificity-determinants of the SCF subtype of E3
ubiquitin ligases. They comprise two essential domains: the F-box motif for
association with the core E3 ligase complex, via binding to Skpl, and a protein-
protein interaction motif for recruitment of substrates for ubiquitination. Particular
SCF complexes are designated by their associated F-box components (eg. SCF,cdc4
SCF |3'TrCP).
The F-box motif consists of approximately 50 amino acids and is usually
found at the N-terminus of the protein. It was identified as a region of homology
among Cdc2. Met30, (3-TrCP, Scon2 and MD2 but its implication in inter-protein
associations was recognised on the basis of its presence in cyclin F (hence the
name F-box) (Bai et ah, 1996). An intact F-box is necessary for association with
Skpl as confirmed by mutagenesis studies, but may not be sufficient as indicated
by the inability of the minimal F-box of Grrl to bind ySkp2 in a yeast two-hybrid
assay (Li and Johnston, 1997). In accordance with this finding, a mutation of two
residues near the C-terminus of Skp2 (away from the F-box region), abolished
binding to both human cyclin A (as anticipated) and Skpl (Lisztwan et ah, 1998).
Taken together, these observations suggest that the stability of F-box-Skpl
interactions may be dependent on sequences lying outside the F-box. The
consensus sequence derived from the alignment of 234 sequences indicates that
there are very few invariant positions which makes the detection of the F-box motif
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particularly difficult. The most conserved residue in the F-box sequence is a
proline preceded usually by a leucine, found in the N-terminal region of the
protein. This bipeptide was identified as essential for binding of Cdc4 to ySkpl
(Bai et al., 1996), it was, however, not required for Skp2-hSkpl interaction (Yam
et ah. 1999).
The C-terminus of the protein is occupied by the protein interaction motif that
is responsible for substrate recognition. Two such motifs present in the majority of
the F-box proteins so far characterised, are Tryptophan-Aspartic acid (WD40)
repeats and Leucine-rich repeats (LRR). The presence of a particular protein
interacting domain, other than the F-box, determines the nomenclature of the
protein.
F-box proteins containing WD repeats are classified as FBXW (previously
Fbw). The occurrence of leucine-rich repeats in F-box proteins is indicated by
FBXL (previously Fbl) whereas FBXO (previously Fbx) denotes a protein with
either another or no protein binding motif (Cenciarelli et ah, 1999) (Winston et ah,
1999a). WD40 repeats and leucine -rich repeat regions constitute members of a
group of domains that are able to associate with phosphoSerine/Threonine
(pSer/Thr) modules and phosphorylated sequence motifs. Other members of the
group include WW domains, 14-3-3 proteins and forkhead-associated (FHA)
domains (Yaffe and Elia, 2001).
H1)40 repeats
WD40 domains display a (3-propeller structure analogous to that of clathrin
(ter Haar et ah, 2000) that allows binding of linear polypeptide motifs within the
grooves formed by adjacent propellers. The WD40 domain of the F-box protein p-
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TrCP (Transducin repeat Containing Protein) recognises the following consensus
sequence DpSGXXpS in both IkBu and p-catenin (Winston et al.. 1999b).
Leucine-rich repeats (LRR)
Leucine-rich repeat proteins constitute a superfamily that can be divided into
at least six subfamilies, based on differences in the length and the consensus
sequence of the repeats (Table 2) (Kajava. 1998). The crystal structure of
ribonuclease inhibitor (RI), a protein made up entirely of leucine-rich repeats,
revealed that LRRs correspond to structural units giving rise to a p-sheet and an u-
helix (Kobe and Deisenhofer, 1995b). These units are arranged so that the sheets
and helices are parallel to a common axis, with the p-strands lining the inner
circumference and the a-hclices flanking the outer surface of a horseshoe-shapped
molecule. The concave face of the structure is exposed to the solvent and serves as
the surface of interaction between the LRR-containing protein and its substrate.
The non-globular (horseshoe) shape of the molecule increases the area available for
interaction, whereas the exposure of the p-sheet-lined concave face to the solvent,
possibly renders this structure a protein-binding motif (Figure 14). Amino acid
substitutions within the beta-strand permit alterations in specificity by modification
of the surface area. This flexibility is indicative of a role of LRRs not only in
recognising specific substrates but also in adjusting to the requirements of a
specific interaction (Kobe and Deisenhofer. 1995b). Rl displays 16 LRRs and
belongs to the subfamily that contains repeats of 28-29 residues, whereas the most
common size of a consensus sequence is 24 residues.
A member of the cysteine-containing subfamily, namely Grrl, mediates the
ubiquitination of G1 cyclins Clnl and Cln2. It displays an unusually high density
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of cationic charges in the inner circumference of its LRR region. These positively
charged residues are thought to be involved in binding to phosphorylated substrates
(Hsiung et al., 2001). It is believed that a single LRR does not fold into a defined
structure but a number of such motifs are required to jointly form a module (Krantz
et al., 1991). The number of repeats within a single domain is thought to modulate
the function of the LRR. All the LRR-eontaining proteins identified so far are








Typical 24 (20-27) LxxLxxLxLxxNxLxx
LpxxoFxx








24 (23-25) LxxLxxLxLx xNxLt/s
GxIPxxLGx
SDS22-like 22 (21-23) LxxLxxLxLxxNr/KIrr/
KKIEN/GLEx
Bacteria 20 (20-22) PxxLxxLxVxxNxLxx
LPD/EL
Table 2. LRR subfamilies. The LRR superfamily is grouped in six classes based
on repeat consensus sequences. Bold and uppercase letters indicate,respectively,
more than 70% and 40% occurrence of the residue in a certain position. Lowercase
letters indicate more than 30% identity (x: any amino acid, o: non-polar amino
acid). Underlined is the constant part of the repeat sequence (Adapted from Kajava,
1998).
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FIGURE 14. Crystal structure of the LRR-containing protein Ribonuclease
Inhibitor (RI). The association of RI with its substrate ribonuclease A (shown in
red) is facilitated by the distinct arrangement of the LRRs to form a horseshoe-like
structure. RI is a protein entirely made of LRRs. Each repeat comprises a (3-sheet
(blue) associated with an a-helix (purple).
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1.6.5.3 Mechanism of action of the SCF complex
1.6.5.3.1 The F-box hypothesis
Evidence from a number of studies suggests that F-box proteins recruit
phosphor)lated substrates to the SCF complex (Hsiung et al.. 2001) (Latres et al.,
1999) (Skowyra et al., 1997). However, it has been unclear whether
phosphorylation is essential only for the recognition of the SCF substrates by the F-
box proteins, or it plays a role in the process of the ubiquitination reaction itself. It
is possible that phosphorylation induces a conformational change in the substrate to
reveal preferred ubiquitination sites (Montagnoli et al., 1999). A new strategy
devised to target non-SCF substrates for ubiquitination via engineering of the F-
box component, has provided insight into the phosphorylation requirements of the
target proteins. Physiologically stable cellular proteins can be destined for
destruction through association with an F-box protein that has been engineered to
bear binding determinants for the desired protein. Targeted proteolysis experiments
have demonstrated that substrate recognition is dependent on F-box binding alone
and does not require phosphorylation. Hence degradation via the SCF complex
might depend exclusively on substrate binding to the F-box component (Zhou et
al., 2000). The recent finding that the F-box protein Ebi mediates ubiquitination of
unphosphorylated p-catenin. supports the view of a phosphorylation-independent
substrate recognition manner of particular F-box proteins (Matsuzawa and Reed,
2001). Phosphorylated p-catenin is recognised by the F-box protein FWDl/p-
TrCP/Slimb (see section 1.6.5.4.2), which facilitates its ubiquitination by the SCF
complex. The identification of two distinct, although structurally related F-box
proteins, which mediate the ubiquitination of the same substrate by binding to
different sites on the target protein, provides evidence against the previously
expressed view that a particular substrate may associate with a single F-box
protein.
The F-box subunit may not always bind the protein targeted for ubiquitination
directly. The HIV protein Vpu contains a recognition motif found also in IkB and
p-catenin that directs binding to p-TrCP and mediates their destruction. In the case
of Vpu, the motif does not act to target the protein for degradation but facilitates
destruction of its bound CD4 receptor (Margottin et al., 1998). Substrate binding
may also be enhanced by the formation of functional homo- or heterodimers of F-
box proteins (Suzuki et al., 2000; Wolf et al., 1999), whose potential role in
catalysis is not known. According to "The F-box Hypothesis" a large number of
F-box proteins present in the cell mediates the destruction of an even larger number
of substrates through association with Skpl in multiple degradation pathways (Bai
et al., 1996). It suggests that Skpl is responsible for the turnover of all SCF targets
via its interaction with different F-box proteins bearing specific substrates. The
notion that numerous F-box proteins utilise the same core SCF' complex poses a
problem of maintaining an equilibrium between the F-box component and the
limiting amount of core complex. This is possibly overcome by the regulated
turnover of F-box proteins in an SCF- dependent manner. Regulation of multiple F-
box proteins via auto-ubiquitination has been documented to occur following
release of their substrates from the complex (Zhou and I low ley, 1998) (Mathias et
al., 1999) (Galan and Peter, 1999).
1.6.5.3.2 Transfer of Ub residues to Lys side chains of the target protein
Recruited substrates are tagged with ubiquitin via the action of the
cullin/RING-H2 heterodimer. The mechanism of transfer on Ub moieties in the
SCF complex appears to be different from HECT- domain mediated ubiquitination
(Figure 15). Whereas HECT domains of E3 enzymes bind Ub through a C-terminal
Cys residue and subsequently pass it on to the substrate, in the case of SCF
treatment of Cdc53/Hrtl with the alkylating agent N-ethylmaleimide (NEM) that
inactivates sulfhydryls had no effect on the auto-ubiquitination of yeast Cdc34
(Seol et al., 1999). This was indicative of the operation of a mechanism that does
not involve a core complex Cys residue. It has been proposed that the cullin/RING-
H2 conjugate triggers a conformational change in ubiquitin-bearing E2 (E2-Ub)
that results in reduction of the energy barrier for the formation of the oxyanionic
intermediate generated during the transition state of Ub transfer from the catalytic
cysteine of E2 to the E-amino group of a substrate Lys side chain (Seol et al.,
1999). The application of such a conformational switch would ensure that E2
enzymes specifically ubiquitinate SCF-bound targets and not random cellular
proteins that they might encounter given their substantial excess compared with
SCF complexes. It also suggests that the efficiency of the core SCF can be
controlled and reach its maximal level upon encountering the F-box protein- bound
target, since a Ub moiety is directly transferred from E2 to the substrate (Deshaies,
1999).
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FIGURE 15. Mechanism of action of HECT-domain and RING-finger
ubiquitin ligases. The HECT domains of E3 enzymes bind Ub through a C-
terminal Cys residue and subsequently pass it on to a Lys side chain of the
substrate, whereas the cullin/RING-H2 conjugate mediates a direct transfer of Ub
from E2 to the target protein, in a mechanism that does not involve prior





1.6.5.4 Substrates of the SCF
Proteins regulated via the SCF pathway represent a broad range of
polypeptides involved in a wide variety of processes including control of cyclin-
dependent kinase (CDK) activity in the cell cycle, signal transduction cascades,
transcriptional activation and DNA replication. A number of transcription factors,
tumour suppressors and oncoproteins are regulated selectively by the SCF
machinery. The best characterised systems that depend on SCF-mediated
ubiquitination include the hedgehog, wnt/wingless and NF-tcB pathways all of
which depend on the action of the same F-box protein, namely p-TrCP or its
Drosophila homologue Slimb (supernumerary limbs) (Figure 16).
1.6.5.4.1 The hedgehog pathway
The hedgehog (Hh) pathway in Drosophila controls the development of
limbs and the formation of the anterior-posterior axis in wing and leg imaginal
discs, by regulating the expression of wingless (wg) and decapentaplegic (dpp)
genes (Hammerschmidt et al., 1997). Ectopic Hg signalling results in mutants with
duplicated wings and legs. In the absence of Hh signal, the transcription regulator
Cubitus interuptus (Ci), a 155 kDa microtubule-associated protein, undergoes
proteolytic processing to yield a 74 kDa N-terminal protein that lacks the
cytoplasmic tethering domain. This truncated polypeptide is released from the
microtubule complex and translocates to the nucleus where it functions as a
transcriptional repressor of uy and dpp genes. This processing of Ci is ubiquitin-
dependent, mediated by the F-box/WD40 protein Slimb and requires
phosphorylation of the substrate by protein kinase A (PKA) (Craig and Tyers,
1999). The 155 kDa form of Ci accumulates in the presence of Hh signalling. It
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translocates to the nucleus by an unknown mechanism that permits its release from
the microtubule complex, and acts as a transcriptional activator of downstream
genes (Maniatis, 1999).
1.6.5.4.2 The WntlWingless pathway
The Wnt/Wingless pathway plays a central role in development and
organogenesis. It regulates processes as diverse as segmental pattern formation,
CNS patterning and asymmetric cell divisions (Wodarz and Nusse, 1998). In
Drosophila and Xenopus it controls segmental pattern formation and dorsal axis
determination, respectively (Jiang and Struhl, 1998). The Drosophila Wg ligand
stimulates a signal transduction cascade that targets the transcription factor
Armadillo (Arm) which lies downstream of the wingless receptor and the serine
kinase Zeste-White 3 (ZW3). The Xenopus and mammalian homologues of Wg,
Arm and ZW3, are Wnt-1. (3-catenin and glycogen synthase kinase 3(5 (GSK 3(3),
respectively (Orford et al., 1997). In mammals (3-catenin plays a significant role in
cell-cell adhesion and growth factor signal transduction. It exists as membrane-
associated through its interaction with E-cadherin and a-catenin that leads to the
formation of the adherens junction and it is also found in a cytoplasmic pool which
is important for signalling (Gumbiner, 1995). The mammalian Wnt signalling
cascade is initiated through binding of the Wnt-1 ligand by the cell surface receptor
Frizzled. This interaction causes inhibition of GSK 3(3 which fails to phosphorylate
(3-catenin. As a result the cytoplasmic levels of the protein increase and excess
hypophosphorylated (3-catenin translocates to the nucleus where it associates with
T cell factor/ lymphocyte enhancer binding factor (TCF/LEF) transcription factors
and modulates expression of their target genes (Uuber et al.. 1996). One of these
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genes was identified as the proto-oncogene c-myc (Pennisi, 1998). p-catenin also
associates with the adenomatous poliposis coli (APC) tumour suppressor gene
product. De-regulation of APC, P-catenin, and E-cadherin expression, leads to
elevated levels of cytoplasmic p-catenin which increase the transcriptional activity
of TCF/LEF, resulting in tumour formation in a variety of tissues (Sadot et al.,
2000).
In the absence of Wnt-l signalling, active GSK 3f5 phosphorylates p-catenin in
a reaction that occurs in a complex comprising APC and Axin/conductin
(Munemitsu et al., 1995). The phosphorylated N-terminal six amino acid region
(DSGIHS) of p-catenin is recognised by the F-box protein p-TrCP which links beta
catenin to the core SCF complex for ubiquitination and subsequent degradation
(Orford et al., 1997) (Latres et al., 1999).
FIGURE 16. Substrates of the SCF complex. (A) The hedgehog pathway.
Hedgehog (Hh) signalling inhibits the action of PKA whose function is to
phosphorylate the Cubitus interuptus (Ci) 155 component of a transcriptional
regulator. Phosphorylated Ci 155 is tagged with Ub and partially degraded by the
proteasome to yield a functional 75 kDa product that acts as a transcription
repressor. (B) The YVnt/Wingless pathway. In the absence of Wnt/wg signalling,
p-eaten in in a complex with APC and axin. is phosphorylated by GSK 3p and
subsequently ubiquitinated and degraded by the 26S proteasome. Accumulation of
cytoplasmic p-catenin results in nuclear translocation and leads to elevated
expression of oncogenes, with the consequent formation of tumours in a variety of
tissues. (C) The NF-kB pathway. The nuclear factor kB (NF- kB) exists as a
heterodimer of p50 and p65 subunits, sequestered in the cytoplasm by binding to
the inhibitor IkBu. Phosphorylation of IkBq by the kinase IKK, upon tumour
necrosis factor (TNF) signalling, results in IkBcx ubiquitination and degradation.
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1.6.5.4.3 The NF-kB pathway
NF-kB (nuclear factor kB) is a member of the Rel family of transcription
factors that control expression of genes involved in the inflammatory, immune and
stress responses (Maniatis, 1999) (Baeuerle and Baltimore, 1996). NF-kB 1, the
best characterised type comprises two subunits, namely p50 and p65 (RelA). The
smaller subunit, p50, is the processed N-terminal fragment of a 105 kDa precursor
molecule, via limited ubiquitin-dependent proteolysis (Palombella et al., 1994)
(Coux and Goldberg, 1998). The p50/p65 heterodimer is sequestered in the
cytoplasm by association with the inhibitor IkBq which masks the nuclear
localisation signal of the complex and abolishes its ability to bind DNA (Arenzana-
Seisdedos et al., 1995) Extracellular signals such as tumour necrosis factor- a
(TNF-a), lead to the activation of an iKB-kinase complex (IKK) that
phosphorylates IkBcx on residues Ser-32 and Ser-36 of its N-terminal DSGLDS
region, which is very similar to the (3-catenin phosphorylation site. The
phosphorylated domain is directly recognised by the F-box protein (3TrCP (Yaron
et al., 1997). This modification targets the protein for destruction in the
Ub/proteasome pathway. Degradation occurs while IkBcx is still bound to the NF-
kB complex (Chen et al., 1995) (Alkalay et al., 1995). Released NF-kB is able to
translocate to the nucleus and exert its transcriptional activity (Orian et al., 1995)
(Yaron et al., 1998).
1.6.6 The anaphase promoting complex (APC) / cyclosome ligase
The APC was the first multi-subunit ubiquitin ligase described. It contains the
cullin homologue Apc2, associated with a RING-H2 finger protein, Apcl 1, which
is similar to Rbxl. Its activation requires the action of two classes of WD repeat-
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containing proteins; Cdc20/Fizzy and Cdhl/Hcti/Fizzy-related (Zachariae and
Nasmyth, 1999). The proteins targeted for destruction by the APC display one of
the following destruction signals; the nine-residue destruction box (D-box) or a
transposable seven-residue motif, the KEN box. The D-box is present in all
substrates that use the Cdc2 adapter and some Cdhl-associated substrates whereas
the KEN-box is found exclusively linked to Cdhl. This adapter is not only able to
target D-box and KEN-box substrates but also Cdc20 itself. APC-mediated
ubiquitination appears to be dependent on phosphorylation of the complex but not
necessarily of its substrates (Jackson et ah, 2000).
1.6.7 The Cullin2/ Elongin B/ Elongin C (CBC) complex
The CBC ubiquitin ligase shares striking structural similarities with the SCF
complex. It is composed of a core that contains Cullin (Cul2) associated with the
RING finger protein Rbxl, the Skpl homologue Elongin C, as part of the Elongin
BC heterodimer, and a SOCS (Suppressors Of Cytokine Signalling) box-
containing protein equivalent to but distinct from F-box proteins (Deshaies, 1999).
The association of Elongin B and Elongin C, referred to as the Elongin BC
complex, was identified intitially as a positive regulator of the RNA polymerase II
elongation factor Elongin A. and subsequently as part of the von Hippel Lindau
(VHL) tumour suppressor complex, where it functions in tumour suppression and
negative regulation of hypoxia-inducible genes (Kamura et ah. 1998). Elongin B is
a 118 aa protein that contains an N-terminal ubiquitin homology (UbH) domain (84
aa) that is fused to a 34 aa C-terminal tail of Elongin C, which comprises 112
amino acids and is similar to Skpl (Bai et ah, 1996). The Elongin BC complex has
been reported to interact with the SOCS box motif found in proteins that belong to
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the SOCS, ras, VVD40 repeat, SPRY domain and ankyrin repeat families. The
SOCS box is an ~50 aa motif composed of two blocks of conserved sequence,
separated by 2-10 non-conserved residues. The N-terminal conserved domain (~12
aa) is a consensus BC box. SOCS box proteins are modular, comprising a SOCS-
box motif at the extreme C-terminus and either an SH2, Ras-like, WD40 repeat,
ankyrin repeat or SPRY domain at the extreme N-terminus (Kamura et al., 1998).
SOCS box -containing proteins act as the substrate recruiting component of the
complex. A known substrate -selecting protein that participates in the formation of
a CBC ligase, is VHL. Association of VHL with the core CBC to form a complex
termed CBCVHL or VBC, occurs via the BC box present in VHL.
Rbx 1 acts as the mediator of the E2-E3 interaction and also associates with
Elongin C (Kamura et al., 1999).
An additional component of the CBC that has no corresponding subunit in the SCF
complex, is Elongin B which is believed to function as an adaptor by binding VHL,
Elongin C and Cul2. Its precise function remains elusive. The CBC complex has
been observed to bind to and regulate the activity and stability of multiple proteins
including kinases involved in the JakV STAT pathway (Kamizono et al., 2001).
1.6.8 Cul3-5 based ubiquitin ligases
Cul3-5 based E3s have not been well characterised yet. It is not currently
known whether they conform to the theme that applies to the rest of the
superfamily members. It is believed that they possibly involve an Skp 1 -like subunit
that associates with both the Cullin and a receptor which recruits the
(phosphorylated?) substrate. A RING-H2 component is most probably the mediator
of E2 binding to the ligase complex (Deshaies, 1999).
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1.6.9 Phosphorylation -dependent degradation signals
Post-translational modification of a protein by phosphorylation could serve to
target it for ubiquitination. Sequences in polypeptides rich in proline, glutamic
acid, serine and threonine, referred to as PEST (in single letter abbreviation) have
been found to function as signals for degradation (Rechsteiner and Rogers, 1996).
Phosphorylation of the yeast G1 cyclin Cln3 at a PEST region is necessary for its
destruction (Yaglom et al., 1995). The sequence SSSTDSTP at positions 99-106 of
the transcriptional activatitor Gcn4, a PEST-like motif, acts as a signal for its
degradation. Gcn4 in yeast controls expression of genes involved in the synthesis
of amino acids and purines (Kornitzer et al., 1994). Targeting could also occur
through phosphorylation of a residue that lies outside the PEST motif as is the case
for cyclin D1 (Diehl et al., 1997).
A short E3 binding segment present in IkBoi (DSGLDS), and p-catenin
(DSGIHS), depends on phosphorylation of the two Ser residues for binding to the
ubiquitin ligase complex (Laney and Hochstrasser, 1999).
Phosphorylation of a target protein by a kinase appears to be essential for
recognition of the substrate by a specific ubiquitin ligase. It is also evident that
different ubiquitin ligases recognise distinct patterns of phosphorylation as well as
additional motifs on target proteins (Hershko and Ciechanover, 1998). WW
domains of ubiquitin ligases are able to recognise proline-rich sequences or
phosphoserine and phosphothreonine containing elements (XPPXY or PY) present
in their substrates. Rsp5 ubiquitin ligase (the yeast homologue of mammalian
Nedd4 which was found to interact with an epithelial sodium channel), recognises
via its WW domain, the heptapeptide sequence SPTSPSY present in the C-
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terminus of its target, the large subunit of yeast RNA polymerase II (Rpbl) (Laney
and Hochstrasser, 1999).
A functional connection between phosphorylation and ubiquitination was also
evident in the case of the proto-oncogene encoded signal- transducing transcription
factor c-Jun, a member of the AP-1 family. Signal transduction through c-Jun is
dependent upon phosphorylation by mitogen-activated protein kinase (MAPK)-
type enzymes. MAPK phosphorylation of c-Jun causes an increase in its
transactivating potential and DNA-binding activity and occurs in sites proximal to
a 27 amino acid region found at the amino- terminus of the protein, termed the 5
domain (Treier et al., 1994). The 6 domain is required for both polyubiquitination
and degradation of c-Jun and its absence from v-Jun renders it stable. It has been
demonstrated that phosphorylation of c-Jun in vivo resulted in its stabilisation by
suppression of ubiquitination (Musti et al., 1997). Fusion of the 67 N-terminal
amino acid region of c-Jun that includes the 6 domain, to (3-galactosidase, an
otherwise stable protein, resulted in its rapid turnover. The ability of this motif to
mediate ubiquitination and degradation of a previously stable heterologous protein,
classifies it as a necessary and sufficient transferable degradation signal (Treier et
al., 1994).
1.6.10 N-terminal ubiquitin as a degradation signal
Ubiquitin chains attached to a polypeptide at specific lysine residues serve as a
recognition cue for the proteasome and lead to destruction of the tagged protein.
Non-removable ubiquitin residues found at the N-termini of polypeptides function
as primary degradation signals. Proteins that bear DNA-encoded linear Ub adducts
in their N-termini are degraded by a Ub/proteasome-dependent system termed the
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UFD pathway (Ubiquitin/Fusion/Degradation) (Johnson et al., 1995). The targeting
of a protein by the UFD pathway results in the formation of a multiubiquitin chain
on the non-removable Ub moiety, a modification necessary for subsequent
recognition by the proteasome.
The action of a ubiquitin conjugating enzyme (E2) is not essential in the UFD
unlike the N-end rule pathway. Physiological substrates for the UFD pathway are
largely unknown but may include proteins that bear Ub-like domains (eg Elongin
B). It is also possible that targeting by UFD depends on recognition of Ub residues
within a post-translationally added multi-ubiquitin chain, a hypothesis which
excludes the presence of Ub-like domains on potential substrates (Johnson et al.,
1995). The identification of yeast Rad23, a conditionally short-lived protein that
comprises a Ub-like N-terminal region as a physiological substrate for UFD,
favours the view that Ub-like N-terminal domains of other proteins may act as
degradation signals. The Ub-like region of Rad23 is implicated in its role in UV-
damaged DNA repair which implies that its metabolic instability is related to its
function. This could be the case for other Ub-like domain bearing proteins
(Varshavsky, 1997).
1.6.11 Internalisation signals
Ubiquitination of a number of cell surface receptors, activated by tyrosine
kinase-dependent phosphorylation, has been observed to occur upon binding of
specific ligands (Bonifacino and Weissman, 1998). Ligand-dependent
ubiquitination of T-cell antigen receptor (TCR), platelet -derived growth factor
receptor (PDGFR) (3 and c-Met receptors has been documented (Cenciarelli et al.,
1992) (Jeffers et al., 1997) (Mori et al., 1995). In the case of c-Met, inhibition of
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the proteasome blocked degradation of the protein, which implied a role of this
protease in the turnover of the receptor. TCR and PDGFRp, on the other hand, are
stabilised by treatment with the lysosome inhibitors monensin and ammonium
chloride (Bonifacino and Weissman, 1998). When the proteasomal pathway is not
employed, conjugation of ubiquitin to membrane receptor and transporter proteins
has been found to mediate their endocytosis and subsequent degradation in the
lysosome (vacuole in yeast). The association between ligand-induced
ubiquitination and endocytosis of membrane proteins has been studied in the yeast
G-protein coupled receptor Ste2, which binds the pheromone a-factor. Binding to
a-factor results in internalisation and rapid degradation of the receptor. The
cytoplasmic tail of Ste2 contains a region that is regulated by serine
phosphorylation, SINNDAKSS, identified as essential for both endocytosis and
ubiquitination of the protein (Wu and Haber, 1996).
The consensus sequence DAKTI, reminiscent of the last five residues of
SINNDAKSS, found in the linker region which connects the two homologous
transmembrane regions of Ste6 transporter, is necessary for its ubiquitination and
internalisation. The linker region of Ste6 comprises an N-terminal acidic stretch
termed the A-box and a C-terminal basic region called the B-box, collectively
referred to as the D-box ("destabilisation-box"). DAKTI is found within the A-box
region of Ste6 and can act as a ubiquitination signal in heterologous proteins only
as part on the entire D-box motif. It is thus necessary but not sufficient to mediate
ubiquitination and endocytosis (Kolling and Losko, 1997).
Internalisation of the uracil permease Fur4 is associated with ubiquitination
and vacuolar degradation. Mutants defective in internalisation, accumulate as
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ubiquitin conjugates. A point mutation in the D-box ("destruction box") of Fur4
results in its inability to be degraded, as does the mutation of serine to alanine in
the N-terminal PEST region of the transporter.
The way in which ubiquitin mediates endocytosis is not clear. It has been
suggested that ubiquitin could bind to components of the intemalisation machinery
such as clathrin in mammalian cells or the actin cytoskeleton in yeast (Bonifacino
and Weissman, 1998). It has also been proposed that the process involves
proteolysis of the cytosolic tail of the substrate (Hershko and Ciechanover, 1998).
A third way in which ubiquitin could facilitate internalisation of plasma membrane
proteins is by affecting the location of a protein within the plasma membrane.
Ubiquitin-induced translocation of a protein to a region of the membrane that forms
an early endosome is possible either via multimerisation of the receptor or by
utilising Ub as a localisation signal (Hicke, 1999).
Unlike polyubiquitination, which acts as a signal for proteasomal degradation,
endocytosis appears to relay on conjugation of either a single Ub molecule or two
residues linked to Lys63 of ubiquitin itself. It has recently been demonstrated that
mono-ubiquitination is not only important for receptor intemalisation, but also for
endosomal sorting (Katzmann et al., 2001).
Protein sorting and cell surface receptor downregulation in the mutivesicular
body (MVB) pathway involves ubiquitin as a signal required for entry in the
pathway. MVB is also important for deliver}' of hydrolases to the lysosome. A
conserved component of the endosomal machinery termed ESCRT-1 (Endosomal
Sorting Complex Required for Transport), recognises ubiquitinated MVB
substrates and functions in both yeast and mammalian cells to transport these
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substrates into budding late endosomal vesicles that will form an MVB.
Subsequent fusion of the mature MVB with the lysosome will result in delivery of
internal vesicles and their cargoes to the lysosomal lumen for destruction. ESCRT-
1 is able to bind Ub via its Vps23 component, which comprises a Ubc-like domain.
It has been suggested but not proven, that this interaction is direct.
Ubiquitin-tagged receptors are targeted to the vacuole following internalisation
in yeast. In mammalian cells, however, ligand-induced and constitutive endocytosis
are often followed by re-cycling or dissociation from the ligand and re-location at
the cell surface. It is not known whether these recycling processes coincide with
cycles of ubiquitination and de-ubiquitination of the target plasma membrane
proteins.
1,6.12 De-ubiquitinating enzymes
Release of ubiquitin from its adducts is essential for two processes: Ubiquitin
biosynthesis and the degradation pathway. Ubiquitin is synthesised either as a
linear polyubiquitin precursor or as an N-terminal fusion of two ribosomal proteins
and acts as a chaperone that targets them to the ribosomal complex. In the former
case individual Ub molecules are released from the chain by specific enzymatic
cleavage between the fused residues that renders them available for conjugation to
the substrate protein. The last ubiquitin residue in the precursor chain contains an
additional C-terminal amino acid that must be removed in order to expose the
active C-terminal glycine. In the second type of precursor, ubiquitin is cleaved
from the ribosomal complex after incorporation of the proteins it is fused with
(Ciechanover, 1998).
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In the process of degradation, ubiquitin has to be released from mis-targeted
proteins in the "proof-reading" mechanism of the pathway, from the lysine side
chains of the substrate upon encounter with the proteasome and from the end
proteolytic products. Multi-ubiquitin chains removed from substrates must also be
disassembled to recycle Ub molecules. Cleavage of Ub residues, in any case, is
performed by either of the two classes of thiol proteases that recognise the C-
terminal region of Ub. Ubiquitin C-terminal hydrolases (Uch) and Ubiquitin-
specific proteases (UBP) (Hochstrasser, 1996).
Uch proteases are ~25 kDa enzymes, which play a role in the post-translational
processing of Ub precursor molecules and mediate Ub release from adducts with
amines and thiol groups.
UBPs are larger enzymes (~100 kDa), involved in the cleavage of Ub from
cellular proteins or free poly-ubiquitin chains (Ciechanover, 1998). UBPs exist
either as free enzymes or associated with the 19S component of the proteasome and
may function in an energy dependent or independent manner. De-ubiquitinating
enzymes may act to inhibit or promote proteolysis. Binding of a UBP specifically
to a protein that bears a degradation signal results in inhibition of proteolysis by
preventing the assembly of a multi-Ub chain (Varshavsky, 1997). Inhibition of
protein degradation is also accomplished by removal of the Ub tag from incorrectly
targeted polypeptides.
Acceleration of proteolysis is mediated by release of Ub from inactive
precursors or terminal proteolytic products thus ensuring re-use of Ub moieties.
De-ubiquitinating enzymes promote the function of the proteasome by catalysing
the disassembly of multi-Ub chains which could bind to the proteasome and inhibit
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its action, or by modifying the chains to render them easily recognisable by the 26S
proteasome.
1.6.13 The proteasomal pathway
Proteolysis is an essential cellular process but could also prove dangerous
unless spatially and temporally regulated. To control protein breakdown, the cells
have devised a strategy referred to as compartmentalisation whereby the proteolytic
action is restricted to specific sites, accessible only by polypeptides that bare a
degradation signal (Baumeister et al., 1998). A degradation compartment can be a
membrane-defined organelle, (e.g. the lysosome) or a self-assembled complex of
unrelated proteolytic subunits that form a barrel-shaped structure. Subunit
assembly in the latter case, termed self or auto-compartmentalisation, yields
molecular destruction tools with greater flexibility than lysosomes (Lupas et ah,
1997). These proteases display localisation signals that allow them to perform their
function in various cellular locations in both the cytosol and the nucleus whenever
their action is required. A paradigm of this type of protein regulation is the
proteasome.
1.6.13.1 Structure and function of the 26S proteasome
The proteasome is the most abundant protease in the cytosol, accounting for
approximately 1% of the total cellular protein content (Hirsch and Ploegh, 2000). It
comprises a catalytic core, referred to as the 20S subunit, linked to a regulatory
structure termed the 19S cap that binds to both ends of the 20S component to form
the intact 26S proteasome complex (Figure 17).
The 20S proteasome is a cylindrical structure of 11 nm in diameter and 15 nm
in length (Lupas et ah, 1997). It comprises two different types of subunits, namely
76
a and (3 with distinct structural and functional roles that are further divided in
seven subfamilies. Each 20S complex contains seven different a and seven
different (3 subunits, arranged in the following order al-7 (31-7 p 1-7 al-7, so that
the a components form the outer rings and the (3 subunits the inner rings of the four
stacked- ring structure (Hirsch and Ploegh, 2000) (Coux et al., 1996). Both a and
(3-type subunits belong to a family of N-terminal (Ntn) hydrolases that consist of
two central antiparallel (3-sheets flanked on either side by a-helices. The active site
cleft is formed by an aperture at one end of the structure (Lowe et al., 1995).
The a subunits are more conserved both within and among species and are
capable of forming rings, unlike (3 subunits whose assembly requires the prior
formation of a rings. They possess a nuclear localisation signal (NLS) and thus
control the nuclear action of the intact proteasome. Their role includes the
generation of a physical barrier that controls the access of substrates to the catalytic
core and association with the 19S and 1 IS modifiers of proteolytic activity of the
complex. Despite the fact that they are catalytically inactive, they are necessary for
the stabilisation of the two-ring structure of the (3 chains.
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FIGURE 17. Structure of the 26S proteasome. Electron microscopic image of
negatively stained specimens of the Drosophila melanogaster 26S proteasome. It
comprises a catalytic core of four seven -membered stacked rings (a7|37|37cx7),
termed the 20S subunit, linked to a regulatory structure, the 19S cap, on either side.
Two superimposed states of the 26S complex (one in grey and one in colour) are
shown, indicating the flexibility in the linkage of the 19S caps to the 20S core.
(White arrows indicate direction of motion, scale bar is 20 nm) (After Baumeister,
1998).
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The (3 subunits are generated by cleavage of an N-terminal pro-sequence to
reveal an active terminal threonine residue. The crystal structure of the 20S
proteasome has revealed a distance of 28 A between the active Thr sites of adjacent
(3 subunits which suggests that the length of the generated proteolytic products
could be approximately 8 amino acid residues. They are involved directly in
peptide hydrolysis and can display peptidase activity even when expressed in the
absence of a subunits (Coux et al., 1996). Adjacent pairs of identical |3 subunits,
located on different (3 rings, give rise to six proteolytic sites. Each pair exhibits one
of the following three distinct catalytic activities: a trypsin-like activity which
cleaves after basic residues, a chymotrypsin-like one that cleaves after large
hydrophobic residues and a post-glutamyl peptidyl hydrolytic (PGPH)-like one
with a preference for acidic residues (Coux et al., 1996) (Ciechanover, 1998). In
vertebrates, the presence of three additional interferon- y (IFN-y) inducible |3
subunits (LMP2, LMP7 and MECL1), may alter the peptidase activity of the
proteasome (Hirsch and Ploegh, 2000). The exchange of three proteasomal
subunits, namely X, Y and Z for the IFN-y inducible (3 subunits LMP2, LMP7 and
MECL1, respectively, leads to stimulation of trypsin-like and chymotrypsin-like
activities, whereas the PGPH-like activity is reduced. These subunit exchanges, as
well as point mutations in constitutive (3 chains are also thought to have given rise
to two less characterised activities of the proteasome; BrAAP activity, which is
targeted to branched-chain amino acids and SNAAP activity, that cleaves after
small neutral residues (Meng et al., 1999).
To generate the complete 26S proteasome complex, the 20S core associates
via its a subunits with a large regulatory complex that comprises at least 18
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proteins whose molecular weights range from 25 to 110 kDa, in an ATP-dependent
fashion. This complex, termed the 19S cap or proteasomal activator 700 (PA700),
is responsible for selective degradation of ubiquitinated proteins and the activation
of the peptidase activities of the 20S component. It comprises a Ub-chain binding
site and a number of ATPases. It also displays isopeptidase activity for removal of
Ub chains from degradation substrates prior to their entry into the catalytic
complex.
Substrate recognition by the 26S proteasome is possibly accomplished by the
interaction of particular 19S subunits with the multi-Ub chains of target proteins. It
has been demonstrated that ubiquitin ligase-bound substrates interact directly with
subunits of the 19S particle. Yeast Ubrl and Ufd4 that constitute components of E3
ubiquitin ligases employed in the N-end mle and UFD pathway, respectively, have
been found to associate with Rnp2, Rptl, Rpt6 and exclusively Rpt6, respectively
(Xie and Varshavsky, 2000). A model of delivery of substrates to the proteasome
proposed by Xie and Varshavsky, predicts interaction of E2-E3 complexes with
target proteins recognised by the presence of specific degrons, subsequent
ubiquitination and delivery of the bound substrate to chaperone-like proteins of the
19S component of the 26S proteasome for degradation (Xie and Varshavsky,
2000).
The precise mechanisms of entry of substrates into the catalytic core and exit
from the proteasome are not completely understood. The differences displayed by
the bacterial Thermoplasma acidophilum and the yeast proteasomes as far as entry
into the catalytic compartment is concerned, do not permit the deduction of a
general mechanism. The T. acidophilum proteasome contains two entry sites at the
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ends of the cylinder which are in contact with the seven a subunits. These pores
are absent from the yeast proteasome, which appears to require rearrangement of
the a subunits in order to allow entry of the substrate. Such rearrangements may
occur following association with the 19S cap which would provide the necessary
ATPase activity. The interface between a and (3 rings in the yeast proteasome,
unlike its bacterial counterpart, exhibits narrow side orifices coated with polar
residues, which lead to the active Thr sites of the (3 subunits. ATP-dependent
rearrangement of these residues leads to generation of openings of approximately
10 A in diameter which may serve as passage pores for unfolded protein substrates
(Hershko and Ciechanover, 1998).
Another activator of the 20S that does not require ATP to exert its effect is the
11S or proteasomal activator 28 (PA28), a ring-shaped hexamer comprising
alternating a and (3 subunits, that binds 20S on either or both ends. Association of
20S with two 1 IS particles leads to the formation of a complex that unlike the 26S
proteasome, degrades only peptides and not intact ubiquitinated proteins. This is
indicative of a role in processing 26S-generated proteolytic fragments into smaller
peptides that can be recognised as epitopes by the class I MHC complex
(Ciechanover, 1998). In support of this view, a proteolytic complex that consits of
20S bound to both 19S and 11S on either side, has been reported, that is able to
perform proteolysis of intact Ub-tagged proteins and subsequent trimming of the
resulting peptides (Hendil et al., 1998).
1.6.13.2 Subcellular localisation of the proteasome
Proteasomes are found dispersed in the cytosol or associated with ER
membranes and the centrosome. The NLS signal present in a rings of the 20S
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particle, is responsible for the nuclear distribution of the 26S complex.
Fractionation studies have revealed the localisation of proteasomes at the nuclear
envelope (Enenkel et al., 1998). Such diversity in the intracellular distribution of
the proteasome could be the result of the action of modulators (e.g. the 19S or 1 IS
particles) to serve as adapters that link the proteasome with subcellular
compartments. An alternative mechanism would involve the implication of IFN-y-
inducible |3 subunits. However, both models contain drawbacks. In the former, a
negative point is the complexity of the existence of multiple adapters for different
types of association. In the latter, the presence of IFN-y-inducible (3 subunits
exclusively in vertebrates would fail to explain subcellular distribution in other
types of organisms.
Hirsch and Ploegh suggest a model that arises by analogy to the association of
the ribosome with the ER membranes. Proteasomes have been documented to
associate with both soluble and membrane-bound proteins. Ubiquitination of
membrane proteins occurs while the substrates are still embedded in the membrane.
Subsequent interaction of the Ub-tagged polypeptide with the proteasome could
result in anchoring the protease complex to the membrane and thus altering its
subcellular localisation. Release of the proteasome from the membrane-bound
complex and return to the pool of free proteasomes would follow substrate
degradation (Hirsch and Ploegh, 2000). The same principle would apply for
substrates bound to other organelles such as the centrosome or the cytoskeleton.
Proteasomes are absent from the ER lumen but their association with the ER
membrane suggests a role in turnover of ER-resident polypeptides. ER-localised
chaperones probably function to recognise partially folded or mis-folded proteins
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and transport them to sites where their cytosolically exposed regions could be
tagged by Ub molecules. These regions act to recruit the proteasome to the ER
membrane. Interaction of the substrate with the proteasome results in removal of
the protein from the ER membrane through, possibly, a protein-conducting
channel. According to this view, which resembles the co-translational translocation
of polypeptides accomplished by the ribosome, the proteasome is indirectly linked
to the membrane in a process referred to as "co-degradational translocation"
(Hirsch and Ploegh, 2000).
1.6.13.3 Ub-independent function of the proteasome
The proteasome was identified by its association with the ubiquitin pathway of
protein degradation, as the protease responsible for the destruction of ubiquitinated
polypeptides. However, it is also able to function in the regulation of proteins that
do not bear Ub tags.
This process, that is also ATP-dependent, has been observed in the cases of
casein, albumin and the oncoprotein c-Jun, to be reduced by several -fold but still
operate despite the absence of Ub. The latter is also rapidly degraded in a Ub-
dependent manner in vivo. The enzyme ornithine decarboxylase involved in
polyamine biosynthesis, is regulated by the 26S proteasome in a Ub-independent
fashion, presumably due to the exposure of a cryptic degradation signal found at its
C-terminus that is revealed upon interaction with antizyme and serves as a
recognition cue for the proteasome (Coux et al., 1996). Ubiquitin-independent
degradation via the proteasome may exist for other unidentified cellular proteins.
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1.6.13.4 Inhibition of the proteasome
The discovery of a number of inhibitors of the proteasome has been proven a
very powerful research tool in the study of its structure and function as well as its
participation in the ubiquitin-mediated degradation of specific proteins.
Additionally, these molecules have a potential role in medicine and biotechnology.
Their ability to mediate the turnover of transcription factors by blocking the
proteasomal degradation pathway, may lead to regulation of a number of genetic
diseases. Their application in cancer therapy is also a possibility but careful
assessment of potential toxic effects would be necessary.
1.6.13.4 (a) Non-specific inhibitors
Peptide aldehydes
The first inhibitors to be identified, were the peptide aldehydes, N-acetyl-Leu-
Leu-norleucinal (ALLN) and N-acetyl-Leu-Leu-methional (ALLM) which were
found to covalently and irreversibly modify the Thr active site of (3 subunits, thus
blocking the degradation of the majority of cellular proteins. Peptide aldehyde
inhibitors subsequently identified, include Carbobenzyl-(Cbz)-Leu-Leu-norvalinal
(MG-132) and Cbz-Leu-Leu-norvalinal (MG-155) which act to suppress the
chymotrypsin-like activity of the proteasome (Lee and Goldberg, 1998). Cbz-Ile-
Glu-(0-t-Bu)-Ala-leucinal (PSI) is another aldehyde inhibitor that is able to block
the activity of the 26S proteasome without affecting the ATPase or isopeptidase
activities.
Peptide aldehydes are described as reversible inhibitors because their removal
restores proteolytic activity and they generally do not affect cell viabilty for 10-20
hours (Lee and Goldberg, 1996). However, their action was not specifically
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targeted to the proteasome, since at higher concentrations they were observed to
inhibit lysosomal cysteine proteases and calpains (Hershko and Ciechanover, 1998)
(Lee and Goldberg, 1998).
1.6.13.4 (b) Proteasome-specific inhibitors
Proteasome inhibitors that are much more specific than peptide aldehydes in the
sense that they target only a few non-proteasomal peptidases or act exclusively to
inhibit the proteasome, are classified in this group. Such inhibitors include
lactacystin, carbobenzyl-Leu-Leu-Leu-vinyl sulfone (Cbz-L3VS), peptide boronic
acids and epoxomicin (Fenteany et al., 1994) (Bogyo et al., 1997) (Meng et al.,
1999).
Lactacystin
Lactacystin is a Streptomyces metabolite that inhibits cell- cell progression and
induces de-differentiation in Neuro 2A murine neuroblastoma cell line (Dick et al.,
1996). Hydrolysis of lactacystin gives rise to its active analogue clasto -lactacystin
|3-lactone which can readily penetrate cells. |3-lactone acts as a pseudosubstrate
that binds to the hydroxyl groups on the active site Thr of the (3 subunits and
inactivates irreversibly the chymotrypsin and trypsin-like activities of the
proteasome. Despite its apparent specificity for the proteasome, lactacystin also
inhibits cathepsin A and tripeptidyl peptidase II (Geier et al., 1999).
Vinyl sulfone and boronic acids
Similar to that of lactacystin, is the action of Cbz- L3VS. It covalently modifies
the N-terminal active site Thr of (3 subunits. Its action is irreversible and affects all
three characterised peptidase activities of the proteasome. It is also able to inhibit
non-proteasomal proteases such as cathepsin S (Lee and Goldberg, 1998).
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A class of proteasome inhibitors that contain an inhibitory boronate group
linked to a natural or synthetic peptide sequence [Cbz-Leu-Leu-Leu-B(OH)2], are
able to reversibly attach to proteasomal catalytically active sites. Although their
activity rate is approximately 100 times slower compared to peptide aldehydes,
they display higher specificity for proteasomal proteases.
Epoxomicin
Epoxomicin is a natural a,'(3'-epoxyketone product, isolated from an
Actinomycetes strain, which displayed anti-tumor activity against murine B16
melanoma tumors. It has been found to covalently bind to the IFN-y-inducible (3
subunits LMP7 and MECL1 as well as their normal counterparts Y and Z subunits
of the 20S proteasome. It inhibits primarily the chymotrypsin-like activity but it
also affects the trypsin- like and PGPH-like at 100- and 1000-fold slower rates,
respectively (Meng et al., 1999).
Epoxomicin is cell permeable and can inhibit proteasomal activity potently,
selectively and irreversibly. It has been reported to inhibit the chymotrypsin-like
activity 80-fold faster than lactacystin and 4-fold faster than clasto -lactacystin (3-
lactone. It targets the proteasome highly specifically, since it does not inhibit any
of the known non-proteasomal proteases affected by other peptide-based inhibitors.
At concentrations up to 50 p,M, it remains unreactive against trypsin,
chymotrypsin, cathepsin B, papain and calpain. Epoxomicin is described as a
unique molecular probe, which possesses the versatility to investigate the function
of the proteasome in normal and pathological processes (Meng et al., 1999).
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1.6.14 Functional diversity of the ubiquitin pathway
The ubiquitin pathway is employed in a wide range of cellular processes,
including the cell cycle, cellular response to stress and extracellular signals,
modulation of cell surface receptors, ion channels, DNA repair, differentiation and
development, organelle biogenesis, the immune and inflammatory responses and
apoptosis. Defects in the pathway have been implicated in the pathogenesis of a
number of inherited and acquired diseases, which is hardly surprising, given the
variety of substrates and processes associated with the ubiquitination cascade
(Ciechanover, 1998). Conjugation to Ub may serve the regulation of protein levels
by specific degradation but it could also function to promote protein synthesis.
Ubiquitin has been described to act as a chaperone to facilitate organelle
biosynthesis (Finley et al., 1989).
In the following section, the diversity of the cellular role of ubiquitin will be
demonstrated focusing on its involvement in the pathogenesis of a number of
diseases. A distinction between the destructive and non-destructive functions of the
ubiquitin system will also be presented.
1.6.14.1 Destructive role of Ub
1.6.14.1 (a) Implication of the Ub pathway in disease
Cell survival and differentiation depend on spatial and temporal regulation of
protein levels and defects in relevant control mechanisms, lead to manifestation of
pathological states. Aberrations in the ubiquitin system of protein turnover, give
rise to alterations in the steady-state levels of substrate proteins, thus resulting in
the onset of either of two types of diseases. In the first type, pathology is due to
accelerated degradation of a substrate, whereas decreased turnover rates of target
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proteins are characteristics of the second type. This second type includes diseases
that arise by mutations in either the enzymes involved in the system, or in
recognition motifs on substrate proteins (Figure 18) (Hershko et al., 2000). Gain-
of-function mutations result in accelerated degradation, whereas loss-of-function
ones, lead to stabilisation of target polypeptides.
The degradation of p53 tumour suppressor, mediated by E6-AP ubiquitin ligase,
is accelerated via its association with the human papilloma virus (HPV) E6 protein.
E6 renders p53 recognisable by the ligase. The level of p53 is extremely low in
uterine cervical carcinomas, which suggests that the virus uses the removal of the
tumour suppressor as a means to transform cells.
Mutations in E6-AP that prevent association with its unidentified native
substrate(s) (p53 is not a native substrate for E6-AP), result in their accumulation
which appears to be toxic for the developing brain. Built-up of protein due to
malfunction in E6-AP, is responsible for a pathological state described as
Angelman's syndrome. It is a rare inherited disorder demonstrated by seizures,
mental retardation and abnormal gait.
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FIGURE 18. Pathogenesis of Ubiquitin System-related diseases. De regulation of
the function of the ubiquitin system of protein degradation is responsible for the
manifestation of two types of disease: pathological states may arise either due to
increased degradation of a protein, or owing to accumulation of a substrate protein, as
a result of a decrease in its degradation rate (Adapted from Hershko, 2000).
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Decreased rates of protein degradation as a result of mutations in recognition
motifs on target proteins, have been observed in the cases of (3-catenin and ENaC.
P-catenin is involved in signal transduction and differentiation of the colorectal
epithelium. Mutation in the phosphorylation-targeting sequence of p-catenin which
links it to the ubiquitin ligase complex, is responsible for stabilisation and
accumulation of the protein. Uncontrolled activity of P-catenin is associated with
colorectal carcinomas and malignant melanomas. Stabilisation of P-catenin may
also be caused by mutations in adenomatous poliposis coli, a member of the
degradation complex.
The amiloride-sensitive epithelial sodium channel (ENaC), is involved in
sodium transport in kidney and other epithelia and it also regulates blood pressure.
It is a heterotrimer of aPy subunits, each containing two proline rich (PY)
sequences. These sequences mediate binding to Nedd4 ubiquitin ligase at the WW
domain. Deletion of PY motifs from P or y subunits, gives rise to a pathological
state termed Liddle's syndrome in which accumulation of the channel is the cause
of hypertension owing to excessive re-absorption of sodium and water (Staub et al.,
1996).
Immunohistochemical studies in many neurological disorders such as
Alzheimer's (AD), Parkinson's (PD) and Lewy body diseases, amyotrophic lateral
sclerosis (ALS) Creutzfeld-Jacob disease (CJD), Huntington's Disease (HD) and
Spinocerebellar Ataxias (SCA), have revealed the presence of ubiquitin conjugates
in both cytoplasmic inclusion bodies and in structures associated with the
endosome/lysosome (Arnold et al., 1998). It is not possible to conclude with
certainty the precise role of ubiquitin in the pathology of these diseases.
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Aggregation of ubiquitinated proteins could be due to cell-specific defects in either
an enzyme involved in the pathway (e.g. a ligase), in a recognition motif of the
substrate itself (e.g. phosphorylation site), or incorrect assembly of the proteasomal
machinery. In any case, protein accumulation is responsible for the pathology and
eventual death of specific neuronal populations.
Inclusions result either from the self-tendency of unfolded proteins to associate
and form insoluble aggregates or in a more complicated process that involves the
transport of smaller aggregates along microtubules in a dynein-dependent
retrograde manner, to form larger structures termed aggresomes (Johnston et al.,
1998). Aggresomes are membrane-free cellular structures, formed when the cell's
capacity to degrade misfolded proteins is exceeded. They contain ubiquitinated
proteins, heat-shock proteins (hsp), ubiquitin-conjugating enzymes and
proteasomes (Kopito, 2000). The presence of proteasomes in these structures
indicates that aggresomes may be sites of proteolysis. An alternative view is that
proteasomes are trapped within aggresomes, by polypeptides that are refractory to
proteolysis, thus possibly reducing the overall capacity of the cells to degrade
proteins (Sherman and Goldberg, 2001). Sequestering of unfolded proteins in the
aggresome may serve to prevent their association with other cellular constituents
and risk disruption of various cellular processes.
In polyglutamine-repeat containing proteins in HD and SCA, there is evidence
to suggest that the extended polyglutamine sequence hinders degradation by the
26S proteasome through interactions with other molecules that prevent entry of the
substrate in the 20S catalytic complex. Partial degradation releases smaller
fragments with deleterious polyglutamine domains (Wellington et al., 1998).
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Aggregation and abnormal association of mutant huntingtin with other cell
proteins, results in impaired neuronal function and subsequent cell death. HD
patients experience extensive neuronal loss in the striatum and cerebral cortex that
is demonstrated by a reduction in brain size at the later stages of the disease.
Patients with another major neurological disorder, Parkinson's disease, display
inclusions of a-synuclein, termed Lewy bodies, in their substantia nigra. These
inclusions contain large amounts of ubiquitn and proteasomes which suggest that
a-synuclein may be ubiquitinated, either prior to or following aggregation. The
identification of parkin, a protein whose mutation results in one form of hereditary
PD, as a ubiquitin ligase, classifies it as a candidate for a-synuclein ubiquitination
(Sherman and Goldberg, 2001).
Heritable peripheral neuropathies caused by an increase in PMP22 expression,
appear to be associated with the accumulation of the protein in aggresomes
(Notterpek et al., 1999). Duplication of a 1.5 Mb region in human chromosome 17,
that includes the PMP22 gene, results in a group of peripheral neuropathies
collectively referred to as Charcot-Marie-Tooth type 1A (CMT1A) disease. In
normal individuals, PMP22 is rapidly turned over in the Schwann cells. It has been
suggested that the cell regulates specifically the levels of PMP22 via the
ubiquitin/proteasome pathway. However, overexpression of the protein could
overload the degradation machinery of the cell, leading to intracellular
accumulation of PMP22. Inhibition of the proteasome with the inhibitor
lactacystin, resulted in accumulation of ubiquitinated PMP22 in aggresomes. The
possible implication of ubiquitinated protein aggregates in peripheral neuropathies
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remains unclear. It is still not known whether ubiquitinated proteins undergo
degradation in inclusion bodies or accumulate associated with proteasomes.
1.6.14.2 Non-destructive role of Ub in ribosome biogenesis
Ubiquitin has been established as a major regulator of protein turnover. An
alternative role of the protein has been proposed, that involves its reversible
association with a substrate in order to regulate its function without affecting its
metabolic stability. Association with Ub has been observed to promote the
formation of cellular components, whereby ubiquitin acts in a chaperone-like
manner. One such example is the biogenesis of the ribosome.
Natural gene fusions give rise to linear ubiquitin adducts that are post-
translationally processed to yield free ubiquitin molecules. In yeast S. cerevisiae,
the hybrid proteins UBI1, UBI2 and UBI3 consist of Ub fused to amino acid "tail"
sequences. These "tails" have been identified as ribosomal proteins whose
association with Ub promotes ribosome biogenesis. The Ub moiety of UBI1-UBI3
possibly functions to transiently stabilise the tails and facilitate their incorporation
into the nascent ribosomes. This is probably accomplished by increasing the rate of
transport to and association with the ribosome, thus reducing the degradation rate
of newly synthesised UBI1-UBI3, while transported to the ribosome (Finley et al.,
1989).
In intact yeast ribosomes, ubiquitin is ligated to the L28 component of the large
ribosomal subunit. Heavily ubiquitinated ribosomes have been found to be active in
translation, in vitro. The ubiquitination of L28 is cell cycle dependent. It exhibits
an increase during S phase and it declines in G0 and G,. Considering the fact that
L28 is a stable protein, ubiquitination in this case plays a non-proteolytic role
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(Spence et al., 2000). The multi-ubiquitin chain that is conjugated on L28 is formed
by ligation of the C-terminus of one Ub residue on Lys63 of the previously linked
ubiquitin. Ligation on Lys48 gives rise to chains that are preferentially recognised
and degraded by the proteasome. This variant multiubiquitin chain (Lys63- linked)
has been found to be necessary for the correct function of the translation machinery
of the cell.
The ubiK63R yeast mutant, where lysine 63 has been substituted by an arginine,
displays hypersensitivity to the translation inhibitors anisomycin and trichodermin,
that target the peptidyl transferase centre, where L28 is located. This is indicative
of a role of ubiquitinated L28 in the elongation phase of protein synthesis (Spence
et al., 2000). The precise mechanism of such a role remains to be elucidated.
Potential new functions of ubiquitin are currently being investigated and it is
assumed that the signal-recognising components of the pathway are much more
numerous than previously appreciated. The interpretation of ubiquitin-based
signalling, thus, may be critically influenced by the properties of the factors being
involved in the pathway.
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1.7 BACKGROUND TO THE PROJECT
L-periaxin was identified as a cytoskeleton-associated protein localised in the
periaxonal membranes of Schwann cells. Its pattern of developmental expression
and shift in localisation from the adaxonal to abaxonal membranes of myelin-
forming Schwann cells, following their association with axons, implied a role in
the stabilisation of the myelin sheath. This potential role was further supported by
studies performed on mice that lacked a functional Prx gene (PrxPrx- deficient
mice appeared to form a normal myelin sheath, which was, however, unstable,
leading to demyelination and the observation of clinical symptoms associated with
neuropathic pain.
The recently identified participation of L-periaxin in a DRP2-dystroglycan
complex implicated L-periaxin in the regulation of the terminal stages of the
myelination process. L-periaxin associates with the DRP2-dystroglycan complex
via a highly basic N-terminal domain, which also contains a NLS signal that is
responsible for targeting the protein to the nucleus in embryonic Schwann cells. A
PDZ domain, found upstream of the basic region, serves in mediating
homodimerisation of the protein, which is believed to contribute to the stability of
the DRP2-dystroglycan complex.
The protein also comprises a region of repeats and a highly acidic region
proximal to the C-terminus. Acidic regions have been described as protein
interaction motifs, therefore the potential role of the C-terminal acidic domain of
L-periaxin was sought. Mutations in human L-periaxin are responsible for the
manifestations of DNS and CMT4F neuropathies. Furthermore, a recently
identified mutation that results in a truncated version of L-periaxin, which lacks the
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C-terminus (including the acidic domain), is responsible for the early onset of
autosomal recessive demyelinating peripheral neuropathy similar to CMT 4F (A.
Williams, personal communication). This development increased the possibility of
an important functional role of the C-terminal region of the protein, which was
investigated.
1.8 PROPOSED STUDY
In an attempt to identify a potential functional role for the acidic domain and
the C-terminus of L-periaxin, the possibility of their involvement in protein-protein
interactions was assessed. The yeast-two hybrid genetic assay was employed in
conjunction with biochemical methods, in order to identify and subsequently verify
the association of L-periaxin with peripheral nerve proteins. The significance of the
observed in vitro interaction was addressed by investigating the physiological role
of the identified L-periaxin binding partner.
The effect of mutation of the interacting protein in the level of expression and
localisation of L-periaxin, as well as the morphology of the Schwann cell and the
process of myelination, was also considered. The generation of a transgenic mouse
which over-expressed a mutant version of a positively interacting clone (dominant




2. MATERIALS AND METHODS
2.1 GENERATION OF L-PERIAXIN CONSTRUCTS FOR THE
YEAST TWO-HYBRID SCREEN
Binding partners of L-periaxin were sought by applying the yeast two- hybrid
technique described earlier (section 1.5). Truncated constructs of L-periaxin, to be
used as "baits", were generated as follows (Figure 19). PeriCl (762-1383 aa)
contained the region 37 amino acid residues after the repeat domain up to the C-
terminus of the protein (623 aa). PeriC2 (996-1383 aa) consisted of the C-terminal
389 amino acids. PeriRA3 (700-1081 aa) encompassed a region of 370 residues
between the end of the repeat region and the beginning of the acidic domain.
Smaller constructs were also created in an attempt to deduce the minimal region of
periaxin employed in interactions with library clones. PeriR5 contained 283 residues
(712-995 aa) and PeriA6 encompassed 170 amino acids (996-1165 aa) which
included the end of the repeat region and the whole of the acidic domain,
respectively. PeriA7 (996-1080 aa) was a truncated version of PeriA6 which lacked
the last 85 amino acids of the acidic domain. The 216 C-terminal amino acids of L-
periaxin were used in PeriC8, whereas PeriC9 encompassed the extreme C-terminus
of the protein (54 aa). All constructs were generated by PCR reactions using full
length rat L-periaxin in pSPORT vector as template and were confirmed by













FIGURE 19. Full length L-periaxin and constructs used in yeast two-hybrid.
(Amino acid residues shown).
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2.1.1 PeriCl
To generate PeriCl, full length L-periaxin in pSPORT was used as template in a
PCR reaction with primers SVl~p300 to amplify a 735 bp product which possessed
an EcoRI restriction site at the 5' end.The PCR reaction mix (50 pi) consisted of 2 pi
template (200 ng), 5 pi 2 mM dNTPs, 5 pi 5pM primers, 5 pi Dynazyme Buffer xlO,
sterile Milli Q water and 0.5 U Dynazyme thermostable DNA polymerase. A
negative (no template) control reaction was also performed. The conditions used
were: denaturation at 94 °C for 1 min, annealing at 55 °C for 1 min and exten sion at
72 °C for 30 s for 5 cycles, followed by 26 cycles of 94 °C for 40 s, 55°C for lmin
and 72 °C for 30 s. The final stage comprised 1 cycle of denaturation at 94 °C for 40
s, annealing at 55 °C for 1 min and elongation at 72 °C for 5 min.
The SVl-p300 PCR product was digested with EcoRI and Xhol (Gibco BRL).
The PCR product (22 pi) was incubated with 3 pi Buffer H (Mannheim Boehringer
BCL), and 15 U of each enzyme (1.5 pi) in a final volume of 30 pi with Milli Q at 37
°C overnight. It was subsequently run on a 2% agarose TBE gel to resolve two
fragments of 438 and 297 bp respectively. The 438 bp fragment was used to ligate to
periaxin in pSPORT that had previously been digested with the same restriction
enzymes. This gave rise to a periaxin construct that lacked the initial 2553 bp of the
protein. This was digested with the restriction enzymes EcoRI and Bglll. For this
purpose, 2 pi mini-prep DNA were used in a digestion reaction with 2pl React 3
buffer (Gibco BRL) and 10 U of each enzyme (1 pi) to a total volume of 20 pi with
Milli Q water. The double digests were run on a 1% agarose gel in TAE and purified
using the QIAEX kit for agarose gel extraction (Qiagen) according to the
manufacturer's instructions. They were subsequently ligated into the cloning vector
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pODB8 between the EcoRI and BamHI restriction sites of its multiple cloning site
(MCS). For the ligation reaction, 4 pi of each of the vector and insert DNA were used
with 1 pi ligation buffer (Fermentas MBI) and 1 U T4 DNA Ligase (1 pi) (Fermentas
MB I), ligation was possible because BamHI and Bglll are described as
compatible enzymes, i.e. they yield complementary sticky ends (G |GATCt C for
BamHI and A |GATCf T for Bglll). pODB8 contains the binding domain region of
GAL4 (147 bp) and includes the TRP1 gene which permits growth of the host yeast
cells in media lacking the amino acid tryptophan.
2.1.2 Peri C2
The construction of PeriC2 required a PCR reaction with primers SV2-CSG2
under the same conditions as for PeriCl described earlier. A 752 bp product was
digested, in a total volume of 35 pi, with 2 pi React 3 buffer, 15 U EcoRI (1.5 pi), 3.5
pi Milli Q for 1.5 h at 37 °C, followed by addition of 2 pi React 3 buffer, 15 U StuI
(1.5 pi), 1.5 pi Milli Q and incubation at 37 °C overnight. The double digest gave rise
to two fragments of 500 and 189 bp, respectively. The latter fragment was ligated to
periaxin in pSPORT, previously digested with EcoRI/ StuI. A construct of the C-
terminal 1167 bp of the protein was formed which was subsequently ligated into the
GAL4 binding domain vector pODB8, as described for PeriCl.
2.1.3 PeriRA3
PeriRA3 was generated by PCR with primers SV3F-SV3R. To amplify a 1.1 kb
fragment, the following conditions were required: 5 cycles of denaturation at 94°C for
lmin, annealing at 58°C for 1 min and extension at 72 °C for 4 min. This was
followed by 28 cycles of 94 °C for 40 s, 58 °C for 1 min and 72 °C for 4 min. The
final cycle involved denaturation at 94 °C for 40 s, annealing at 58 °C for 1 min and
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extension at 72 °C for 5 min. The product contained an EcoRI and a BamHI
restriction site at the 5' and 3' end respectively, which allowed ligation into the cloning
vectors pSPORT and pODB8, after they were digested with the same enzymes. For
this purpose, 25 pi purified (QIAEX) PCR product were digested with 3.5 pi REact 3
buffer and 15 U each enzyme (1.5 pi) in a total volume of 35 pi with Milli Q. The
reason for generating a construct in pSPORT was to use it in sequencing reactions, as
this vector contains the sequencing primer T7.
2.1.4 PeriR5
PeriR5 comprised 283 aa between positions 712 and 995. It was generated as a
PCR product using primers SV3F and SV5R under the same conditions as for
PeriRA3. The product contained an EcoRI site at the 5' end and a 3' end BamHI site
which were used to ligate into the cloning vector pODB8.
2.1.5 PeriA6
PeriA6 was generated using primers SV2F2 and SV4R. To amplify a region
comprising 170 aa (positions 996-1165) including the acidic domain of the protein, a
PCR reaction was carried out under the following conditions: denaturation at 94 °C for
1 min, annealing at 60 °C for 30 s and extension at 72 °C for 1 min (5 cycles). The
next stage consisted of 28 cycles of denaturation at 94 °C for 40 s, annealing at 60 °C
for 30 s and extension at 72 °C for 1 min. The final cycle was performed at 94 °C for
40 s, 60 °C for 30 s and 72 °C for 2 min. The product was cloned into pODB8 between
the EcoRI and BamHI sites of its MCS region.
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2.1.6 PeriA7
PeriA7 was constructed using primers SV2F2 and SV3R under the same PCR
conditions as for PeriA6. It was designed to encompass 85 amino acids between
positions 996 and 1080. It was cloned into pODB8 between EcoRI and BamHI.
2.1.7 PeriC8
PeriC8 comprised the 216 C-terminal amino acids of L-periaxin (residues 1168-
1383). It was generated as a PCR product with primers SV6F and DLS24 under the
same conditions described for PeriA6. It was also cloned in pODB8 between the
EcoRI and BamHI sites of the vector.
2.1.8 PeriC9
The extreme C-terminus of L-periaxin (54 aa) was amplified in a PCR reaction
with primers SV7F and DLS24 (PCR conditions as described for PeriA6). The product
contained an EcoRI site at its 5' end and a BamHI site at the 3' end. It was cloned into
the GAL4 binding domain vector pODB8.
Maps of the plasmids used for the generation of the GAL4 hybrid proteins are
shown in APPENDIX I (p. 133).
102










































Table 3. Oligonucleotide primers for the generation of L-periaxin
constructs. Restriction sites are underlined and the presence of a STOP codon
is indicated.
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2.2 SEQUENCING OF THE PCR PRODUCTS
The PCR products for constructs PeriCl, periC2 and PeriRA3, in the cloning
vector pSPORT, were sequenced in a manual sequencing reaction with the T7
promoter primer. Sequencing of all other constructs was performed using the
automated sequencing service at the Department of Biochemistry, University of
Dundee, UK.
In the manual sequencing reaction, 1 pg plasmid DNA was denatured with 2 pi
2M NaOH in a final volume of 8 pi, for 10 min at room temperature. The sample was
subsequently precipitated with 3 pi 3M sodium acetate pH 5.5, 7 pi Milli Q water and
60 pi absolute ethanol at -70 °C for 20 min. The DNA was then centrifuged at 4 °C
for 30 min at 13,000 rpm and the pellet was washed with 200 pi 70% ethanol.
Following a 5 min centrifugation, the pellet was vacuum dried for 5 min and re-
suspended in 5 pi distilled water. The denatured DNA sample was annealed to T7
sequencing primer (1 pi, 5 pM) with the addition of 1 pi annealing buffer and
incubation at 37 °C for 20 min followed by 10 min at room temperature. The
annealed template was labelled in a 4-min incubation at room temperature with 3 pi
labelling mix. This consisted of 1.5 pi Label Mix A, 1 pi T7 DNA polymerase
diluted 1:4 v/v with dilution buffer, and 0.5 pi [a-^^S] dATP. The reaction was
terminated by the addition of 2.3 pi of the labelling mix to each of 4 tubes containing
1.3 pi of A, G, T, C termination mixes, that had been pre-warmed at 39 °C for 4 min.
After a 5 -min incubation at 39 °C, 2.5 pi of STOP buffer were added to each of the 4
tubes and the samples were placed on ice or stored at -20 °C overnight, prior to
electrophoresis. All the reagents for labelling were provided in the Pharmacia T7
labelling kit. Electrophoresis of the labelled DNA samples was performed on a
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sequencing gel that consisted of 6% acrylamide: bisacrylamide, 42% urea, 0.005%
TEMED, 0.0025% APS in TBE. Aliquots of DNA (1.8 pi) were pre-heated at 80 °C
for 3 min and then loaded on the gel and run at 60 W for approximately 3.5 h. The gel
was subsequently embedded into a fixative solution (5% methanol, 5% acetic acid) for
30 min and dried onto 3 MM Whatman paper under vacuum for 1 h at 80 °C. The
dried gel was exposed to X-ray film (Agfa Curix RP-1 Plus) for 48 h at room
temperature. It was developed for 3 min using Kodak X-ray developer and fixed for 2
min with Kodak Industrex fixer.
2.3 EXPRESSION OF PERIAXIN CONSTRUCTS
2.3.1 Fusion protein expression and extraction from yeast cells
The constructs were used to transform yeast strains CGI945 and Y190 as
described in the LiAc/SS-DNA/PEG transformation protocol (Gietz and Sciesti, 1995)
(see section 2.4). Colonies (3) of approximately 1-2 mm in size were allowed to grow
in 9.4 ml synthetic dropout (SD) medium that lacked the amino acid tryptophan (-T)
with 0.4 ml 50% glucose, for 48 h at 30 °C, 210 rpm. The yeast cultures were spun at
3,000 rcf for 5 min and the cell pellet was re-suspended in 50 ml YPAD medium,
supplemented with 25% Glucose (final concentration). The culture was allowed to
grow at 30 °C, 210 rpm until the OD600 was approximately 0.6. At this point, the
culture was harvested in pre-chilled Sorvall 50 ml tubes, half way filled with ice and
spun at 1,000 rpm, at 4 °C for 5 min in a Sorvall RC 5B centrifuge. The supernatant
was discarded and the pellet was re-suspended in 50 ml ice cold H20, to be spun as
before. The final pellet was immediately frozen by immersion in liquid nitrogen and
stored at -70°C.
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To extract the expressed fusion protein from the yeast cells, the frozen pellet was
quickly thawed by resuspension in 100 pi Complete Cracking Buffer per 7.5 OD600
units (see APPENDIX I, p. 132). The OD^ units were estimated by multiplying the
final culture volume by the OD600 reading obtained from the spectrophotometer. To
determine the absorbance at 600 nm, 1 ml culture was used. The Complete Cracking
Buffer had been pre-warmed at 60 °C and the pellet was briefly incubated in a water
bath at the same temperature for no longer than 2 min to avoid the risk of proteolysis.
The cell suspension was transferred to a 1.5 ml screw-cap microfuge tube which
contained 80 pi sterile glass beads (Sigma) per 7.5 OD600 units, and subsequently
incubated in a water bath at 70 °C for 10 min. lOOmM PMSF (1% in Complete
Cracking Buffer) was added and the sample was vortexed for 1 min. Cellular debris
and unlysed cells were pelleted by centrifugation at 13,000 rpm for 5 min at 4 °C, and
the supernatant (SI) was removed into a sterile 1.5 ml screw-cap microfuge tube and
placed on ice. The pellets were re-suspended in 50 pi Complete Cracking Buffer and
boiled at 100 °C for 5 min. PMSF was added as previously and the suspension was
vortexed vigorously for 1 min. This was followed by centrifugation at 13,000 rpm at 4
°C for 5 min and then the supernatant (S2) was combined with SI. The final
supernatant was boiled for 4 min and immediately loaded onto an SDS polyacrylamide
gel for protein separation by electrophoresis (SDS-PAGE).
2.3.2 Western Blotting
Proteins resolved according to size by SDS-PAGE were transferred onto
nitrocellulose membrane (0.45 pm, Schleicher & Schuell) in a buffer containing 25
mM Tris-HCl pH 8.3, 250 mM glycine and 20% methanol. The transfer was carried
out in a Hoefer Mighty Small Transphor Unit (Pharmacia Biotech) refrigerated
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apparatus for 2 h at 0.5 A. The nitrocellulose filter was then blocked in 5% dried
skimmed milk, 0.1% Triton X-100 in PBS overnight. It was subsequently rinsed with
0.2% gelatin, 0.1% Triton X-100 in PBS and incubated with the primary antibody,
diluted in the same buffer, for 1 h on a shaker. The primary antibodies, raised in
rabbits, were specific for the C-terminus of periaxin for PeriCl and PeriC2 (1369-
1383 aa, provided by Prof. P.J. Brophy) and the repeat region of the protein for
PeriRA3 (713-728 aa, obtained from N. Groome). Following 3 washes, for 10 min
each, the filter was incubated with donkey anti-rabbit IgG HRP-labelled antibody
(SAPU), in the same buffer as for the primary antibody, for 1 h. Excess secondary
antibody was removed with three 10- minute washes. The peroxidase was detected
using the enhanced chemiluminescence (ECL) method (Amersham).
2.4 YEAST TRANSFORMATION IN THE LiAc/ss-DNA/PEG
PROTOCOL
Yeast S. cerevisiae cultures (2.5 xlO8 cells) were grown at 30 °C, with shaking at
210 rpm, in a 50 ml culture supplemented with glucose (20% final concentration),
until the cell density reached 2 xlO7 cells/ml (approximately after 5 h). The culture
was harvested in a sterile 50 ml Falcon tube and pelleted by centifugation at 3,000 rcf
(Megafuge 1.0 Heraeus benchtop centrifuge) for 5 min. The supernatant was discarded
and the cell pellet was re-suspended in 25 ml sterile MilliQ H20. It was subsequently
spun for 3 min at 3,000 rcf. The supernatant was removed and the cells were re-
suspended in 100 mM LiAc (1 ml) and transferred to a 1.5 ml microfuge tube. The
cells were precipitated at 13,000 rpm (Biofuge 13 Heraeus benchtop centrifuge) for 15
s and the LiAc was removed. They were subsequently resuspened in 100 mM LiAc, to
a final volume of 400 pi and mixed by vortexing. The yeast cell suspension was
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distributed to sterile 1.5 ml microfuge tubes (50 pil/tube). The LiAc was removed
following centrifugation for 20 s. The transformation mix consisted of the following
components, added in the order listed below: 50% PEG (240 pi), 1 M LiAc (36 pi), 2
mg/ml ss-DNA (25 pi) previously boiled for 5 min and kept on ice, 0.1-10 pg plasmid
DNA and MilliQ H20 to a final volume of 50 pi. The contents of each tube were
mixed by vortexing and subsequently incubated in a 30 °C water bath for 30 min. This
was followed by heat shocking in a 42 °C water bath for 22 min. The transformation
mix was then spun at 6,000 rpm for 15 s. The supernatant was removed and the cell
pellet was re-suspended in 1 ml MilliQ H20. A fraction of the transformation mix was
delivered onto the appropriate dropout medium plates, which were subsequently
incubated at 30 °C for 2-4 days to allow growth of the transformants.
2.5 REPORTER GENE AUTOACTIVATION TESTS AND
TRANSFORMATION EFFICIENCY CONTROLS
Yeast strains CGI945 and Y190 were transformed, according to the
LiAc/ssDNA/PEG transformation protocol, with each of the constructs and allowed to
grow on media lacking the amino acid tryptophan (-T) or both tryptophan and
histidine (-TH). The plates were assessed for expression of lacZ in the former case,
and growth in the latter. Expression of lacZ would give a blue product upon reaction
of its product, (3-galactosidase, with the chromogenic substrate X-gal. This was
investigated by filter lifts on the -T plates according to the Colony Filter-Lift Assay
(see section 2.6). A positive control for the lacZ reaction is the interaction between
pVA3-l and pTDl-1. PVA3-1 encodes a DNA-BD fusion of murine p53 in the
cloning vector pAS2-l whereas pTDl-1 codes for SV40 large T-antigen fused to
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DNA-AD in pACT II. The former plasmid contains the TRP1 gene as a nutritional
marker whereas the latter expresses the LEU2 gene which encodes the amino acid
leucine. Interaction between the two fusion proteins encoded by these plasmids would
permit growth on -TLH medium. The negative control for this reaction was the co-
transformation with plasmids pTDl-1 and pLam5'-l. The latter plasmid contains the
TRP1 gene and encodes a fusion of the GAL4 DNA binding domain with human
lamin which has been reported not to form complexes nor to interact with most other
proteins. Yeast carrying these two plasmids would be able to grow deprived of
tryptophan and leucine but would require the presence of histidine in the growth
medium. Empty pODB80 vector was used as a control for autoactivation. This
plasmid has the same backbone as pODB8, but lacks the HA epitope found in this
vector. It was considered possible that this epitope could interfere with the activation
of the lacZ gene.
2.6 COLONY FILTER-LIFT ASSAY
The detection of an interaction between proteins in the yeast two-hybrid is
accomplished by the observation of growth in media that lack certain amino acids and
by the expression of lacZ. In the latter case, reconstitution of a functional transcription
factor, as a result of the association of the two test proteins, leads to expression of the
downstream lacZ gene. This is observed by the formation of a blue product upon
interaction of (3-galactosidase, the product of the lacZ gene, with its substrate X-gal.
The colony filter- lift assay is based on the visualisation of this reaction by the
appearance of a blue product.
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Following a three-day incubation at 30 °C, the plates containing yeast colonies
grown in the absence of the amino acids tryptophan and/or leucine, were removed
from the incubator and overlaid with a circular 70 mm sterile filter paper (Whatman #
5) that was allowed to soak on the agar for a few seconds. The filter paper was
subsequently removed with forceps and soaked in liquid nitrogen for 15 s (colony face
up). The frozen filter was then allowed to thaw on 3 MM paper, before it was placed in
a 90 mm petri dish, on top of a second filter which had been soaked in 1ml Z buffer
(60 mM Na2HP04* 2 H20, 40 mM NaH2P04 • 2 H20, 10 mM KCL, 0.1 mM MgS04 •
7 HzO), supplemented with 5% X-gal (20 mg/ml stock in DMF) and 0.27% (3-
mercaptoethanol (Sigma M3148). The petri dishes were placed in tightly sealed Ziploc
plastic bags and incubated at 37 °C. They were checked periodically for the
appearance of blue colouration, which would take from approximately 30 min to 8 h.
2.7 RAT SCIATIC NERVE cDNA LIBRARY SCREEN IN THE
YEAST- TWO HYBRID SCREEN
PeriCl was chosen as "bait" in order to screen a rat sciatic nerve cDNA library by
employing the yeast two-hybrid method. The choice was based on the fact that it was
the largest construct and encompassed regions of L-periaxin that were present in every
other constuct generated for the yeast two-hybrid screen.
The cDNA library was constructed by Dr C.S. Gillespie. Poly-A m RNA from
P9 and P14 rat sciatic nerve was isolated and reverse transcribed using random
nonamers incorporating a Xhol site at the 5' end of the transcript. Second strand
synthesis and EcoRI adaptor ligation were carried out using the cDNA Synthesis kit
(Stratagene # 200401) according to the manufacturer's instructions. Size fractionated
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cDNA was ligated to X ACT II between the EcoRI and Xhol restriction sites of the
vector. The complexity of the directional cDNA library was estimated at 2.8 x 10^
independent clones. Since the transformation efficiency was 1.36 x 10^/pg,
transformation with 30pg library DNA would result in screening the library 1.4 times.
Yeast strain Y190 was transformed with 60 pg PeriCl in pODB8 and 30 pg library
DNA following the protocol described in section 2.4. The transformation mixture was
plated on -TLH 30 mM 3-AT plates (400 pl/plate) and also 1 pi of a 1:10 dilution, 1 pi
and 2 pi on -TL plates to estimate the efficiency of the transformation. The
transformation efficiency was estimated according to the following formula; cfu x
resuspension vol. (pi) / Vol. Plated (pi) x library DNA (pg). This was calculated at
1.07 x 105 which means that the complexity of the library was covered once. The
plates were allowed to grow at 30 °C for 2 weeks.
2.8 TESTING FOR SPECIFIC LIBRARY-"BAIT" INTERACTIONS
The colonies grown on -TLH 30 mM 3-AT were subsequently used in further tests
to assess the specificity of interaction with PeriCl. The possibility of interaction with
the rest of the constructs was also assessed. The procedure to accomplish this included
segregation of the AD and BD plasmids brought about by growth in Synthetic Dropout
(SD) medium (2.58 ml) with 50% glucose (120 pi) and a dropout amino acid solution
that lacks leucine (300 pi) for 48 h at 30 °C, 210 rpm. Segregation was followed by
isolation of yeast plasmid from Ihe putative positive clones.
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2.8.1 Isolation of plasmid from yeast
Overnight cultures in SD/Glucose/-L medium (3 ml) were centrifuged for 1 min at
13,000 rpm and the supernatant discarded. The pellet was re-suspended in 200 pi 100
mM NaCl, 10 mM Tris-HCl pH8.0, 1 mM EDTA, 0.1% SDS and glass beads (0.45
mm, SIGMA) were added just before addition of 200 pi phenol: chloroform. The
samples were vortexed for 1 min and centrifuged at 13,000 rpm for 1 min. The top
aqueous layer was retained and re-extracted with 200 pi phenol: chloroform as before.
The top layer was collected in a 1.5 ml eppendorf tube and the DNA was purified with
QIAEX kit for plasmid DNA purification (Qiagen) according to the manufacturer's
instructions. The purified DNA was used to transform E.coli DH5a (Inoue et al.,
1990).
2.8.2 Isolation of yeast plasmid from bacteria and insert analysis
Alkaline lysis of the bacteria and isolation of amplified plasmid was necessary for
assessment of the presence and size of a library insert. E.coli colonies transformed
with yeast plasmid were grown overnight at 37°C, 210 rpm in 5 ml LB Broth with 20
pi ampicillin (25 mg/ml). The culture (3 ml) was centrifuged for 1 min at 13,000 rpm
and the pellets were re-suspended in 100 pi 25 mM Tris-HCl pH 8.0, 10 mM EDTA,
0.9% w/v glucose followed by addition of 200 pi 200 mM NaOH, 1% SDS. After a 5-
min incubation on ice, 150 pi 11.5% v/v glacial acetic acid, 29.4% w/v potassium
acetate in Milli Q water were added and the samples were incubated on ice for 5 min.
Subsequently, a phenol: chloroform extraction step was performed with 450 pi
phenolxhloroform, vigorous vortexing and centrifugation for 10 min at 13,000 rpm.
The supernatant (350 pi) was removed and precipitated with 2 vol absolute ethanol at -
70 °C for 15-20 min and spun for 20 min at 4 °C, 13,000 rpm. The pellets were
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washed with 70% ethanol (500 pi), centrifuged for 5 min and dried at room
temperature. The dried pellets were re-suspended in 30 pi TE/RNase cocktail
(Ambion) (50:1).
Isolated plasmid was used in a series of digests with either EcoRI/XhoI restriction
enzymes, as the library inserts had been cloned between those two sites, or Bglll
which flanks the whole multiple cloning site of pACT II vector. Plasmid DNA (2 p.1)
was digested in a reaction with 6 pi Milli Q water, 1 pi enzyme buffer and 10 U
restriction enzyme (or 0.5 U of each enzyme in a double digest) in a total volume of 10
pi. Failure of segregation of the two plasmids which would lead to the indication of a
false positive interaction with PeriCl, was accounted for by double digests with the
restriction enzymes EcoRI and BamHI. These are the sites in which PeriCl had been
cloned into pODB8. A band of ~2kb, which is the size of PeriCl, would indicate the
presence of the binding domain vector in the clone.
Clones found to contain a library insert and devoid of the binding domain vector
were subsequently used in transformations with PeriCl and the empty pODB80 vector
in Y190. Activation of lacZ was again tested by filter lifts. Colonies that displayed a
specific interaction with PeriCl were subsequently tested for interaction with the rest
of the L-periaxin constructs by filter lifts. Positively interacting clones were sequenced
with the GAL4 AD forward primer (5' AGG GAT GTT TAA CAC TAC 3') by
automated sequencing.
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2.9 VERIFICATION OF INTERACTIONS BY BIOCHEMICAL METHODS
2.9.1 Generation, expression and purification of GST-fusion proteins of the
interacting clones
2.9.1.1 Generation procedure
GST-fusions of the positively interacting library clones 11a and 26a were
generated in the cloning vector pGEX-KG .
Clone 11a
Clone 11a in the activation domain plasmid pACT II (200 ng) was digested with
EcoRI and Xhol (5 U each enzyme) in a total volume of 20pl with 2 pi Buffer H and
12pl MilliQ H20. The reaction was carried out at 37°C for 1.5 h. The digested DNA
was purified from a 1% agarose TAE gel using the QIAEX II kit (Qiagen) and ligated
into vector pGEX-KG that had previously been digested with the same restriction
enzymes. For the ligation reaction, which was performed at room temperature
overnight, purified 1 la (4 pi) and empty vector pGEX-KG (4 pi) were incubated with
T4 DNA Ligation buffer (1 pi) and T4 DNA Ligase (1 U) (Fermentas, MBI).
Clone 26a
To construct a GST-fusion of clone 26a, a PCR product was generated using
primers 26aF3 and 26a R1 that contained an EcoRI and a Sail restriction site,
respectively. Primer sequences are shown in Table 4. The PCR reaction mix (50 pi)
consisted of 2 pi template (200 ng), 5 pi 2 mM dNTPs, 5 pi 5 pM primers, 5 pi
Dynazyme Buffer xlO, sterile Milli Q water and 0.5 U Dynazyme thermostable DNA
polymerase. A negative (no template) control reaction was also performed. The
conditions used were: denaturation at 94 °C for 40 s, annealing at 60°C for lmin and
extension at 72°C for 1.5 min for 5 cycles, followed by 28 cycles of 94 °C for 40 s, 60
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°C for 30 s and 72 °C for 1.5 min. The final stage comprised 1 cycle of denaturation
at 94 °C for 40 s, annealing at 60 °C for 30 s and elongation at 72 °C for 3 min. The
PCR product was digested with EcoRI/ Sail and ligated into pGEX-KG as described
for clone 1 la.




















Table 4. Oligonucleotide primers for clone 26a.
2.9.1.2 Expression of GST- fusion proteins
GST-fusion constructs were expressed in the bacterial strain E. coli BL21
CodonPlus RIL (DE3) (Stratagene) at 25 °C (clone 11a) and 30 °C (clone 26a).
Overnight cultures of both clones (5 ml LB Broth / 20 pi ampicillin) grown at 37 °C,
were diluted 1:100 and incubated with shaking at the temperature indicated above until
OD600 was 0.5. At this point, 400 pi culture was removed, spun at 13,000 rpm for 3
min and the pellet was re-suspended in 100 pi MilliQ water, 50 pi protein sample
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buffer (X3) and 10 jxl 1 M DTT. It was then boiled for 4 min and stored at -20 °C as
an un-induced sample. The rest of the culture was induced with ImM IPTG (final
concentration) and samples were removed and processed as before, at 30, 60 and 120
min following induction. Samples were separated on 12% SDS gel and stained with
Coomassie Blue.
2.9.1.3 Purification of GST- fusion proteins
GST-fusions of clones 11a and 26a were grown in 2X 500 ml cultures each, at 25
and 30 °C respectively, to an OD600of 0.5- 0.6 and subsequently induced with ImM
IPTG for 2 h. The cultures were spun down at 4,000 rpm, for 10 min at 4 °C and
subsequently re-suspended in 13 ml TBS/ 2 mM DTT/ Protease inhibitors (1 tablet per
50 ml TBS) (Boehringer). The re-suspended pellets were sonicated 6 x 10 and then
spun for 40 min at 10,000 rpm, 4 °C. The supernatants were incubated with
Glutathione Sepharose 4B (Pharmacia) on a rotating wheel at 4 °C for 30 min. The
Sepharose resin was pelleted by centrifugation at 1,700 rpm for 5 min at room
temperature and subsequently washed 3 times with 10 ml IX PBS containing 2 mM
DTT, 1 mM benzamidine and 0.5 mM PMSF. (The final wash was carried out without
PMSF). The matrix was loaded into a column (Biorad) 10 cm X 1 cm and the fusion
proteins were eluted with 5 ml 10 mM Glutathione (Sigma) in 50 mM Tris-HCl pH
8.0. The protein yield was estimated both by reading the A280 and by SDS-PAGE on a
12% SDS gel stained with Coomassie Blue. The intensity of the bands to BSA
samples of known concentration was compared.
2.9.2 Pull down assay from sciatic nerve homogenate
Four sciatic nerves from PI3 rats were homogenised in 160 p,l lysis buffer
containing 25 mM Tris HC1 pH 7.5, 150 mM NaCl, 0.5% CHAPS, 5 mM NaF, 100
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pg/ml leupeptin (Sigma), 100 ug/ml antipain (Sigma), 7 pg/ml chymostatin (Sigma), 1
mM benzamidine, 1 mM TLCK (Sigma), 10 mM EDTA, 10 mM EGTA 1 mM PMSF.
The homogenate was placed on ice for 5 min and subsequently spun at 13,000 rpm for
10 min at 4 °C. The supernatant was split into two tubes, each containing 100 pi
Sepharose beads. The volume was taken up to 700 pi with lysis buffer and the lysate
was pre-cleared on a wheel at 4 °C for 45 min. 10% of the sciatic nerve lysate was
boiled in sample buffer and stored at -20 °C as "input" lysate. GST-fusion protein (6
pg), or GST -alone (negative control) were conjugated to 40 pi Sepharose beads at 4
°C for 45 min. The beads were washed 3 times with 1 ml lysis buffer to remove
unbound protein. Pre-cleared sciatic lysate (280 pi) was then added to the conjugates,
which were incubated for a further 45 min at 4 °C in a rotating wheel. The samples
were subsequently spun for 1 min at 3,000 rpm, 4 °C and the supernatants were
discarded. The pellets were washed 5 times with 1 ml buffer, re-suspended in 60 pi
HzO/ Sample Buffer/DTT and boiled for 4 min. The proteins were resolved by
electrophoresis on an 8% SDS gel and a Western Blot was performed to assess the
presence of L-periaxin bound to the fusion proteins.
2.9.3 Preparation of in vitro transcribed/ translated L-periaxin
2.9.3.1 (a) In vitro transcription of L-periaxin
In vitro transcription of full length L-periaxin in the vector pSV-SPORT was
carried out using 1 pg DNA, 5 pi transcription buffer, 2 pi DTT, 0.5 pi Rnasin
(Promega kit), 2 pi RNA CAP and 1 pi T7 polymerase to a final volume of 20 pi with
MilliQ water. The reaction was performed for 1 h at 37 °C. 1 pi of the product was run
out on a 1% agarose TAE gel to check the quality of the synthesised RNA and 1 pi
RQ1 Dnase (Rnase free) was added to the reaction mix to eliminate any unused DNA
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template by incubating at 37 °C for 15 min. DEPC treated H20 (100 pi) was added to
the mix, followed by 1 vol of phenol/chloroform. The mix was vortexed and spun for
3 min at 13,000 rpm at room temperature. The top layer was removed into a clean
tube, and an equal volume of chloroform was added. The contents of the tube were
mixed using a benchtop vortex and subsequently spun for 3 min at 13,000 rpm, at
room temperature. The top layer was again retained and the RNA was precipitated
with 0.5 vol. 7.5 M ammonium acetate and 2.5 vol. 100% ethanol at -70 °C overnight.
The mix was subsequently spun for 30 min at 13,000 rpm, 4 °C and the RNA was re-
suspended in 15 pi DEPC H20. The concentration was estimated by reading the A250.
2.9.3.1 (b) In vitro translation of L-periaxin
In vitro translation was carried out using the Rabbit Reticulocyte Lysate system
(Promega, L4960) according to the manufacturer's instructions. 1 pg RNA was
incubated with 35 pi rabbit reticulocyte lysate, 1 pi amino acid mix (-methionine), 4 pi
35S-methionine (ICN), 1 pi Rnasin Inhibitor (Promega) in a total volume of 50 pi with
DEPC H20, at 30 °C for 1.5 h. 1 pi of the translation product was removed to estimate
the efficiency of radioactivity incorporation and the rest was frozen in liquid N2 and
stored at - 70 °C.
The retained 1 pi was placed onto a circle of 3MM paper (Whatman) and was
allowed to dry for 30 min. The 3MM paper filter was incubated in 300 ml 10% TCA
for 15 min on ice and then in 300 ml 5% TCA for 5 min on ice. It was subsequently
boiled in 300 ml 5% TCA for 15 min and then washed twice for 5 min with 300 ml ice
cold 5% TCA. Finally, the filter was washed in 300 ml 100% ethanol for 3 min and
allowed to dry for 30 min before being decolourised with 5 pi 15% H202. The filter
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was placed in a scintillation vial with 5 ml Optiphase Hisafe (Wallac Scintillation
Products) and the 35S incorporation was estimated in a scintillator (Beckman LS 6500).
2.9.3.2 Pull down assay using in vitro transcription/ translation product of L-
periaxin
GST-fusions of 11a and 26a as well as GST-alone in the vector pGEX-KG (6 pg)
were coupled to 33 pi Glutathione Sepharose 4B in the presence of 300 pi binding
buffer (25 mM Tris HC1 pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.05% NP 40, 1 mM
DTT, 10 pg/ml leupeptin, 2 pg/ml pepstatin, 0.7 pg/ml chymostatin, 10 pg/ml
antipain, 1 mM benzamidine, 0.5 mM TLCK, 1 mM PMSF). The Sepharose beads had
previously been washed twice with 100 pi binding buffer to remove residual ethanol.
The binding of the fusion proteins to the beads was carried out at room temperature for
40 min on a rotating wheel. The beads were subsequently washed 3 times with 1 ml
buffer to remove unbound material and 1 X 106 cpm of translated L-periaxin was
added to each tube with 350 pi binding buffer and allowed to mix on a wheel for 1.5 h
at 4 °C. The beads were washed 5 times with 1 ml binding buffer and re-suspended in
25 pi H20/protein sample buffer/DTT. The mix was boiled for 3 min and the proteins
were resolved on an 8% SDS gel by SDS-PAGE. The gel was stained with Coomassie
Blue for 30 min and destained with 10% acetic acid/ 20% methanol to assess protein
loading. It was then processed for fluorography using Amplify (Amersham Pharmacia
Biotech) with mild shaking for 30 min and dried on 3 MM paper (RAPIDRY).
Autoradiography was performed overnight.
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2.10 NORTHERN BLOTTING OF 26a
2.10.1 Construction of hybridisation probe for northern blot
A hybridisation probe comprising the C-terminal 750 bp of clone 26a (376-1100
bp) was generated in the cloning vector pGEM 11 (Promega) that contains the
sequences of promoters SP6 and T7. Clone 26a in the vector pACT II (cloned between
EcoRI and Xhol) was digested with 5 U Xhol in a total volume of 10 pi, with 1 pi
REact 2 buffer. The clone contained an internal Xhol site at position 376 bp. A
fragment of 750 bp generated by the digest was ligated into pGEM 11 that had
previously been digested with Xhol. The ligation reaction (4 pi vector, 4 pi insert, 1 pi
Ligation buffer, 4 pi T4 DNA ligase) was performed at 14 °C overnight. The
orientation of the insert was assessed by restriction enzyme analysis.
2.10.2 Radioactive labeling of hybridisation probe
The probe (30 ng) was labeled using RANDOM PRIME DNA LABELLING kit
(Gibco BRL). The DNA was boiled in distilled water (23 pi total volume) for 3 min
and subsequently placed on ice for 1 min. Following a brief spin, nucleotide mix (6 pi)
and random primers mix (15 pi) were added. The probe was subsequently incubated
with 1.85 M Beq 32P (ICN) and 3 U Klenow fragment enzyme at 25 °C for 1 h. The
reaction was terminated with 5 pi STOP buffer and 100 pi lOmg/ml sheared salmon
sperm DNA. The labelled probes were stored at -70 °C.
2.10.3 Preparation of RNA samples
Trigeminal nerve and brain total RNA from a PI5 rat (5 pg) was dried in 0.5 ml
eppendorf tubes and re-suspended in 10 pi denaturation buffer (50% formamide, 20%
formaldehyde, 10% DEPC H20, 10% 10X MOPS, 10% 0.5 mg/ml ethidium
bromide). The samples were incubated for 10 min at 70 °C, placed on ice for 1 min
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and spun briefly. Sterile sample buffer was added (1 pi) and the samples were
separated on a 1.35% agarose/formaldehyde gel by electrophoresis at 70 V, 200 mA
for approximately 2 h. The RNA was transferred onto a nylon transfer membrane
(Schleicher & Schuell) for 2 h under a pressure of 50 mbar. The filter was dried
overnight at 80 °C.
2.10.4 Hybridisation process
The membrane was soaked briefly in distilled water and placed in a 50 ml Falcon
tube with 6 ml Quickhyb solution (Qiagen) and allowed to warm up at 65 °C for 30
min. The probe was boiled at 98 °C for 10 min and allowed to hybridise to the filter at
65 °C for 1.5 h. Following hybridisation, the filter was washed twice with Low
Stringency buffer (2X SSC, 0.1% SDS) for 10 min each time, at room temperature. It
was subsequently washed twice with Low Stringency buffer (0.2 X SSC, 0.1% SDS)
for 30 min each time. The filter was dried at room temperature and wrapped in Saran
film. Autoradiography was performed over a period of 48 h.
2.11 ISOLATION OF FULL LENGTH 26a (rFbxl6) cDNA
The missing 5' end sequence of the full length 26a cDNA was obtained by 5'
RACE (Rapid Ampification of cDNA Ends). Sciatic nerve RNA from P3, 9 and 16
rats (5 pg) was used in a 5' RACE reaction with the clone-specific reverse primer
26aR8 and the 5' RACE primer provided in the GeneRacer kit (Invitrogen, Cat. No.
45-0079). The reaction was performed according to the manufacturer's instructions, by
Dr CS Gillespie.
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2.12 GENERATION OF C-TERMINAL ANTIBODIES AGAINST CLONE
26a IN RABBITS
2.12.1 Preparation of KLH-coupled peptides for injection
In order to raise antibodies specific to the C-terminus of clone 26a, the following
peptides were synthesised by Research Genetics and supplied as dehydrated PBS salts:
26aCl: CLPRGLKRAYRGLEEV and 26aC2: CSLNLRGTRVTPSTVSSV. Both
peptides were provided as amidated at their C-termini and coupled to Keyhole Lympet
Haemocyanin (KLH) via their N-terminal Cysteine residues. Conjugation to KLH
enhances antigenicity. The supplied dehydrated salts were re-suspended in MilliQ H20
to a final concentration of 1 mg/ml and dissolved at room temperature. Aliquots (2
ml) were prepared in 50 ml Falcon tubes and stored at - 40 °C. Prior to injection, each
2 ml aliquot was mixed with 3 ml Complete Freund's Adjuvant (Sigma) and mixed by
vigorous shaking at 4 °C overnight. The mix was spun briefly and 1.5 ml aliquots, 3
for each peptide, were prepared in 3 ml syringes (Becton Dickinson). Each aliquot
was administered to a female New Zealand White rabbit. A boost injection was
performed 3 weeks later. This time, the peptides were mixed with 3 ml Incomplete
Freund's Adjuvant (Sigma). The rabbits were bled 2 weeks later to test for antibody
production. All injections were carried out by Professor P.J. Brophy at the CTVM
Facilities, Easter Bush, Edinburgh.
2.12.2 Assessment of rabbit anti-serum by Western Blotting
Test bleeds (3 ml) were collected in 5 ml Bijoux tubes and were allowed to clot at 4
°C overnight. The serum was removed into 1.5 ml microfuge tubes and spun at 13,000
rpm, 4 °C for 2 min to remove clotted blood. It was then aliquoted and stored at -40 °C.
To assess the specificity of the anti-serum, a Western blot was performed using 10 ng
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purified GST-26a protein and GST-alone (negative control) with 26aCl and 26aC2 at
1:2,000 dilution. The secondary antibody used was anti-rabbit IgG-HRP at a dilution of
1:2,000 (Diagnostics Scotland). The ECL method (Amersham) was applied as described
earlier. A Western blot was also performed to test the affinity purified anti-serum using
10 and 25 ng of GST-26a. The 26a antibodies were used at a dilution of 1:1,000. The
dilution of the secondary a-rabbit antibody was 1:2,000.
2.12.3 Affinity purification of anti-serum
The anti-serum obtained from 4 rabbits (2 for each peptide), was affinity purified
using an a-aminohexyl Sepharose 4B column, conjugated to non-KLH-coupled
peptide, a-aminohexyl Sepharose 4B (1ml) was pipetted into a 15 ml Falcon tube,
spun briefly to remove excess ethanol and washed 4 times with 3 ml IX PBS. It was
re-suspended in 2 ml 1 X PBS and 5 mg of MBS were added. The tube was placed on
a rotating wheel at room temperature for 2 h and was subsequently spun, and washed 4
times with 3 ml 1 X PBS. The final spin (5 min) served to pack the Sepharose gel. The
buffer was removed and the gel was incubated with non-KLH coupled peptide on a
windmill at room temperature overnight. Prior to incubation with a-aminohexyl
Sepharose 4B, 10 mg of each peptide were dissolved in 800 pi 10 mM HC1 in a 1.5 ml
microfuge tube. The pH was adjusted to 6.0 with 100 mM NaOH.
The peptide/ Sepharose conjugate was washed 4 times with 1 X PBS. Anti-serum (5
ml) was added to the column and allowed to mix on a windmill at 4 °C overnight.
Following an overnight incubation, the slurry was loaded onto a 10 cm X 1 cm column
(Biorad) and was allowed to settle. The flow-through was collected in 20 ml Universal
tubes and kept on ice in case the anti-serum hadn't bound to the matrix. The column
was washed with 5 ml 20 mM sodium citrate until A280 was ~0. 50 mM citric acid pH
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2.5 (6 ml) was added, and 0.5 ml fractions were collected into 1.5 ml microfuge tubes,
already containing 0.35 ml 1 M HEPES pH 7.5. The yield was determined by reading
the A280 of the collected fractions. When the absorbance at 280 nm reached
approximately 0, the column was washed 4 times with 20 mM sodium citrate pH 7.7
and 4 times with 1 X PBS. It was stored in 1 X PBS/ 0.01% sodium azide at 4 °C.
2.13 UBIQUITINATION EXPERIMENTS
Isolation of the full sequence of clone 26a, revealed that it was part of the rat
homologue of a previously identified F-box containing protein, namely Fbl6/Fbxl6
(rFbxl6). F-box proteins are known to be components of ubiquitin ligases, responsible
for the recruitment of ubiquitination substrates. This was indicative of a potential role
of rFbxl6 in the ubiquitin-mediated proteolysis of L-periaxin. To investigate this
possibility, a series of experiments to assess ubiquitination of L-periaxin as well as the
involvement of the proteasome in its turnover, were conducted as described below.
2.13.1 Immunoprecipitation of ubiquitinated L-periaxin and (3-catenin
from P21 mouse sciatic nerve
The sciatic nerves from four P21 wild type mice were treated with either the
proteasomal inhibitor epoxomicin (5 pM) or its solvent DMSO (1%) as described in
section 2.14.2 and boiled in 2% SDS (120 pl/4 nerves) for 10 min. The tubes were
subsequently spun for 10 min at room temperature. The supernatants were removed to
sterile microfuge tubes, where 4 vol of Solution A (50 mM Tris HC1 pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 2.5% Triton X-100, 10 pg/ml leupeptin, 10 pg/ml
antipain, 1 mM benzamidine, 0.5 mM TLCK, 1 mM PMSF) were added. The
supernatant was divided into two tubes. Half was pre-cleared with 25 pi 50% slurry of
Protein A/ 500 pi buffer (for periaxin) and the other half with 25 pi Protein G/ 500 pi
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buffer (for (3-catenin), at room temperature for 30 min. The tubes were spun for 1 min
at 4 °C. The supernatants were retained and incubated with either 3 pi rabbit
polyclonal a-repeat periaxin antibody, or 5 pi mouse monoclonal anti- (3-catenin
antibody (Santa Cruz) at room temperature for 2 h on a windmill. Protein A (or Protein
G) slurry (30 pi) was subsequently added to each tube and they were placed back on
the windmill for 1 h. The mix was spun for 2 min at 4 °C and the supernatant was
discarded. The pellets were washed 5 times with 1 ml Solution A, re-suspended in 25
pi H20/protein sample buffer/DTT and boiled for 10 min. The proteins were resolved
by SDS-PAGE on a 6% SDS gel (periaxin) and 12% SDS gel ((3-catenin). Western
blots were performed to assess the presence of ubiquitinated forms of L-periaxin and
(3-catenin in sciatic nerve, using a mouse monoclonal anti-ubiquitin antibody (Santa
Cruz) at 1:500 dilution. To ensure that both L-periaxin and (3-catenin had been
immunoprecipitated from sciatic nerve, the blots were also probed with anti-repeat
periaxin (1:20,000) and anti-(3-catenin (1:1,000) antibodies.
2.13.2 Inhibition of the proteasomal pathway with epoxomicin to block L-
periaxin degradation
Sciatic nerves from eight P21 wild type mice were removed and placed in 35 mm
petri dishes containing 1 ml 1 X PBS. The nerves were stripped of the epineurium and
placed in a 24-well tissue culture plate (Greiner), as follows: 8 nerves were incubated
in 200 pi RPMI-1640 medium (Sigma), supplemented with 2 mM L-Glutamine and 5
pM epoxomicin (Calbiochem), the rest were incubated with 1 % DMSO (vehicle
control) in 200 pi RPMI-1640/ 2 mM L-Glutamine. The nerves were allowed to
metabolise at 37 °C, 5% C02 for 90 min. Four epoxomicin- treated sciatics and four
DMSO-treated ones were taken and boiled in 2% SDS, to be used in an
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immunoprecipitation experiment exactly as described in section 2.9.1. The purpose
was to investigate whether there would be an increase in the levels of
immunoprecipitated periaxin by inhibiting the function of the proteasome. One sciatic
nerve from each group (ie. Epoxomicin- treated, DMSO- treated) was also taken and
boiled in 25 pi H20/ protein sample buffer/DTT for 4 min and stored at -20 °C. To the
rest of the samples, the translation inhibitor cycloheximide (CHX) (Sigma) was added
to a final concentration of 50 pg/ml and the nerves were placed back in the incubator
at 37 °C, 5% COz. One nerve from each group was removed and boiled as before at
45, 90 and 180 min following addition of CHX. The proteins were resolved on an 8%
SDS gel by SDS PAGE and a Western blot was performed using the rabbit anti-repeat
periaxin antibody (1:20,000).
2.14 TISSUE DISTRIBUTION OF 26a
The level of expression of 26a in different tissues was assessed by Western Blot
using homogenates from brain, spinal cord,sciatic nerve,liver, lung, kidney, heart and
skeletal muscle from P21 mice.
The tissues were homogenised in 160- 320 pi lysis buffer (150 mM NaCl, 50 mM
Tris-HCl pH 7.5, 10 pg/ml leupeptin, 0.7 pg/ml chymostatin, 10 pg/ml antipain, 200
mM benzamidine, 100 mM TLCK, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 1%
SDS) using a drill. The homogenate was boiled for 10 min and spun for 5 min at
13,000 rpm. The supernatant was removed to a clean tube and the protein
concentration was estimated using the Micro BCA Protein Assay Reagent Kit (Pierce)
according to the instructions provided by the manufacturer. A fraction of total protein
(30 pg) was separated on a 12% SDS polyacrylamide gel by SDS-PAGE and the
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presence of Fbxl6 was detected by Western Blotting using the 26aCl antibody at
1:1,000 dilution.
2.15 TRANSGENESIS
The effect of L-periaxin stabilisation in the process of myelination in the sciatic
nerve was investigated by inhibiting the turnover of the protein. To accomplish this,
transgenic mice would be generated which over-expressed a deletion mutant of
rFbxl6, (rFbxl6AF) that lacked the F-box motif (dominant negative). The mutant
version of rFbxl6 would be able to bind L-periaxin via its C-terminal LRR region, but
fail to target it to the SCF complex for ubiquitination and subsequent degradation. The
original library clone found to interact with L-periaxin, 26a, comprised the LRR
region but did not contain the F-box, so it was suitable to use in the transgenic
construct.
2.15.1 Generation of rFbxl6AF transgenic construct
To generate rFbxl6AF, a fusion of FLAG-tagged clone 26a in the vector
pBluescript SK II under the control of the mouse P0 promoter (construct mPo TOT
asp, provided by Dr. L. Wrabetz), was created. 26a was initially cloned into the
FLAG vector pCMV-2B (Stratagene). A PCR product was formed with primers 26aF2
and 26aRl (see Table 4) that contained a BamHI and a Sail restriction site
respectively, using 26a in pACT II as template (1:500). The reaction was performed
under the conditions described in section 2.7.1. The PCR product (~ 1.1 kb) was
purified as before and ligated into pCMV-2B between the BamHI and Sal I sites of its
MCS.
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FLAG-26a was subsequently cloned into mPO TOT asp in the AscI site of the
vector (Figure 20). A PCR product was generated using 26a in pCMV-2B as template
(1:500) with primers 26aF6 and 26aR7 that contained an AscI restriction site (Table
4). The conditions used were: denaturation at 94 °C for 1 min, annealing at 58 °C for
lmin and extension at 72 °C for 30 s, for 5 cycles, followed by 28 cycles of 94 °C for
40 s, 58 °C for 1 min and 72°C for 30 s. The final stage comprised 1 cycle of
denaturation at 94 °C for 40 s, annealing at 58 °C for 1 min and elongation at 72 °C
for 5 min. The product was purified and digested with 15 U AscI in a reaction mix of
35 pi, containing 3.5 pi NE Buffer 4 (New England Biolabs). Vector mPO TOT asp
(200 ng) was also digested with 10 U AscI in a total volume of 10 pi, with 1 pi NE
Buffer 4. The reactions were carried out at 37 °C for 2 h. FLAG-26a was ligated into
mPO TOT asp overnight at room temperature.
FLAG-26a in mPO TOT vector was used to transform E.coli DH5a cells, and the
transgenic DNA was purified using the CLONTECF1 MIDI PREP kit according to the
manufacturer's instructions. In order to remove the vector sequence, the DNA (46 pg)
was digested with 30 U PacI in a total volume of 150 pi with 15 pi NE Buffer 1,
supplemented with 1.5 pi BSA (10 mg/ml) at 37 °C, overnight. This was subsequently
digested with 60 U NotI, to a final volume of 200 pi, with 20 pi REact 3 buffer. The
digested DNA was separated on 0.8% low melting point agarose gel in TAE. The band
corresponding to the transgene was excised and incubated with 0.04 vol 25 X agarase
buffer (Boehringer) at 65 °C for 15 min. It was subsequently cooled down to 45 °C for
10 min before addition of 3.6 U of agarase (Boehringer). The reaction was allowed to
proceed for 2 h at 45 °C.
128
BamHI AscI AscI Smal
El E2 E3 E4 E5 E6
(2091) (656) (213) (135) (61) (102)




FIGURE 20. Structure of rFbxl6AF construct for transgenesis. A fusion of rFbxl6
that lacks the F-box motif (original 26a clone), with a FLAG tag at its N-terminus, was
introduced to Exon 1 of the mouse P0 gene in the cloning vector pblueScript SK+1I.
(Exon sizes in kb are shown in brackets).
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2.15.2 Purification of transgenic DNA for nuclear transfer
The transgene was purified using an Elutip D-column Set (Schleicher & Schuell)
according to the manufacturer's instructions. Following agarase treatment, the DNA
was diluted in 10 ml low salt buffer (0.2 M NaCl, 20 mM Tris HC1 pH 7.5, 1 mM
EDTA pH 7.4) and put through the Elutip.
Elution was performed with high salt buffer (1 M NaCl, 20 mM Tris HC1 pH 7.5,
1 mM EDTA pH 7.4) and the DNA was collected in a pre-cleaned microfuge tube. It
was precipitated with 2 vol 100% ethanol at -70 °C for 30 min and spun for 40 min at
4 °C. The pellet was washed with 500 pi 70% ethanol, spun for 5 min at room
temperature and allowed to dry. It was subsequently re-suspended in 50 pi millipore
filtered injection buffer (10 mM Tris HC1 pH 7.5, 0.1 mM EDTA pH 8.0). The
concentration was estimated by running 1 pi and 1:1 dilution on a 1% agarose TAE
gel, against 2 and 4 pi High DNA Mass Ladder. An aliquot of the DNA (~ 1.75 pg)
was dialysed against 1 1 injection buffer at 4 °C for 48 h, with 3 changes of buffer over
that period of time. The DNA sample to be dialysed was placed on the interior of the
cap of a microfuge tube that had been cut so that the rim of the tube was still intact. A
small square piece of prepared dialysis tubing (SIGMA) was placed over the cap and
the rim was fitted over the tubing to keep it in place. (The dialysis tubing was prepared
by boiling in water/ EDTA/sodium bicarbonate for 10 min and was rinsed in injection
buffer just prior to use). The DNA sample was flicked onto the tubing and the cap was
floated on the injection buffer. The DNA concentration was estimated after dialysis, as
described previously. The sample was diluted with injection buffer to 2.5 pg/ml and
stored in 20 pi aliquots at -70 °C.
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2.16 IMMUNOSTAINING OF SCIATIC NERVE SECTIONS
Sciatic nerve transverse cryosections (7 pm in thickness) from P21 mouse were
used to investigate the pattern of immunostaining of 26aC2 antibody. The tissue was
fixed with 4% paraformaldehyde (PFA) on TESPA-treated microscope slides for 5
min. Excess PFA was removed with 1 X PBS and the tissue was subsequently
incubated in methanol at -70 °C for 10 min. To prevent non-specific binding, the tissue
was treated with blocking buffer (5% fish gelatin, 0.1% Triton X-100, IX PBS) for 1
h, prior to incubation with the primary antibodies 26aCl (1:200) and periC2 (1:
5,000) in the same buffer, overnight. The primary layer was removed with 5 washes
with 0.1% Triton in PBS. The secondary antibodies, goat anti-rabbit FITC (1:200)
(SAPU) and donkey anti sheep TRITC (1:100) (Northeast), were applied for 1.5 h.
Unbound antibodies were removed with 1 X PBS (4-5 washes for 5 min each time).
The slides were sealed with coverslips (22X22 mm) (BDH) and the sections were
viewed under the electron microscope (Olympus BX60).
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APPENDIX I
20X SSC (3 M NaCl, 0.3 M Na Citrate)
10X MOPS (0.2 M MOPS, 50 mM Na Acetate, 10 mM EDTA)
TBS (For 50 ml use 0.4 g NaCl, 0.01 g KC1, 0.15 g Trizma base, pH 7.4)
0.2M sodium phosphate buffer pH7.4 (0.5 M Na2HP04, 0.5 M NaH2P04)
Cracking Buffer stock solution (8 M Urea, 5% w/v SDS, 40 mM Tris-HCl pH6.8,
0.1 mm EDTA, 0.4 mg/ml Bromophenol blue, MilliQ H20)
Complete Cracking Buffer (88.5% v/v Cracking buffer stock, 0.88% v/v (3-
mercaptoethanol, 45 mM PMSF, 0.1 mg/ml Pepstatin A, 0.03 mM leupeptin, 145 mM
benzamidine, 0.37 mg/ml aprotinin)
Plasmid resuspension buffer (25 mM Tris-HCl pH 8.0, 10 mM EDTA, 0.9% w/v
glucose)
Plasmid lysis buffer (200 mM NaOH, 1% SDS). 11.5% v/v glacial acetic acid, 29.4%
w/v potassium acetate in Milli Q
Plasmid neutralisation buffer (11.5% v/v glacial acetic acid, 29.4% w/v potassium
acetate in Milli Q)
Solution A (50 mM Tris HC1 pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
2.5% Triton X-100, 10 pg/ml leupeptin, 10 pg/ml antipain, 1 mM benzamidine, 0.5
mM TLCK, 1 mM PMSF)
Lysis Buffer (25 mM Tris HC1 pH 7.5, 150 mM NaCl, 0.5% CHAPS, 5 mM NaF,
100 pg/ml leupeptin,100 pg/ml antipain, 7 pg/ml chymostatin, 1 mM benzamidine, 1
mM TLCK, 10 mM EDTA, 10 mM EGTA, 1 mM PMSF.
Glutathione Sepharose 4B binding buffer (25 mM Tris HC1 pH 7.5, 150 mM NaCl,
1 mM EDTA, 0.05% NP 40, 1 mM DTT, 10 pg/ml leupeptin, 2 pg/ml pepstatin, 0.7
pg/ml chymostatin, 10 pg/ml antipain, 1 mM benzamidine, 0.5 mM TLCK, 1 mM
PMSF).
Z buffer (60 mM Na2HP04- 2 H20, 40 mM NaH2P04 • 2 H20, 10 mM KCL, 0.1 mM
MgS04 • 7 H20),
YPAD (2% w/v Difco peptone, 1% w/v yeast extract, 2% v/v glucose, 0.003%
adenine hemisulphate)
SD (0.67% w/v yeast nitrogen base without amino acids, 10% v/v sterile 10 X amino




















pACT2 and pODB8 hybrid cloning vectors. pACT2 generates a hybrid that contains
amino acids 768-881 of the GAL AD and pODB8 generates a hybrid which contains
amino acids 1-147 of the GAL4 DNA-BD. Both vectors comprise a hemagglutinin (HA)
peptide at the 3' end of the GAL4 sequence.The hybrid proteins are expressed from the
constitutive ADH1 promoter (P). The transcription is terminated at the ADH 1
transcription termination (T) signal. pACT2 contains the nutritional marker LEU2,
whereas pODB8 carries theTRPl marker for nutritional selection. Restriction sites of the




3.1 PERIAXIN CONSTRUCTS PERIC1, PERIC2 AND PERIRA3 WERE
EXPRESSED IN YEAST, AS REVEALED BY WESTERN BLOTS
Total protein extracts from yeast strains Y190 and CGI945 transformed with
PeriCl, PeriC2 and PeriRA3 in the cloning vector pODB8, and empty pODB80 vector
were resolved by SDS-PAGE (12% gel). Following electrophoresis, the Western
Blotting technique was used to assess the expression of the three constructs. Periaxin
anti- C-terminus rabbit antibody (1:20,000) (PJ Brophy) followed by donkey anti-
rabbit IgG HRP-labelled antibody (1:2,000) (Diagnostic Scotland) were used to reveal
the expression of PeriCl (85 kDa) and PeriC2 (60 kDa). The use of periaxin anti-
repeat rabbit antibody (1:15,000) (PJ Brophy) with the same secondary antibody as for
the other two constructs, allowed the detection of PeriRA3 (57 kDa) (Figure 21). The
Western Blots revealed the expression of all three constructs in both strains indicating
that they were not toxic to yeast and therefore would be suitable to use for detection of
interacting partners.
3.2 REPORTER GENES LACZ AND HIS3 WERE NOT AUTOACTIVATED
BY PERIAXIN CONSTRUCTS
In order to be able to use the periaxin constructs as "baits" in a yeast-two hybrid
screen, the possibility of autoactivation of the two reporter genes (lacZ and HIS3),
thus giving a false positive interaction, was investigated. Yeast strains Y190 and
CGI945 are described as "leaky" for the expression of HIS3 gene (Clontech Manual
PT 3024-1) which reflects the fact that basal levels of HIS3 expression in those two
strains are sufficient to sustain growth on synthetic dropout medium which lacks
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histidine. To overcome this problem, 3-amino, 1-2-4 triazole (3-AT) was used, at an
optimum concentration, in -TH and -TLH media to suppress background growth. 3-
AT is an inhibitor of HIS3-encoded imidazole glycerol phosphate (IGP) dehydratase
and thus blocks histidine synthesis. IGP-dehydratase then converts imidazole glycerol
phosphate to imidazole acetol phosphate in the biosynthetic pathway of histidine from
PRPP (5-phosphoribosyl-a-pyrophosphate) (Stryer, 1975). The concentration of 3-AT
sufficient to suppress background growth in CGI945 was 2 mM and in Y190 was 30
mM. In both cases a range of 3-AT concentrations was tried; 0-7 mM for CGI945 and
25-45 mM for Y190.
The results are summarised in Table 5 and indicate no autoactivation of either
reporter gene.
Sample Medium/ Growth Medium/ lacZ
pODB80 -TH no -T white
PeriCl/pODB8 -TH no -T white
PeriC2/pODB8 -TH no -T white
PeriRA3/pODB8 -TH no -T white
PVA3-+pTDl-l -TLH yes -TLH blue
PTD1 l+pLam5-1 -TLH no -TL white
Table 5. Assessment of autoactivation of the reporter genes lacZ and HIS3 of
PeriCl, PeriC2 and PeriRA3 periaxin constructs in the binding domain (BD)
vector pODB8, in yeast strains CG1945 and Y190.
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FIGURE 21. Expression of PeriCl, PeriC2 and PeriRA3 constructs in yeast
strain Y190. PeriCl (85 kDa) appears to be expressed at much lower levels than
PeriC2 (60 kDa) and PeriRA3 (57 kDa).
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3.2.1 Transformation efficiency tests
PeriCl was used to screen a sciatic nerve cDNA library, prepared using RNA
from 9-day and 14-day old rats, which was cloned into pACT2 activation domain
vector between the EcoRI and Xhol sites. pACT2 contains the LEU2 gene for
nutritional selection. The efficiency of transformation of the periaxin "bait" PeriCl
with the library "prey" plasmid in both yeast strains was assessed by co-transforming
PeriCl with 1 and 2 pg library DNA. The amount of "bait" was in all cases double that
of the library used. 1 and 5 pi of the transformation mixtures were plated on -TL
plates and the number of colonies formed were counted. The results obtained are
shown in Table 6.
Although the efficiency in CGI945 was higher when 1 pg library DNA were used
and the values obtained for 2 pg library were not significantly different for the two
yeast strains, it was decided that Y190 would be used for the library screen because it










2 1 1.42 x 105









2 1 4.2 x 104
4 2 1.36 x 105
Table 6. Transformation efficiency of PeriCl and rat sciatic nerve library cDNA
co-transformed in yeast strains CG1945 and Y190. Co-transformation efficiency
was not significantly different between the two strains tested. Although CGI945
showed higher efficiency, Y190 was selected for the library screen due to its higher
sensitivity in (3-gal assays.
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3.3 ISOLATION AND HANDLING OF PUTATIVE PERIC1 POSITIVE
INTERACTING LIBRARY CLONES
3.3.1 Assessment of interaction between the positive library clones and
PeriCl, PeriC2 & PeriRA3
During a 2-week incubation period at 30 °C, 167 colonies (~2 mm diameter) were
recovered and re-grown on -TLH 30 mM 3-AT medium. The colonies, allowed to
grow for 3 days, were tested by X-gal filter lift to assess for activation of the lacZ
gene. Of the 167 colonies picked originally, 118 gave a positive blue colour as a result
of hydrolysis of X gal by p-galactosidase, the enzyme encoded by lacZ. Plasmid DNA
rescued from these colonies, which was found to contain a library insert and lack the
binding domain vector, was subsequently used with PeriCl to co-transform yeast
strain Y190. Co-transformations with empty pODB80 vector served as negative
controls. Activation of lacZ was again tested by filter lifts, which revealed that 11
colonies out of 118 specifically interacted with PeriCl. Interaction of these library
clones with PeriC2 and PeriRA3 was also assessed. The results are shown in Table 7.
It is apparent that the clones interacted with variable strength with different periaxin
constructs. All clones were sequenced with the Gal4 AD forward primer. The












1.0 +++ + ++
11c 0.4 ++ + +
4c 1.1 + + .
8a 1.8 +++ - ++
19d
22) 2.0 +++ ++ _
14f 1.2 + + _
19e 0.4 ++ +++ ++
Table 7. Specific interactions of clones isolated from a rat sciatic cDNA
library screen with periaxin constructs PeriCl, PeriC2 and PeriRA3
using the yeast two-hybrid system. (Key: +++: strong; ++: medium; +: weak
and no interaction). The strength of the interactions was assessed by the
relative time required for blue colonies to appear on the filter and the strength
of the blue colouration compared with the interaction between pVA3-l and
pTDl-1 (positive control).
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3.3.2 Clones 11a (18b) and 26a (13a) were chosen for further study
Sequencing of all the library clones which interacted with PeriCl and/ or PeriC2
& PeriRA3 allowed the prediction of their amino acid sequence using the Mac Vector
™ 7.0 package. The prediction was feasible because the sciatic nerve library fragments
were cloned into pACT in - frame with the Gal4 AD. This translation reading frame
was predetermined. Clones 8a (19d) and 4c translated to only a few amino acids (4 and
5, respectively) and were subsequently abandoned. The NCBI database was searched
for proteins that bore similarities to the clones isolated from the yeast two-hybrid
library screen. The BLAST analysis package revealed that clone 1 la (18b) was novel.
It displayed 50% identity with the Drosophila melanogaster gene product CGI3293, a
protein of unknown function, whose sequence was obtained during the D.
melanogaster genome sequence project by Celera Genomics (NCBI accession no.
AAF50701).
Clone 26a (13a), was identified as the rat homologue of the Mus musculus F-box
protein containing leucine-rich repeats (Fbl6/Fbxl6), to which it was 94.3% identical
(NCBI accession no. NM_013909). F-box proteins have been identified as
components of SCF ubiquitin ligase complexes that are involved in the turnover of
regulatory proteins.
Clones 11c and 14f were eliminated as false positives. 11c encoded the rat
homologue of Bip, which is an ER chaperonin (Flynn et al., 1991). L-periaxin is
synthesised on free polysomes and would not, under physiological conditions,
encounter lumenal ER proteins. 14f was 97% identical with murine fibulin-2, which is
a protein localised to the extracellular matrix (Grassel et ah, 1999). L-periaxin is not a
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transmembrane protein and therefore would not associate with fibulin-2 in the cellular
environment.
The remaining two clones did not seem to represent strong candidates for binding
partners of L-periaxin. Clone 22j translated to 34 aa. Its N-terminal 23 residues
displayed 78% identity with human myeloid/ lymphoid or mixed lineage leukaemia
(NCBI accession no. gi 5174571). The nucleotide sequence of clone 19e showed
100% identity (over a 20 bp region) with human DNA sequence from clone RPI-
47A22 from chromosome 20ql2 (NCBI accession no. AL117374). The predicted
amino acid sequence of 19e (27 aa residues) did not display any significant similarities
with sequences in the NCBI database.
The interactions of L-periaxin with clones 11a and 26a were the subject of further
investigation, in order to prove their validity and deduce their significance. The choice
of the two clones was based on the fact that 11a was novel and could subsequently
prove of interest, whereas 26a,being a member of the F-box family of proteins, could
mediate the regulation of periaxin by the Ubiquitin system. Nucleotide sequences of
clones 1 la and 26a are shown in APPENDIX II (p. 169-170).
3.3.3 GST-fusions of clones 11a and 26a interacted with L-periaxin in
sciatic nerve pull down assays
To prove the validity of the observed interactions of clones 11a and 26a with L-
periaxin in the yeast two-hybrid screen, biochemical methods were employed. A pull
down experiment using sciatic nerve homogenate and GST-fusions of 1 la and 26a was
performed. The aim was to detect L-periaxin in sciatic nerve, bound to the GST-fusion
protein, which had previously been attached to Sepharose beads. The detection of L-
periaxin would be carried out by Western Blotting, using a periaxin specific antibody.
GST-fusions of clones 1 la and 26a were generated in the vector pGEX-KG as
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FIGURE 22. L-periaxin interacts with GST-fusions of clones 11a and 26a in
sciatic nerve pull down assays. L-periaxin was detected after binding to the GST-
fusion proteins of clones 1 la and 26a, but not to GST alone, by Western Blotting
using the Periaxin anti-repeat antibody (1:20,000).
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described in section 2.9.1. As can be seen in Figure 22, the GST-tagged clones were
able to interact with L-periaxin from sciatic nerve homogenate. This interaction was
specific, since GST-alone failed to bind to L-periaxin. It also appeared that the
association of 1 la with L- periaxin was stronger than the 26a-Periaxin interaction.
3.3.4 GST-lla and GST-26a interacted with an in vitro
transcription/translation product of L-periaxin
To obtain further evidence in support of a true interaction between the library
clones 11a & 26a and L-periaxin, an in vitro transcription/translation of L-periaxin
was produced, to be used in pull down assays. The purpose was to assess binding of
the in vitro transcription/translation product to GST-fusions of the two clones. The
pull down assay, carried out as described in section 2.9.3.2 revealed that both clones
interacted with L-periaxin in vitro (Figure 23, A & B), as detected by autoradiography.
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A B
FIGURE 23. GST-fusions of clones 26a (A) and 11a (B) interact specifically with
L-periaxin generated by in vitro transcription/translation. Radioactively labelled
(,sS-Met) L-periaxin generated by in vitro transcription/translation binds to GST-
fusions of clones I la and 26a, as detected by autoradiography. The protein did not
associate with GST alone.
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3.3.5 Clone 11a interacts with a region of 170 aa of L-periaxin including the
entire acidic domain, whereas clone 26a requires a minimum of 85
residues, which comprises part of the acidic region of L-periaxin
Clones 11a and 26a were isolated from a rat sciatic nerve cDNA library screen
due to their association with a construct of L-periaxin, which comprised the C-
terminal 623 amino acid residues of the protein (PeriCl). The possibility of an
interaction with constructs PeriC2 and PeriRA3 was also assessed (Table 7) before
moving on to the smaller constructs, in an attempt to deduce the minimal region of L-
periaxin that participates in these interactions. Yeast two-hybrid assays were
performed with both clones and all of the periaxin constructs (Figure 24).
It is apparent from Figure 24 that neither the extreme C-terminus, nor the end of
the repeat region of L-periaxin is required for interaction with either of the two clones.
Clone 11a did not associate with PeriRA3, PeriR5, or the C-terminal constructs PeriC8
and PeriC9. Its interaction with PeriC2 and PeriA6, with equal strength indicates the
necessity of the acidic region for association with L-periaxin. The fact that the whole
of the acidic region is needed is indicated by failure to interact with PeriA7, a
truncation of the acidic domain.
Clone 26a displayed relatively strong association with construct PeriA7, whereas
association with its larger version (PeriA6) was weaker (possibly due to protein
folding issues). This was indicative of the requirement of 85 aa of L-periaxin,




PeriCl (762-1383) I 111 +++ +++
PeriC2 (996-1383) I I I □ ++ +
PeriRA3 (709-1080) ■ Tl " ++
PeriR5 (709-996) M. 1
PeriA6 (996-1165) I 1 1 ++ +
PeriA7 (996-1080) I I 1 " ++
PeriC8 (1168-1383) I '
PeriC9 (1330-1383) □
FIGURE 24. Yeast two-hybrid assay to investigate potential interactions of clones
11a and 26a with all L-periaxin constructs. Clone 11a requires the whole of the
acidic domain of L-periaxin (996-1165) for interaction, whereas clone 26a associates
with 85 aa that include the start of the acidic region (996-1080). (Amino acid residues
shown in brackets, (3-gal assay: +++ : strong, ++: moderate, -: no interaction).
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3.4 FOCUSING ON CLONE 26a
The interactions of both 11a and 26a with L-periaxin were confirmed
biochemically by the application of pull down assays. The region involved in the
observed interaction was narrowed down to 996-1165 aa of L-periaxin for clone 1 la,
and 996-1080 aa of the protein, for clone 26a.
Clone 26a was identified as 94.3% identical with the C-terminal region of a
mouse F-box-containing protein, namely Fbxl6. F-box-containing proteins are
components of SCF ubiquitin ligase complexes and so the association of such a
polypeptide with L-periaxin would imply its targeting to the ubiquitin pathway for
protein degradation. It was, therefore, decided to pursue further the investigation of the
role of clone 26a as a binding partner of L-periaxin. The determination of the size of
the mRNA molecule coding for the full -length 26a protein was determined by
Northern Blotting. Isolation of the full-length protein, in order to assess the presence
of an F-box motif, was carried out by Dr CS Gillespie in 5' RACE reactions. In order
to study the functional significance of the interaction between clone 26a and L-
periaxin, the possibility of ubiquitination of the latter protein was investigated. The
involvement of the proteasome in its degradation was also assessed. Finally, the
generation of a transgenic mouse, which overexpressed clone 26a (ie an F-box deletion
mutant of rFbxl6), was attempted in an effort to study the impact of L-periaxin
accumulation on sciatic nerve morphology and the process of PNS myelination. Clone
1 la was not pursued further by me.
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3.4.1 The size of the mRNA of the full length 26a protein was determined
by Northern Blotting
A hybridisation probe, comprising the C-terminal 750 bp of clone 26a, was used in
Northern Blotting with brain and trigeminal nerve total mRNA from PI5 rat. The
probe was radioactively labelled and hybridised as described in sections 2.10.2-
2.10.4. Autoradiography was carried out over a period of 48 h. A message of









FIGURE 25. inRNA of clone 26a was detected in both brain and trigeminal nerve
of PIS rat, by Northern Blotting. The size of the message of the full length 26a
protein was estimated at approximately 1.7 kb. Its presence in brain indicates that it is
not a PNS- specific protein.
3.4.2 Full length 26a protein is the rat homologue of the mouse F-box-
containing protein Fbl6/Fbxl6
Isolation of the full length 26a protein, proved that it was indeed the rat homologue
of mouse Fbxl6, to which it displayed 95% identity (Figure 26). The full length cDNA
was 1692 bp, of which 197 bp, represented 5' end UTR sequence (Figure 27). This
was in agreement with the size determined by Northern Blot. The predicted size of the
protein was 487 amino acids, with an expected MW of 53.5 kDa. In Western blots of
sciatic nerve, using the C-terminal 26aCl antibody at a 1:1,000 dilution, the protein
was detected to run near the 60 kDa MW marker.
rFbxl6 contained an F-box, proximal to its N-terminus at positions 59-101 aa and
an LRR region at its C-terminus, which was involved in the interaction with L-
periaxin (Figure 26). The relation between the originally isolated clone 26a and the
full-length protein rFbxl6 is shown in Figure 28.
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FIGURE 26. Amino acid sequence alignment (Clustal W) of the mouse (m) and
rat (r) F-box-containing protein Fbxl6. Identical residues are shown in purple and































































FIGURE 27. Nucleotide and amino acid sequence of rFbxl6. The F-box motif
(blue) and the LRR region (yellow) are indicated.
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Clone 26a
N Leucine Rich Repeats
122 487
rFbxl6
N F-box Leucine Rich Repeats
1 59-101 487
FIGURE 28. Domain structure of clone 26a and rFb\16. Clone 26a represents the
C-terminal region of rFbx!6. It comprises a LRR domain but lacks the F-box motif.
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3.4.3 Alternative models of the 3D structure of Fbxl6 based on
crystallographic data from other F-box-containing proteins.
F-box- containing proteins with a region that is rich in leucine repeats at their
carboxy termini adopt a shape that resembles a horseshoe (see Figure 14). This
arrangement facilitates the interaction between the F-box protein and its substrate by
creating a catalytic groove within which the association between the substrate and the
F-box protein takes place. LRRs are structural components of this arrangement and
therefore the determination of the number of these repeats is necessary for the
deduction of the precise overall structure of the molecule. Multiple alignments of the
LRR region of rFbxl6 using the Clustal W method (Mac Vector) followed by manual
re-adjustment, revealed that it belongs to the Cysteine-containing subfamily (see Table
2). Figure 29 illustrates a predicted distribution of the LRRs in the rFbxl6 molecule.
The consensus sequence CPXLXXLXLXX, where C, P and L represent the amino
acids cysteine, proline and leucine respectively, whereas X is any amino acid, suggests
the presence of twelve complete (1-12) and one incomplete (13) repeat in rFbxl6. The
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FIGURE 29. Clustal W alignment of the LRR region of rFbxl6. The C-terminus of
rFbxl6 contains a LRR region, which was identified as a member of the Cysteine-
containing subfamily. The consensus sequence CPXLXXLXLXX reveals the presence
of a conserved P residue in the repeat region. Each repeat comprises a highly
conserved region, where the L residues are localised, which gives rise to a (3-sheet and
a low homology region that generates an a-helix. (C: cysteine, P: proline, L: leucine,
X: any amino acid). (Adapted from Court, 2001).
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FIGURE 30. Proposed 3D structural model 1 (Ml) of the LRR region of rFbxl6.
The LRR domain of rFbxl6 is arranged in 13 repeats which comprise (3-sheets (blue)
that line the inner circumference and a-helices (purple) that flank the outer
circumference of a concave surface. The overall structure resembles a horseshoe. The
sheets and helices form surfaces, which are parallel to a common axis, perpendicular
to which they are viewed in the upper panel. The lower panel shows a view rotated by
approximately 45°C about the horizontal axis with respect to the upper panel (N- and
C-: amino- and carboxy- terminus, respectively) (After Court, 2001).
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FIGURE 31. Proposed 3D structural model 2 (M2) of the LRR region of rFbxl6.
(A) An alternative model (M2) suggests the substitution of the incomplete 13th repeat of
rFbxl6 by a 12-amino acid C-terminal tail (shown in green). (B) The electrostatic
potential of this arrangement revealed the possibility of an interaction between the
positively charged N-terminal region (blue) and the negative residues of the tail (red)
(Used by permission from Court, 2001).
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A structural model of rFbxl6, which comprised 13 repeats, was created by Mr F.
Court. It was based on crystallographic data available for RI (see Figure 14) using the
pdb viewer software. According to this model (Ml)(Figure 30), each of the 13 putative
repeats of rFbxl6 comprises a (3-sheet, which lines the inner circumference of a
concave surface, and an a-helix flanking the outer circumference. However, in this
model there is an extra (3-sheet without a corresponding a-helix (there are only 12 a-
helices but 13 (3-sheets). The putative 13th repeat did not conform to the consensus
sequence shown in Figure 29 and was previously described as incomplete. Failure to
conform to the consensus sequence and lack of an accompanying a-helix, in
conjunction with its shorter size, compared to the rest of the repeats, implied that the
13th repeat may not in fact constitute a part of the LRR structure. Crystallographic data
obtained for Skp2, an F-box protein of the LRR superfamily, revealed the presence of
a 25-residue C-terminal tail. This tail was found to reside within the concave face of
the LRR structure and associate with the (3-sheet lining in an electrostatic manner. It
was proposed that this feature might participate in or regulate substrate binding. The
likelihood of it being a substrate itself was also raised, considering that the levels of
Skp2 oscillate during the cell cycle (Schulman et al., 2000). The possibility of
attributing such a function to the C-terminal region of rFbxl6 was investigated. An
alternative model (M2) emerged, following constructive discussions with Mr F. Court.
According to M2, deletion of the putative 13lh repeat would give rise to a 12-residue
C-terminal tail (shown in Figure 31 A). Calculation of the electrostatic potential of the
resulting overall structure revealed a highly positively charged region at the N-
terminus of the LRR domain which was available for association with the negatively
charged residues of the tail (Figure 31 B). It is not yet known whether interaction of
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the negatively charged tail with the positively charged region of the LRR structure
actually occurs but the evidence suggests that it is theoretically possible. The
positively charged surface of the LRR is most probably employed in the interaction
with the negative charges of phosphate groups attached to substrates of the SCF
complex (eg. (3-catenin, iKBa). Both models are based on crystallographic data
available for other LRR-containing proteins and neither can be verified until the
crystallographic structure of Fbxl6 is obtained.
3.4.4 rFbxl6 mediates ubiquitination of L-periaxin in the sciatic nerve
The role of rFbxl6 in targeting L-periaxin for ubiquitination via an SCF complex
was assessed by investigating the possibility of formation of an L-periaxin-Ub
conjugate in sciatic nerves. The sciatic nerves of four P21 mice that had been
incubated with either the proteasomal inhibitor epoxomicin (5 pM) or its solvent
DMSO (vehicle control), were boiled in 2% SDS. The purpose of this treatment was to
inhibit degradation of ubiquitinated protein, in case the proteasome was involved in its
turnover, and hence observe elevated levels of L-periaxin conjugated to Ub. The
supernatant, which contained denatured proteins, was used in immunoprecipitations
(IP) with either L-periaxin or (3-catenin. (3-catenin is a known substrate of the SCF
complex (Kitagawa et al., 1999) and was used as a positive control for detection of
ubiquitination. The IP was performed using the rabbit polyclonal anti-repeat antibody
for L-periaxin, and the mouse monoclonal anti- (3-catenin antibody to precipitate (3-
catenin. The detection of ubiquitinated proteins was attempted by Western Blots, using
a mouse monoclonal anti-ubiquitin antibody (Santa Cruz) at 1:500 dilution.
As can be seen in Figure 32, L-periaxin was immunoprecipitated from sciatic
nerve homogenate (a), and it was also recognised by the anti-ubiquitin antibody (b),
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which suggests the presence of Ub residues attached to the protein's lysine side chains.
L-periaxin was not detectable in the non-immune fraction of the IP, with either the
anti-ubiquitin or the anti-Periaxin antibodies. This suggests that the bands seen in the
DMSO- and Epoxomicin-treated lanes represent immunoprecipitated periaxin, and in
(b) conjugated to ubiquitin. It is noteworthy that the epoxomicin-treated samples
appear to contain more protein than the DMSO-treated ones, which indicates a build¬
up of ubiquitinated protein when the degradation pathway is inhibited. In the Periaxin
immunoblot (IB), the equivalent of one sciatic nerve was loaded per lane, which
makes the protein levels comparable, whereas in the ubiquitin IB the equivalent of
three sciatic nerves were used in each lane. The mobility of the protein on SDS PAGE
did not appear to be significantly altered by the presence of ubiquitin. This suggests
that either a single Ub residue is conjugated to L-periaxin, or that residues of the Ub
tag were removed by the action of ubiquitin hydrolases which were not inhibited in the
experiment.
(3-catenin was immunoprecipitated from sciatic nerve homogenate as shown in (c)
and detected as a ubiquitin-conjugate in (d). Assessment of (3-catenin ubiquitination
was a positive control for the L-periaxin ubiquitination assay, since (3-catenin has been
well documented as a substrate of the F-box-containing protein FWDl/(3-TrCP/Slimb,
which targets it for ubiquitination by the SCF complex. However, the process of
ubiquitination of (3-catenin has only been demonstrated in transfected cell lines before
(Kitagawa et al., 1999) (Munemitsu et ah, 1995) (Orford et ah, 1997). This is the first
demonstration of the occurrence of the process in whole sciatic nerve cultures.
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FIGURE 32. L-periaxin and (3-catenin are uhiquitinated in sciatic nerve. L-
periaxin was immunoprecipitated from sciatic nerve treated with \% DMSO or 5 uM
epoxomicin (a) and was also detected as a ubiquitin conjugate (b). Treatment with
epoxomicin appears to result in accumulation of the protein, fj-catenin was also
immunoprecipitated from sciatic nerve homogenate (c) and shown to be ubiquitinated
(d).
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3.4.5 The proteasome is involved in the turnover of L-periaxin in the
sciatic nerve
Immunoprecipitation of L-periaxin from sciatic nerve homogenate which had
been treated with the proteasomal inhibitor epoxomicin, and subsequent
immunoblotting with the anti-ubiquitin antibody, revealed that L-periaxin formed a
conjugate with ubiquitin. The apparently increased levels of the protein upon treatment
of the sciatic nerve with the proteasomal inhibitor epoxomicin, compared to incubation
of the nerve in the solvent DMSO, (Figure 32 a) suggested the involvement of the
proteasomal pathway in regulation of the levels of L-periaxin. To investigate this
possibility, the sciatic nerves of four P21 mice were treated with either 1% DMSO or 5
p,M epoxomicin, as described in section 2.13.2, and were subsequently assessed for
changes in the levels of L-periaxin by Western Blot.
As can be seen in Figure 33, inhibition of the proteasome with epoxomicin results
in accumulation of undegraded L-periaxin. Use of the translation inhibitor CHX
throughout the course of the experiment serves to block protein synthesis and thus
maintains a fixed pool of protein in which changes in the level of L-periaxin could be
detected. In the absence of epoxomicin, the DMSO solvent has no effect on the
proteasome, which functions to degrade L-periaxin; hence the observed decline in the
protein levels by Western Blotting. To ensure that equal amounts of total protein were
loaded on each well, the protein content of each sciatic nerve was established by using




1% DMSO 5 uM Epoxomicin
t=0 t=45 t=90 t=180 t=0 t=45 t=90 t=180
FIGURE 33. L-periaxin is stabilised in sciatic nerve upon inhibition of the
proteasome by epoxomicin. (A) The levels of L-periaxin in sciatic nerves appear to
decline with time when the proteasome is not inhibited (DMSO CHX-treated nerves).
(B) Upon treatment with the proteasomal inhibitor epoxomicin, L-periaxin is stabilised
following addition of the translation inhibitor L UX for 180 min (t: time in min).
\(A
The experiment was carried out three times in order to ensure reproducibility. The
mean density of the bands obtained by Western Blotting was estimated by using the
NIH Image 1.61 software. The data obtained from all three experiments were averaged
and are displayed in Figure 34. The average figures were expressed as percentage
decline of protein levels, assuming that at t=0, the levels of L-periaxin represent 100%
of the protein present in sciatic nerve. Taken in conjunction, Figures 33 and 34 suggest
that the proteasome plays a major role in the regulation of the levels of L-periaxin in




FIGURE 34. Effect of inhibition of the proteasome on the levels of L-periaxin
in sciatic nerve. The proteasomai inhibitor epoxomicin (5 pM) applied to whole
sciatic nerves in culture, appears to maintain the levels of endogenous L-periaxin
near to 100% following a period of 3 h treatment with CHX, which prevents
further protein synthesis (red squares). The application of the solvent DMSO (1%)
does not interfere with proteasomai function and the protein levels decline to
approximately 50% by 120 min after application of CHX (blue triangles).
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3.4.6 Fbxl6 is expressed in a variety of tissues
The expression pattern of Fbxl6 was assessed by Western Blotting using a variety
of tissues obtained from P21 mice, with the 26aCl antibody. Total protein (30 pg)
from each homogenised tissue sample was resolved by SDS -PAGE on a 12% SDS
polyacrylamide gel and assessed for the presence of Fbxl6 by probing with the 26aC 1
antibody. As can be seen in Figure 35, the protein is expressed in comparable levels in
all tissues examined, namely brain, spinal cord, sciatic nerve, skeletal muscle, heart,
lung, kidney and liver. It has also been detected in trigeminal nerve, ovary and testis
samples (data not shown). It seems, therefore, that Fbxl6 is not PNS-specific but that it
is also expressed in tissues where L-periaxin is absent. This suggests the existence of
other substrates of Fbxl6 besides L-periaxin.
3.4.7 Investigation of the significance of L-periaxin ubiquitination by
transgenesis
Due to lack of time, it has not been possible to perform the analysis of the
transgenic animals yet and the results of this study will not be included in this thesis.
3.4.8 The C-terminal antibodies 26aCl and 26aC2 did not immunostain
sciatic nerve sections
Immunostaining of PI 1, P14 and P21 mouse sciatic nerve sections was attempted
with the C-terminal antibodies 26aCl and 26aC2 in order to determine the localisation
of Fbxl6. The staining observed with both antibodies was not specific and firm
conclusions could not be drawn. In order to obtain a better view of the distribution of
the protein, an antibody against its N-terminus will be generated.
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FIGURE 35. FbxI6 is expressed in a variety of tissues. Fbxl6 was detected by
Western Blot in homogenates (30 pg total protein) of brain (B), spinal cord (SC),
sciatic nerve (SN), skeletal muscle (M), heart (H), lung (LG) and liver (L) from P21
mice. The blot was probed with 26aCl antibody (1: 1,000).
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APPENDIX n
10 20 30 40 50 60
CCC GAG CGA GCC CTG CGG CCG CCG GAG CAT CTC CCG CGG CGG AGC AGG AGC CGG ATG GTC
70 80 90 100 110 120
AGA GGA GCC CGG CAG TCC CAG CAG CCG CGG AGT CGC CTG GCC CCC AGA CTG TCT GGC ACA
130 140 150 160 170 180
GTG GAG AAA CCA CCT CGA AAA CGG AAA AGC AGG ACT GAA TTT ACT CTT AAA GAA ACC ATG
190 200 210 220 230 240
TCC TCT GGA GGT GCT GAA GAT GAT ATC CCA CAG GGA GAG AGG AAG ACA GTT ACA GAT TTC
250 260 270 280 290 300
TGT TAT CTT TTG GAT AAA TCC AAG CAA CTG TTT AAT GGC TTA AGA GAT TTG CCT CAG TAT
310 320 330 340 350 360
GGA CAG AAG CAG TGG CAG TCC TAC TTC GGA AGA ACT TTT GAT GTT TAC ACC AAA CTC TGG
370 380 390 400 410 420
AAA TTC CAG CAG CAG CAT CGA CAA GTC TTG GAT AAT CGG TAT GGC TTG AAG CGG TGG CAA
430 440 450 460 470 480
ATA GGG GAA ATC GCT TCC AAG ATC GGG CAG CTG TAT TAC CAC TAT TAT TTA CGA ACT TCT
490 500 510 520 530 540
GAA ACC AGT TAT TTG AAT GAG GCT TTC TCC TTC TAC TCT GCA ATC AGA CAG AGG TCA TAC
550 560 570 580 590 600
TAC TCT CAA GTC AAC AAA GAG GAC AGG CCT GAG TTG GTT GTT AAG AAA CTC CGA TAC TAT
610 620 630 640 650 660
GCA AGA TTT ATA GTA GTT TGT CTT CTT CTT AAT AAA ATG GAC GTT GTG AAA GAC CTG GTA
670 680 690 700 710 720
AAG GAA TTG TCT GAT GAA ATT GAA GAT TAT ACT CAT CGC TTT AAT ACT GAA GAT CAA GTT
730 740 750 760 770 780
GAG TGG AAC CTG GTG CTC CAA GAG GTA GCA GCA TTC ATT GAG GCA GAC CCT GTA ATG GTG
790 800 810 820 830 840
TTA AAT GAT GAT AAT ACC ATT GTT ATC ACA TCC AAT CGC CTT GCT GAG ACA GGA GCC CCC
850 860 870 B80 890 900
TTG CTG GAG CAA GGC ATG ATA GTG GGA CAG TTG TCT CTG GCT GAT GCA CTC ATT ATT GGT
910 920 930 940 950 960
AAT TGT AAC AAT CAG GTC AAA TTC AGC GAA TTA ACT GTT GAC ATG TTC CGG ATG TTA CAA
970 980 990 1000 1010 1020
GCC TTG GAA AGG GAG CCA ATG AAT TTA GCT TCC CAG ATG AAT AAG CCG GGA ATA CAG GAG
1030 1040 1050 1060
CCA GCT GAC AAG CCT ACC AGA CGA GAA AAC GAA CTA GTC TCG AG
Nuceotide sequence of clone 11a
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10 20 30 40 50 60
GAG AAG AAG CTC CTT GCT TGC CTG GAG TGG CTC ATA CCC AAT CGG TTC TCA CAG CTC CAG
70 80 90 100 110 120
AGG TTG ACC CTC ATC CAC TGG AAG TCT CAA GTA CAC TCC GTG TTG GAG CTG GTT AGC AAG
130 140 150 160 170 180
TTC TGT CCA CGG CTC ACC TTC CTG AAG CTT TCA GAT TGC CAC GGT GTG ACA GCT GAA ACG
190 200 210 220 230 240
CTG GTC ATG TTA GCA AAA GCC TGC TGT CAG CTC CAC AGC CTA GAT CTA CAC CAT TCC ATG
250 260 270 280 290 300
GTC GAG TCC ACA GCT GTG GTG AGC TTC TTG GAG GAG GCG GGG TCC CGG ATG CGG AGG CTG
310 320 330 340 350 360
TGG CTG ACC TAC AGT TCC CAG ACC ACA GCC ATC TTG GGT GCA CTG CTG GGC AAC TGC TGC
370 380 390 400 410 420
CCC CAG CTC CAA GTC CTC GAG GTC AGC GCT GGC ATG AGC TGC AAC AAC ACA CCC TTG CAG
430 440 450 460 470 480
CTG CCT GTG GAA GCC CTA CAG AGA GGC TGC CCC CAG CTG CAG GTG CTA CGG CTG CTG AAT
490 500 510 520 530 540
CTG ATT TGG CTT CCC AAG CCT TGT GGC CGA GGA GCG CCC CAG GGA CCA GGA TTC CCC AGT
550 560 570 580 590 600
CTG GAG GAG CTC TGC TTG GCT GGC TCC ACC TGC AGC TTT GTG AGC AAT GAG GTT CTG GGC
610 620 630 640 650 660
CGC TTG CTC CAC TGC TCC CCC AAA CTG CGC CTG CTG GAT CTT CGA GGC TGT GCT AGA ATC
670 680 690 700 710 720
ACT CCT ACT GGG CTG TGT CAT TTG CCG TGT CAA GAG TTG GAG CAG CTC TAC CTG GGC CTG
730 740 750 760 770 780
TAT GGC ATG TCT GAT GGG TTG GCT CTA GCC AAG GAT GGC AGC CCC CTG TTG ACC CAG AAG
790 800 810 820 830 B40
TGG TAT CAC ACC CTG AGG GAG CTG GAC TTC AGT GGC CAA GGC TTC AGC GAG AAA GAC TTG
850 860 870 880 890 900
GAA CAG GCC CTG GCT GTT TTC TCA GGC ACC ACT GAG GGC TTA CCC CCA GCC TTG TGC TCC
910 920 930 940 950 960
CTC AAC CTA AGG GGT ACC CGA GTT ACA CCA AGC ACA GTC AGT TCT GTG ATT AGC AGT TGC
970 980 990 1000 1010 1020
CCG GGG CTG CTG TAT CTC AAT CTG GAG TCC TGT CGT TGT CTC CCA CGA GGT CTG AAG CGT
1030 1040 1050 1060 1070 1080
GCC TAC AGG GGC CTG GAG GAA GTC CAG TGG TGT CTA GAG CAG CTA CTT ACG AGC CCG CCC
1090 1100 1110 1120 1130
TCT TCC AGA GAG TCC ACA TAA CTC AAG ACG GCT CCC CGC TTT GCC CTG CCC TG




This work has focused on the identification of binding partners of L-periaxin, in
an effort to investigate its role in the myelin-forming Schwann cell and its
involvement in the process of PNS myelination. The C-terminal domain of the protein
was used to screen a rat sciatic nerve cDNA library by the yeast two-hybrid method.
The validity of the observed interactions was assessed biochemically. The study of
the significance of the association of L-periaxin with one particular library protein
was also attempted by transgenesis.
4.1 L-periaxin and the F-box hypothesis
Yeast two-hybrid screening of a rat sciatic nerve cDNA library revealed that the
C-terminus of L-periaxin formed an association with the rat homologue of a
previously identified protein in mouse, termed Fbxl6/Fbl6 (Cenciarelli et al., 1999)
(Winston et al., 1999a). Truncated versions of the C-terminus of L-periaxin pointed to
a region which comprised 85 aa residues of its acidic domain, as being sufficient for
the observed interaction.
The clone isolated from the cDNA library represented the C-terminal region of
rat Fbxl6 (rFbxl6), which comprised a leucine rich repeat (LRR) motif. LRRs have
been identified as structural motifs which are implicated in the formation of protein-
protein interactions (Kobe and Deisenhofer, 1995b). The arrangement of the a-
helices and [3-sheets, the constituents of each individual repeat, results in the
formation of a characteristic horseshoe-like molecule, which facilitates the
association between the LRR-containing protein and its substrate (Figure 14, section
1.6.5.2 (d)) (Kobe and Deisenhofer, 1995a).
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Following verification of the yeast two-hybrid interaction by in vitro pull down
assays, the full-length rFbxl6 cDNA was isolated by 5' RACE. The predicted amino
acid sequence indicated the presence of an F-box motif at the N-terminus of the
protein. F-box motifs are features of proteins involved in the recruitment of substrates
for the ubiquitin pathway of protein degradation (Craig and Tyers, 1999). F-box-
containing proteins comprise a C-terminal motif (e.g. WD40 or LRR) which serves
the association with their substrates, whereas the N-terminal F-box component is
necessary to dock the substrate-bearing F-box protein to the core ubiquitin ligase
enzyme (Bai et al., 1996). The complete complex, termed SCF (Skpl/Cullin/F-box),
is responsible for the ubiquitination of the target protein. rFbxl6 appeared to interact
with L-periaxin through its LRR region, as anticipated, leaving the F-box motif free
to associate with the core SCF complex. The interaction of L-periaxin with rFbxl6
implicated the ubiquitin pathway in the regulation of the levels of L-periaxin in the
sciatic nerve. The proposed role of L-periaxin in the stabilisation of the myelin sheath
in the PNS, based on evidence from Prx null mice (Gillespie et al., 2000), as well as
its translocation to the nucleus (Sherman and Brophy, 2000), would require tight
temporal and spatial regulation of the levels of the protein. The ubiquitin pathway
could serve to ensure that an efficient control mechanism operates.
4.1.1 rFbxl6 is expressed in a variety of tissues and may associate with
multiple substrates
Fbxl6 was detected by Western Blot in a variety of tissues including brain, spinal
cord, sciatic nerve, trigeminal nerve, skeletal muscle, heart, lung, kidney, liver, ovary
and testis. Given the fact that L-periaxin is a PNS-specific protein, the observed
pattern of expression of Fbxl6 implied that it could be implicated in the recruitment of
other protein(s) for ubiquitination. Work undertaken by Mr F. Court in Prof. PJ
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Brophy's lab, suggests that rFbxl6 may mediate the ubiquitination of transcription
factors, RNA-binding proteins and cytoplasmic polypeptides (Court, 2001). Although
the validity of the described interactions awaits confirmation, it is likely that rFbxl6
plays a role in the control of more than one cellular process by regulation at the
transcriptional, translational or protein level.
4.1.2 Predicting the 3D structure of the LRR region of Fbxl6: two
possible models emerge
The crystallographic data available for the LRR-containing proteins Ribonuclease
inhibitor (RI) and Skp2 were used as guides in order to predict the number and
arrangement of the repeats in the LRR region of Fbxl6. Alignment of the repeats was
performed using the Clustal W method (Mac Vector) followed by manual re¬
adjustment, according to the general consensus sequence LXXLXLXX of the LRR
superfamily. This revealed a more specific consensus sequence: CPXLXXLXLXX
(where C: cysteine, L: leucine, P: proline, and X: any amino acid), which groups
rFbxl6 in the Cysteine-containing subfamily of LRR-containing proteins. The
alignment shown in Figure 29 predicts the existence of 13 repeats. The first L residue
in the consensus sequence is not part of the (3-sheet but marks the end of the
preceding a-helix (F. Court, personal communication). The second conserved L of
the consensus sequence is found in all repeats, whereas the third conserved L is
missing from repeats 5, 10 and 13. In repeats 5 and 10, the L residue is substituted by
V (valine) and F (phenylalanine) respectively, which are also hydrophobic amino
acids. However, in the 13th repeat, L is substituted by the unrelated hydrophilic amino
acid T (threonine). The fact that it does not completely conform to the deduced
consensus sequence, in conjunction with the absence of an a-helix to accompany the
13th (3-sheet, implies that there may not be a 13lh repeat in the LRR region of Fbxl6. In
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accordance with this view, Winston and co-workers have predicted the existence of
12 repeats in human Fbxl6 (Winston et al., 1999a).
Looking for an alternative arrangement of the LRR region of rFbxl6, Mr. F.
Court and I turned our attention to the F-box-LRR-containing protein Skp2, whose
crystallographic structure was also available (Schulman et al., 2000). A C-terminal
tail of 25 aa residues was identified in Skp2 to reside within the concave surface of
the LRR region. Its association with the |3-sheet interface was of an electrostatic
nature.
In the case of rFbxl6, a 12-residue-C-terminal tail results by abolishing the 13th
repeat. As shown in Figure 31 B, the tail comprises negatively charged residues,
which could interact with the positively charged region of the N-terminus of the LRR,
thus assuming a conformation similar to that of Skp2. The putative roles of this tail
include participation in or regulation of substrate binding, as well as autoregulation
by recruiting the LRR-containing protein to the ubiquitination pathway (Galan and
Peter, 1999) (Schulman et al., 2000). Until the crystallographic structure of rFbxl6
has been deduced, it is not possible to prove the validity of either model.
4.2 Conjugation of ubiquitin residues to L-periaxin
rFbxl6 associates with L-periaxin through its LRR motif and targets the protein for
ubiquitination and subsequent degradation by the proteasome. Covalent attachment of
ubiquitin on the target protein takes place on lysine side chains of the substrate. There
are no consensus sequences for ubiquitin- accepting lysines but it has been
demonstrated that both p27 and IkBcx are ubiquitinated at specific lysines which are
found proximal to their respective F-box protein binding sites (Shirane et al., 1999)
(Spencer et al., 1999). The selection of lysine residues for ubiquitin conjugation is
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determined by spatial and stereochemical constraints imposed by the interaction
between the F-box protein-substrate complex and the SCF catalytic core (Schulman et
al., 2000). The ubiquitin- accepting lysine(s) of L-periaxin have not been identified
(see Future Work), however, it is possible that like p27 and IxBa, these may be found
close to the rFbxl6 binding region of the protein. The region of bcBa which interacts
with the F-box protein (3-TrCP (21-41 aa), comprises the two ubiquitinated lysines at
positions 21 and 22, as well as the two serines (S32 and 36) whose phosphorylation is
essential for (3-TrCP binding (Spencer et al., 1999). The rFbxl6 binding site in L-
periaxin (996- 1080 aa) comprises seven lysine residues, which could be considered
as candidates for conjugation with ubiquitin. Two lysine residues found just up¬
stream of the binding site (K993 and K995) may also be involved. Mutation of these
residues to arginines and assessment of ubiquitination of L-periaxin could provide the
means to deduce the ubiquitination site of the protein. The region of L-periaxin,
which is employed in the interaction with rFbxl6, is also rich in putative
phosphorylation sites. It is not known whether phosphorylation of the protein is
necessary for association with rFbxl6. The seven serines and five threonines found
within the 85 aa binding site of L-periaxin could potentially serve as mediators of the
interaction with rFbx!6 via phosphorylation. This possibility remains to be
investigated.
4.3 Investigation of the L-periaxin- rFbxI6 interaction by transgenesis
rFbxl6 was identified as the F-box -containing protein involved in targeting L-
periaxin to the ubiquitin/proteasome pathway for degradation. Inhibition of the
pathway would be expected to result in accumulation of L-periaxin in peripheral
nerve. One way to impede the normal function of the ubiquitin/proteasome -mediated
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turnover mechanism would be to express a dominant-negative version of rFbxl6 in an
attempt to abolish L-periaxin ubiquitination. A transgenic construct of rFbxl6 which
lacked the F-box motif (rFbxl6AF) was generated under the control of the mouse PO
promoter to ensure PNS-specific expression. rFbxl6AF would compete with
endogenous rFbxl6 for binding to L-periaxin but, unlike its wild-type counterpart, it
would be unable to associate with the core SCF complex and thus fail to ubiquitinate
L-periaxin. Investigation of the effects of accumulation of the rFbxl6-bound L-
periaxin was the purpose of this study. The possibility that failure to ubiquitinate and
thus degrade L-periaxin might be the cause of peripheral neuropathy that resembles
the CMT4F type, (observed in patients with a mutation that abolishes the C-terminal
region of the protein including the Fbxl6 binding site), is very intriguing (Anna
Williams, personal communication). Excessive levels of L-periaxin might have an
impact in the stability of the myelin sheath or induce nuclear translocation and
uncontrolled gene expression, assuming that L-periaxin has a functional role in the
nucleus. Due to a lack of time, the outcome of the transgenic experiment will not be
included in this thesis.
4.4 L-periaxin, (3-catenin and the ubiquitin/proteasome pathway: more
than just a matter of elimination
Immunoprecipitation of L-periaxin from mouse sciatic nerve homogenates and
subsequent Western blotting with an anti-ubiquitin antibody revealed that L-periaxin
was subjected to modification by the conjugation of ubiquitin residue(s). This
modification did not alter the relative mobility of the protein on SDS- polyacrylamide
gels significantly, which implied that the conjugate comprised a few or even a single
ubiquitin molecule. Despite reports that a minimum of four ubiquitin residues are
required for recognition by the proteasome and that mono-ubiquitination serves
176
mainly subcellular targeting, the major ubiquitinated form of neuronal nitric oxide
synthase (nNOS), a protein degraded by the proteasome, is also believed to comprise
only one or a few ubiquitin molecules (Bender et al., 2000). It is also possible that L-
periaxin associates with a number of ubiquitin residues (;> 4), which were removed
during the course of the immunoprecipitation experiment via the action of uninhibited
ubiquitin hydrolases.
To obtain an insight on the potential significance of the involvement of the
ubiquitin/proteasome pathway in the regulation of L-periaxin, we turned our attention
to (3-catenin, a well-documented substrate of the pathway (Maniatis, 1999) (Winston
et al., 1999b).
4.4.1 (3-catenin: a protein implicated in alternative F-box -mediated
pathways of destruction
(3-catenin has been shown to interact with the F-box-containing protein
FWDl/(3TrCP/Slimb, which mediates its ubiquitination via the scFFWD"pTlCP/sl'mb
complex. The protein is subsequently degraded by the proteasome (Kitagawa et al.,
1999; Latres et al., 1999). Recently, a novel pathway for the regulation of the
abundance of (3-catenin has been described, which links (3-catenin degradation to p53
responses (Matsuzawa and Reed, 2001). Matsuzawa and co-workers have elucidated
a network of interactions between Siah-1, which is a RING-finger protein whose
expression is induced by p53, SIP (a novel Siah-interacting protein) and the F-box
protein Ebi, which binds unphosphorylated (3-catenin (unlike the F-box protein (3-
TrCP). According to this pathway, DNA damage-induced p53 expression leads to an
increase in the levels of the RING-finger protein Siah-1, which associates with SIP.
SIP binds to Skp-1 in a complex with Ebi instead of (3-TrCP together with (3-catenin.
The common component of the Wnt and Siah-1 pathways is APC, which appears to
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be irreplaceable in the process of (3-catenin degradation. (3-catenin is an example of a
protein which is not only regulated by two different F-box proteins, namely (3-TrCP
and Ebi, but also shares one of its F-box binding partners ((3-TrCP) with two other
ubiquitination substrates, IkBcx and Vpu (Winston et al., 1999b) (Margottin et al.,
1998). It is therefore apparent that a single F-box protein may mediate the
ubiquitination of more than one substrate and each substrate may associate with more
than one F-box protein in alternative ubiquitin/proteasome -mediated destruction
pathways. The process of ubiquitination of (3-catenin has so far only been
demonstrated in cell lines transfected with (3-catenin (Kitagawa et al., 1999)
(Munemitsu et al., 1995) (Orford et al., 1997). In this work, the occurrence of (3-
catenin ubiquitination in the sciatic nerve has also been shown.
(3-catenin associates with the cytoplasmic tail of E-cadherin, a protein that
mediates cell adhesion, and links it to the actin cytoskeleton by interacting with a-
catenin (Gottardi et al., 2001). This cell adhesion complex clusters (3-catenin to the
cortical cytoskeleton and has been found to be responsible for the stabilisation of both
proteins (Huber et al., 2001). The C-terminal tail of E-cadherin contains motifs which
target the protein to the ubiquitin/proteasome pathway. These motifs overlap the
previously identified (3-catenin-binding site and are therefore masked in the E-
cadherin/(3-catenin complex. Cellular adhesiveness also appears to be dependent on
interaction with (3-catenin, as the cytoplasmic region of cadherin seems to be
unstructured in the absence of (3-catenin (Huber et al., 2001).
Free cytoplasmic (3-catenin is either degraded by the ubiquitin/proteasome
pathway or accumulates upon extracellular signalling (e.g. Wnt) and translocates to
the nucleus where it acts as a transcription factor. Meigs and co-workers have
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recently suggested that, through mechanisms that are not yet fully understood, (3-
catenin may be released from the cadherin complex and translocate to the nucleus in
order to exert its transcriptional regulatory effects (Meigs et al., 2001). They have
presented evidence that members of the G12 subfamily of heterotrimeric G proteins
bind to the cytoplasmic region of cadherins, resulting in the release of p-catenin from
the complex. Displacement of p-catenin from cadherins via an activation-dependent
interaction involving G12 proteins leads to manifestation of p-catenin mediated
transcriptional responses in transfected HEK293 cells. Relocalisation of p-catenin in
HEK293 cells from the adherens junction to the nucleus was observed upon
expression of activated G12 proteins (Meigs et al., 2001).
4.4.2 A hypothetical model for the ubiquitin-mediated regulation of L-
periaxin, based on evidence for p-catenin
Significant similarities in the cellular distribution of L-periaxin and p-catenin in
conjunction with the involvement of the ubiquitin/proteasome pathway in the
regulation of the abundance of both proteins, have pointed to the possibility of
similarity in the cellular roles of the two proteins. As can be seen in Figure 36, both
proteins may be seen clustered to the cortical cytoskeleton through associations with
multi-protein complexes. L-periaxin participates in the recently identified DRP2-
dystroglycan complex (Sherman et al., 2001), whereas P-catenin links E-cadherin to
a-catenin, which in turn tethers the complex to the actin cytoskeleton in adherens
junctions (Aberle et al., 1994). p-catenin is released from E-cadherin via the action of
G12 proteins and translocates to the nucleus where it acts as a transcriptional
activator for the expression of genes under the control of TCF/LEF transcription
factors (Huber et al., 1996). L-periaxin has also been found to localise to the nuclei of
both embryonic and post-natal Schwann cells. L-periaxin, permanently expressed in
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the Schwann cell line 33B (derived from P5 rats), displayed a cell density- dependent
pattern of nucleocytoplasmic distribution. In sub-confluent monolayers of 33B cells
L-periaxin was predominantly localised to the nucleus. This nuclear accumulation
was lost in denser cultures and re-established upon wounding of the monolayer with a
pipette tip (Sherman and Brophy, 2000). Its presence in the nucleus suggests that L-
periaxin may act as a transcription factor, possibly for the regulation of genes that
encode proteins involved in myelination. This view is based on the observation that
L-periaxin is present in the nucleus of Schwann cells prior to the expression of the
myelin proteins P0, MBP and MAG (Scherer et al., 1995) (Sherman and Brophy,
2000). In accordance with the proposed mechanism of translocation of (3-catenin from
the cortical cytoskeleton to the nucleus (Meigs et al., 2001), it is possible that binding
of an as yet unidentified molecule to the C-terminal tail of DRP2, may result in
release of L-periaxin from the complex and subsequent relocation to the nucleus.
Displacement of L-periaxin from the DRP2 complex could also occur through an
association of the L- and S- periaxin isoforms via their PDZ domains.
Shift in the localisation of L-periaxin from the Schwann cell membranes
apposing the axon (adaxonal) to those apposing the basal lamina (abaxonal) has also
been reported to occur as the myelin sheath begins to mature (Scherer et al., 1995), in
a mechanism that has not yet been elucidated.
Finally, the abundance of both proteins is regulated by the ubiquitin/proteasome
pathway of protein degradation, p-catenin appears to be recruited for ubiquitination
by the F-box protein P-TrCP in a phosphorylation-dependent manner and the
heterodimer subsequently associates with the core SCF complex (Latres et al., 1999).
Alternatively, unphosphorylated P-catenin is bound by the F-box protein Ebi and is
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recruited to a distinct E3 ligase complex (Matsuzawa and Reed, 2001). Although this
work has shown that L-periaxin associates with the F-box protein Fbxl6, which
mediates its ubiquitination, it is not yet known whether this interaction requires the
phosphorylation of the protein. It is also not clear whether it involves the participation
of the SCF or an alternative E3 complex (see Future Work). Most recently Fbxl6,
(along with 16 other F-box-containing proteins), was tested by Koepp and co-workers
as a potential mediator of the ubiquitination of Cyclin E (Koepp et al., 2001). Their
data demonstrated that although Fbxl6 was not responsible for recruitment of Cyclin
E to the pathway, it was able to associate with the core SCF complex. Recruitment of
L-periaxin to the ubiquitin/proteasome pathway is a means for its precisely timed and
efficiently controlled regulation, implying an important role for this protein in the
process of myelination. This suggestion is borne out by the severe phenotype of the
periaxin-deficient mouse and the human disease CMT4F.
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FIGURE 36. (A) Cellular functions and regulation of p-catenin. P-catenin links
the cytoplasmic region of E-cadherin to a-catenin and the actin cytoskeleton in
adherens junctions. Displacement of P-catenin from the complex by G12 gives rise
to a pool of free cytoplasmic protein. Upon Wnt signalling, cytoplasmic P-catenin
translocates to the nucleus where it acts as a transcription factor. In the absence of
Wnt, the protein is targeted for destruction in the ubiquitin/proteasome pathway.
(B) Hypothetical model of the function and regulation of L-periaxin. L-
periaxin is able to dimerise through its PDZ domain and participate in a DRP2-
dystroglycan complex which clusters it to the cortical cytoskeleton. Release from
the complex in a mechanism similar to that which applies for P-catenin, would
yield a pool of free monomeric L-periaxin. This would be subject to one of the
following fates: 1. nuclear translocation and possible function as a transcription



















The work presented in this thesis has implicated the ubiquitin/proteasome
pathway in the turnover of L-periaxin. The identification of the F-box-LRR protein
Fbxl6 as the mediator of L-periaxin targeting to the pathway, signals the beginning of
a new series of experiments, that could be designed to investigate the specific
function(s) of the protein.
Identification of the ubiquitin-accepting lysine(s) of L-periaxin and investigation
of the phosphorylation requirements of the interaction with rFbxl6 are two issues
which could be pursued. Evidence from other substrates of the SCF complex suggests
that the ubiquitin-bearing lysines may reside within or near the F-box protein-binding
site of the substrate. Mutation of the seven lysines found within the rFbxl6 binding
site of L-periaxin to arginines, either in turn or in clusters, may lead to the
identification of the residue(s) involved in conjugation of ubiquitin to the protein.
The association of an F-box -containing protein with its substrate(s) may require
the phosphorylation of specific serines or threonines of the target protein, as has been
observed for |3-catenin and IkBci. To investigate whether this phosphorylation
requirement applies to the interaction of L-periaxin with rFbxl6, putative
phosphorylation sites found within the region of L-periaxin employed in rFbxl6
binding could be mutated. In the case of phosphorylation being a requisite for L-
periaxin targeting to the SCF complex for ubiquitination, various approaches could be
taken to exploit this fact.
Abolishing phosphorylation of L-periaxin by mutating the phosphate-accepting
residue(s) of the protein could serve as a mechanism to prevent ubiquitin-mediated
degradation. Conversely, to mimic constitutive phosphorylation of L-periaxin by
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mutation of the serine(s)/threonine(s) involved in its interaction with rFbxl6, might
cause an increase in the turnover rate of L-periaxin. The effects of inhibiting or
enhancing the degradation of L-periaxin by manipulating its phosphorylation state
could be addressed in either a cell culture system or a transgenic animal model. It
would be anticipated that such experiments would specifically target the function of
L-periaxin, while excluding other proteins, which may also be substrates of the same
SCF complex. This may not be the case in dominant negative and over-expression
experiments involving rFbxl6 (see later), where the function of additional proteins
could also be disrupted.
Generation of a transgenic mouse that expresses the F-box deletion mutant of
rFbxl6 (rFbxl6AF) could provide valuable information on the effects of L-periaxin
accumulation in the Schwann cell. The morphology of the Schwann cell and the
structure of the myelin sheath could be assessed as a function of L-periaxin
stabilisation. The shift in L-periaxin localisation from the adaxonal to the abaxonal
Schwann cell membranes could be investigated, as well as any apparent changes in
the structure of the DRP2-L-periaxin complex. The question of the significance of
nuclear localisation of L-periaxin may also be addressed in the transgenic mouse
model. The possibility that L-periaxin stabilisation could induce nuclear translocation
with potential effects in gene expression, is also a matter to be considered. Candidates
upon which L-periaxin might exert transcriptional control are likely to include genes
encoding myelin-associated proteins. The regulation of PO, MBP and MAG in the
rFbxl6AF transgenic mouse could also be investigated.
The effect of rFbxl6 over-expression on the abundance and sub-cellular
distribution of L-periaxin could be assessed in transfected Schwann cell lines
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permanently expressing L-periaxin. An increase in the turnover rate of L-periaxin,
caused by over-expression of rFbxl6, might deplete the levels of cytoplasmic L-
periaxin. As a result, inhibition of the nuclear translocation of the protein would be
expected. It would also be interesting to establish whether clustering to the cortical
DRP2-dystroglycan complex rescues L-periaxin from uncontrolled degradation due to
excessive levels of rFbxl6.
Identification of the rest of the components of the SCF""1'6 complex by means of
immunoprecipitation from a cell culture system may also be attempted. This could be
achieved by the use of an antibody against rFbxl6 to "pull-down" the SCF complex in
which it participates. Characterisation of the putative additional substrates of rFbxl6
could provide an insight to the cellular processes in which it plays a regulatory role.
Determination of the sub-cellular distribution of rFbxl6 by immunostaining, would be
useful in establishing co-localisation with its substrates. An antibody against the N-
terminus of the protein is currently being raised in rabbits for possible use in the
above experiments. It would also be interesting to deduce the manner of regulation of
the abundance of endogenous rFbxl6. Determine whether the ubiquitin/proteasome
pathway is implicated in the turnover of this protein and if so, whether its targeting
for destruction is self-mediated or accomplished by another F-box-containing protein.
The ubiquitin/proteasome pathway is involved in the control of a number of
complex cellular signalling cascades, which is accomplished via multi-component
mechanisms. To gain an insight into the regulation of various cellular functions, it
would be useful to identify substrates of the pathway and elucidate the precise
mechanisms employed for their turnover. Deduction of potential associations between
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